

Author Search

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 16:22:37 ON 06 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15

FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


=> D STAT QUE L41

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 STR



Structure attributes must be viewed using STN Express query preparation.

```

L5          SCR 1840
L13         2810 SEA FILE=REGISTRY SSS FUL L5 AND (L1 AND L3)
L16         814 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L13
L17         75 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L16 AND (PRY<=2003 OR
AY<=2003 OR PY<=2003)
L18         13 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON DUMA J?/AU
L19         345 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON BOYER S?/AU
L20         1854 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON VERMA S?/AU
L21         12 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON ADNANE L?/AU
L22         60165 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON CHEN Y?/AU
L23         15934 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON LEE W?/AU
L24         0 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON PHLLIPS B?/AU
L25         16458 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SMITH R?/AU
L26         16458 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SMITH R?/AU
L27         2169 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SCOTT W?/AU
L28         2303 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON BURKE J?/AU
L29         58323 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON CHEN J?/AU
L30         58323 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON CHEN J?/AU
L31         1090 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON PHILLIPS B?/AU
L32         5608 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON FAN J?/AU
L33         137 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON MIRANDA K?/AU
L34         9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON RAUDENBUSH B?/AU
L35         58 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON REDMAN A?/AU
L36         2853 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SHAO J?/AU
L37         404 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SU N?/AU
L38         24362 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON WANG G?/AU
L39         1023 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON YI L?/AU
L40         5479 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON ZHU Q?/AU
L41         27 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L18 OR L19 OR L20 OR
L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR
L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR
L39 OR L40) AND L17

```

=> D IBIB ED ABS HITSTR L41 1-27

L41 ANSWER 1 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1031893 HCAPLUS Full-text

Serial No.:10/788,426

DOCUMENT NUMBER: 149:307869
 TITLE: Kinase inhibitor phosphonate conjugates useful as antitumor agents
 INVENTOR(S): Cannizzaro, Carina; Chen, James M.; Chen, Xiaowu; Cho, Aesop; Chong, Lee S.; Desai, Manoj; Fardis, Maria; Kirschberg, Thorsten; Mackman, Richard L.; Swaminathan, Sundaramoorthi; Watkins, William J.
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA
 SOURCE: U.S., 205pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 18
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7417055	B2	20080826	US 2004-832811	20040426 <--
US 20050261253	A1	20051124		
AU 2004233989	A1	20041111	AU 2004-233989	20040426 <--
AU 2004233992	A1	20041111	AU 2004-233992	20040426 <--
CA 2519840	A1	20041111	CA 2004-2519840	20040426 <--
AU 2004238225	A1	20041125	AU 2004-238225	20040426 <--
WO 2005002626	A2	20050113	WO 2004-US13283	20040426 <--
WO 2005002626	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060035866	A1	20060216	US 2004-833295	20040426 <--
US 7470724	B2	20081230		
US 20060079478	A1	20060413	US 2004-833293	20040426 <--
US 7452901	B2	20081118		
US 20060199788	A1	20060907	US 2004-833294	20040426 <--
US 7432261	B2	20081007		
CN 101381379	A	20090311	CN 2008-10166733	20040426 <--
AU 2004308974	A1	20050714	AU 2004-308974	20041222 <--
CA 2548951	A1	20050714	CA 2004-2548951	20041222 <--
WO 2005063258	A1	20050714	WO 2004-US43595	20041222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1715871	A1	20061102	EP 2004-815625	20041222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

Serial No.:10/788,426

CN 1933844	A	20070321	CN 2004-80041231	20041222 <--
BR 2004018031	A	20070417	BR 2004-18031	20041222 <--
JP 2007529421	T	20071025	JP 2006-547456	20041222 <--
MX 2005011287	A	20060124	MX 2005-11287	20051020 <--
US 20060264404	A1	20061123	US 2005-258621	20051025
NO 2005005592	A	20060123	NO 2005-5592	20051125 <--
MX 2006007095	A	20060904	MX 2006-7095	20060620 <--
KR 2006129305	A	20061215	KR 2006-714949	20060724 <--
US 20070281907	A1	20071206	US 2007-583683	20070411 <--
JP 2007291111	A	20071108	JP 2007-114889	20070424 <--
JP 2007246533	A	20070927	JP 2007-116178	20070425 <--
JP 2007238624	A	20070920	JP 2007-120311	20070427 <--
PRIORITY APPLN. INFO.:			US 2003-465465P	P 20030425 <--
			US 2003-465569P	P 20030425 <--
			US 2003-465588P	P 20030425 <--
			US 2003-465594P	P 20030425 <--
			US 2003-495382P	P 20030815 <--
			US 2003-495527P	P 20030815 <--
			US 2003-495685P	P 20030815 <--
			US 2003-495686P	P 20030815 <--
			US 2003-513925P	P 20031024 <--
			US 2003-513956P	P 20031024 <--
			US 2003-513974P	P 20031024 <--
			US 2003-514115P	P 20031024 <--
			US 2003-514207P	P 20031024 <--
			US 2003-514324P	P 20031024 <--
			US 2003-514330P	P 20031024 <--
			US 2003-514368P	P 20031024 <--
			US 2003-531932P	P 20031222 <--
			US 2004-536054P	P 20040112
			US 2003-465287P	P 20030425 <--
			US 2003-465325P	P 20030425 <--
			US 2003-465332P	P 20030425 <--
			US 2003-465335P	P 20030425 <--
			US 2003-465339P	P 20030425 <--
			US 2003-465342P	P 20030425 <--
			US 2003-465343P	P 20030425 <--
			US 2003-465347P	P 20030425 <--
			US 2003-465373P	P 20030425 <--
			US 2003-465377P	P 20030425 <--
			US 2003-465394P	P 20030425 <--
			US 2003-465400P	P 20030425 <--
			US 2003-465406P	P 20030425 <--
			US 2003-465415P	P 20030425 <--
			US 2003-465419P	P 20030425 <--
			US 2003-465420P	P 20030425 <--
			US 2003-465422P	P 20030425 <--
			US 2003-465424P	P 20030425 <--
			US 2003-465433P	P 20030425 <--
			US 2003-465449P	P 20030425 <--
			US 2003-465452P	P 20030425 <--
			US 2003-465463P	P 20030425 <--
			US 2003-465467P	P 20030425 <--
			US 2003-465469P	P 20030425 <--
			US 2003-465471P	P 20030425 <--
			US 2003-465472P	P 20030425 <--
			US 2003-465473P	P 20030425 <--
			US 2003-465479P	P 20030425 <--
			US 2003-465480P	P 20030425 <--
			US 2003-465531P	P 20030425 <--

Serial No.:10/788,426

US 2003-465532P	P	20030425 <--
US 2003-465537P	P	20030425 <--
US 2003-465545P	P	20030425 <--
US 2003-465546P	P	20030425 <--
US 2003-465547P	P	20030425 <--
US 2003-465548P	P	20030425 <--
US 2003-465550P	P	20030425 <--
US 2003-465553P	P	20030425 <--
US 2003-465554P	P	20030425 <--
US 2003-465559P	P	20030425 <--
US 2003-465560P	P	20030425 <--
US 2003-465561P	P	20030425 <--
US 2003-465567P	P	20030425 <--
US 2003-465574P	P	20030425 <--
US 2003-465575P	P	20030425 <--
US 2003-465586P	P	20030425 <--
US 2003-465587P	P	20030425 <--
US 2003-465589P	P	20030425 <--
US 2003-465591P	P	20030425 <--
US 2003-465593P	P	20030425 <--
US 2003-465598P	P	20030425 <--
US 2003-465600P	P	20030425 <--
US 2003-465601P	P	20030425 <--
US 2003-465602P	P	20030425 <--
US 2003-465603P	P	20030425 <--
US 2003-465607P	P	20030425 <--
US 2003-465614P	P	20030425 <--
US 2003-465620P	P	20030425 <--
US 2003-465630P	P	20030425 <--
US 2003-465631P	P	20030425 <--
US 2003-465632P	P	20030425 <--
US 2003-465633P	P	20030425 <--
US 2003-465634P	P	20030425 <--
US 2003-465638P	P	20030425 <--
US 2003-465639P	P	20030425 <--
US 2003-465640P	P	20030425 <--
US 2003-465641P	P	20030425 <--
US 2003-465647P	P	20030425 <--
US 2003-465649P	P	20030425 <--
US 2003-465667P	P	20030425 <--
US 2003-465668P	P	20030425 <--
US 2003-465682P	P	20030425 <--
US 2003-465683P	P	20030425 <--
US 2003-465684P	P	20030425 <--
US 2003-465690P	P	20030425 <--
US 2003-465695P	P	20030425 <--
US 2003-465698P	P	20030425 <--
US 2003-465714P	P	20030425 <--
US 2003-465720P	P	20030425 <--
US 2003-465728P	P	20030425 <--
US 2003-465742P	P	20030425 <--
US 2003-465746P	P	20030425 <--
US 2003-465749P	P	20030425 <--
US 2003-465756P	P	20030425 <--
US 2003-465821P	P	20030425 <--
US 2003-465844P	P	20030425 <--
US 2003-493302P	P	20030807 <--
US 2003-493303P	P	20030807 <--
US 2003-493309P	P	20030807 <--
US 2003-493310P	P	20030807 <--

Serial No.:10/788,426

US 2003-495295P	P	20030815 <--
US 2003-495297P	P	20030815 <--
US 2003-495339P	P	20030815 <--
US 2003-495362P	P	20030815 <--
US 2003-495366P	P	20030815 <--
US 2003-495387P	P	20030815 <--
US 2003-495389P	P	20030815 <--
US 2003-495393P	P	20030815 <--
US 2003-495398P	P	20030815 <--
US 2003-495414P	P	20030815 <--
US 2003-495416P	P	20030815 <--
US 2003-495417P	P	20030815 <--
US 2003-495425P	P	20030815 <--
US 2003-495426P	P	20030815 <--
US 2003-495427P	P	20030815 <--
US 2003-495455P	P	20030815 <--
US 2003-495456P	P	20030815 <--
US 2003-495472P	P	20030815 <--
US 2003-495484P	P	20030815 <--
US 2003-495524P	P	20030815 <--
US 2003-495525P	P	20030815 <--
US 2003-495529P	P	20030815 <--
US 2003-495533P	P	20030815 <--
US 2003-495534P	P	20030815 <--
US 2003-495537P	P	20030815 <--
US 2003-495563P	P	20030815 <--
US 2003-495565P	P	20030815 <--
US 2003-495597P	P	20030815 <--
US 2003-495629P	P	20030815 <--
US 2003-495644P	P	20030815 <--
US 2003-495645P	P	20030815 <--
US 2003-495647P	P	20030815 <--
US 2003-495660P	P	20030815 <--
US 2003-495661P	P	20030815 <--
US 2003-495669P	P	20030815 <--
US 2003-495679P	P	20030815 <--
US 2003-495680P	P	20030815 <--
US 2003-495682P	P	20030815 <--
US 2003-495736P	P	20030815 <--
US 2003-495748P	P	20030815 <--
US 2003-495751P	P	20030815 <--
US 2003-495757P	P	20030815 <--
US 2003-495769P	P	20030815 <--
US 2003-495784P	P	20030815 <--
US 2003-495789P	P	20030815 <--
US 2003-513530P	P	20031024 <--
US 2003-513531P	P	20031024 <--
US 2003-513561P	P	20031024 <--
US 2003-513562P	P	20031024 <--
US 2003-513563P	P	20031024 <--
US 2003-513564P	P	20031024 <--
US 2003-513579P	P	20031024 <--
US 2003-513588P	P	20031024 <--
US 2003-513589P	P	20031024 <--
US 2003-513592P	P	20031024 <--
US 2003-513593P	P	20031024 <--
US 2003-513923P	P	20031024 <--
US 2003-513924P	P	20031024 <--
US 2003-513926P	P	20031024 <--
US 2003-513927P	P	20031024 <--

Serial No.:10/788,426

US 2003-513932P	P	20031024	<--
US 2003-513944P	P	20031024	<--
US 2003-513945P	P	20031024	<--
US 2003-513946P	P	20031024	<--
US 2003-513947P	P	20031024	<--
US 2003-513948P	P	20031024	<--
US 2003-513949P	P	20031024	<--
US 2003-513950P	P	20031024	<--
US 2003-513951P	P	20031024	<--
US 2003-513953P	P	20031024	<--
US 2003-513961P	P	20031024	<--
US 2003-513963P	P	20031024	<--
US 2003-513969P	P	20031024	<--
US 2003-513970P	P	20031024	<--
US 2003-513971P	P	20031024	<--
US 2003-513972P	P	20031024	<--
US 2003-513973P	P	20031024	<--
US 2003-513975P	P	20031024	<--
US 2003-513976P	P	20031024	<--
US 2003-513977P	P	20031024	<--
US 2003-513979P	P	20031024	<--
US 2003-513980P	P	20031024	<--
US 2003-513982P	P	20031024	<--
US 2003-514021P	P	20031024	<--
US 2003-514044P	P	20031024	<--
US 2003-514051P	P	20031024	<--
US 2003-514054P	P	20031024	<--
US 2003-514072P	P	20031024	<--
US 2003-514075P	P	20031024	<--
US 2003-514083P	P	20031024	<--
US 2003-514085P	P	20031024	<--
US 2003-514097P	P	20031024	<--
US 2003-514098P	P	20031024	<--
US 2003-514105P	P	20031024	<--
US 2003-514108P	P	20031024	<--
US 2003-514110P	P	20031024	<--
US 2003-514111P	P	20031024	<--
US 2003-514113P	P	20031024	<--
US 2003-514114P	P	20031024	<--
US 2003-514130P	P	20031024	<--
US 2003-514131P	P	20031024	<--
US 2003-514140P	P	20031024	<--
US 2003-514144P	P	20031024	<--
US 2003-514145P	P	20031024	<--
US 2003-514159P	P	20031024	<--
US 2003-514160P	P	20031024	<--
US 2003-514161P	P	20031024	<--
US 2003-514174P	P	20031024	<--
US 2003-514175P	P	20031024	<--
US 2003-514200P	P	20031024	<--
US 2003-514201P	P	20031024	<--
US 2003-514202P	P	20031024	<--
US 2003-514203P	P	20031024	<--
US 2003-514205P	P	20031024	<--
US 2003-514235P	P	20031024	<--
US 2003-514244P	P	20031024	<--
US 2003-514247P	P	20031024	<--
US 2003-514258P	P	20031024	<--
US 2003-514280P	P	20031024	<--
US 2003-514298P	P	20031024	<--

US 2003-514325P P 20031024 <--
 US 2003-514334P P 20031024 <--
 US 2003-514345P P 20031024 <--
 US 2003-514359P P 20031024 <--
 US 2003-514369P P 20031024 <--
 US 2003-514393P P 20031024 <--
 US 2003-514394P P 20031024 <--
 US 2003-514424P P 20031024 <--
 US 2003-514439P P 20031024 <--
 US 2003-514450P P 20031024 <--
 US 2003-514452P P 20031024 <--
 US 2003-514453P P 20031024 <--

ED Entered STN: 27 Aug 2008

AB The invention is related to phosphorus-substituted kinase inhibitory compds. and conjugates, compds. containing such compds. and conjugates, and therapeutic methods that include the administration of such compds. and conjugates, as well as to processes and intermediates useful for preparing such compds. and conjugates. As kinase inhibitors, the compds. of the invention should prove useful as antitumor agents. Methods for preparing the compds. are described. Formulations containing the compds. of the invention are also described.

IT 1060764-61-5P 1060764-63-7P 1060764-65-9P
 1060764-66-0P 1060764-68-2P 1060764-70-6P
 1060764-72-8P 1060764-73-9P 1060764-75-1P
 1060764-77-3P 1060764-79-5P 1060764-80-8P
 1060764-82-0P 1060764-84-2P 1060764-86-4P
 1060764-88-6P 1060764-89-7P 1060764-91-1P
 1060764-93-3P 1060764-95-5P 1060764-96-6P
 1060764-98-8P 1060765-00-5P 1060765-01-6P
 1060765-02-7P 1060765-03-8P 1060765-04-9P
 1060765-05-0P 1060765-07-2P 1060765-09-4P
 1060765-11-8P 1060765-12-9P 1060765-13-0P
 1060765-14-1P 1060765-15-2P 1060765-17-4P
 1060765-19-6P 1060765-22-1P 1060765-25-4P
 1060765-28-7P 1060765-31-2P 1060765-34-5P
 1060765-37-8P 1060765-40-3P 1060765-43-6P
 1060765-46-9P 1060765-49-2P 1060765-51-6P
 1060765-54-9P 1060765-57-2P 1060765-59-4P
 1060765-64-1P 1060765-66-3P 1060765-69-6P
 1060765-71-0P 1060765-78-7P 1060765-80-1P
 1060765-83-4P 1060765-86-7P 1060765-89-0P
 1060765-91-4P 1060765-93-6P 1061231-67-1P
 1061242-41-8P 1061242-42-9P 1061242-44-1P
 1061242-46-3P 1061242-47-4P 1061242-49-6P
 1061242-50-9P 1061242-53-2P 1061242-56-5P
 1061242-58-7P 1061242-59-8P 1061242-60-1P
 1061242-62-3P 1061242-64-5P 1061242-66-7P
 1061242-68-9P 1061242-69-0P 1061242-72-5P
 1061242-75-8P 1061242-76-9P 1061242-77-0P
 1061242-78-1P 1061242-80-5P 1061242-81-6P
 1061242-83-8P 1061242-84-9P 1061242-87-2P
 1061242-90-7P 1061242-91-8P 1061242-92-9P
 1061242-93-0P 1061242-95-2P 1061242-97-4P
 1061243-00-2P 1061243-01-3P 1061243-04-6P
 1061243-06-8P 1061243-08-0P 1061243-10-4P
 1061243-13-7P 1061243-15-9P 1061243-18-2P
 1061243-21-7P 1061243-23-9P 1061243-26-2P
 1061243-27-3P 1061243-30-8P 1061243-31-9P
 1061243-34-2P 1061243-37-5P 1061243-39-7P
 1061243-40-6P 1061243-41-1P 1061243-42-2P

1061243-45-5P 1061243-48-8P 1061243-49-9P
 1061243-50-2P 1061243-53-5P 1061243-56-8P
 1061243-58-0P 1061243-59-1P 1061243-63-7P
 1061243-64-3P 1061243-66-0P 1061243-67-1P
 1061243-68-2P 1061243-71-7P 1061243-72-8P
 1061243-74-0P 1061243-78-4P 1061243-79-5P
 1061243-82-0P 1061243-83-1P 1061243-84-2P
 1061243-87-5P 1061243-88-6P 1061243-91-1P
 1061243-92-2P 1061243-94-4P 1061243-95-5P
 1061243-97-7P 1061243-99-9P 1061244-00-5P
 1061244-02-7P 1061244-04-9P 1061244-06-1P
 1061244-08-3P 1061244-09-4P 1061244-11-8P
 1061244-14-1P 1061244-15-2P 1061244-17-4P
 1061244-19-6P 1061244-21-0P 1061244-23-2P
 1061244-26-5P 1061244-28-7P 1061244-30-1P
 1061244-31-2P 1061244-32-3P 1061244-33-4P
 1061244-34-5P 1061244-38-9P 1061244-39-0P
 1061244-40-3P 1061244-41-4P 1061244-45-8P
 1061244-46-9P 1061244-49-2P 1061244-53-8P
 1061244-58-3P 1061244-60-7P 1061244-62-9P
 1061244-65-2P 1061244-67-4P 1061244-69-6P
 1061244-71-0P 1061244-73-2P 1061244-74-3P
 1061244-77-6P 1061244-80-1P 1061244-81-2P
 1061244-85-6P 1061244-88-9P 1061244-90-3P
 1061244-93-6P 1061244-94-7P 1061244-96-9P
 1061245-00-8P 1061245-02-0P 1061245-05-3P
 1061245-08-6P 1061245-10-0P 1061245-13-3P
 1061245-17-7P 1061245-19-9P 1061245-23-5P
 1061245-25-7P 1061245-29-1P 1061245-32-6P
 1061245-34-8P 1061245-36-0P 1061245-39-3P
 1061245-42-8P 1061245-46-2P 1061245-50-8P
 1061245-53-1P 1061245-56-4P 1061245-57-5P
 1061245-61-1P 1061245-65-5P 1061245-68-8P
 1061245-71-3P 1061245-72-4P 1061245-74-6P
 1061245-75-7P 1061245-78-0P 1061245-81-5P
 1061245-84-8P 1061245-85-9P 1061245-86-0P
 1061245-89-3P 1061245-92-8P 1061245-93-9P
 1061245-94-0P 1061245-96-2P 1061245-99-5P
 1061246-01-2P 1061246-03-4P


RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phosphonate conjugates as kinase inhibitors useful as antitumor agents)

RN 1060764-61-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-63-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-65-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-66-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

C1

RN 1060764-68-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B

C1


RN 1060764-70-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060764-72-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060764-73-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060764-75-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060764-77-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-79-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-80-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-82-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-84-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

Cl

RN 1060764-86-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

Cl

RN 1060764-88-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060764-89-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1060764-91-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1060764-93-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060764-95-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060764-96-6 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1060764-98-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-00-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A







RN 1060765-01-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-02-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-03-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



—Cl

RN 1060765-04-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1060765-05-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1060765-07-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-09-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-11-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-12-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-13-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-14-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-15-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-17-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-19-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-22-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-25-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-28-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B




RN 1060765-31-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-34-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-37-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-40-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-43-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-46-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-49-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-51-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1060765-54-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-57-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-59-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1060765-64-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1060765-66-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1060765-69-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1060765-71-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

Cl

RN 1060765-78-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

Cl

RN 1060765-80-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

—C1

RN 1060765-83-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A





PAGE 1-B





RN 1060765-86-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1060765-89-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1060765-91-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1060765-93-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 1-B




RN 1061231-67-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061242-41-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A







PAGE 1-B

RN 1061242-42-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A





PAGE 1-B




RN 1061242-44-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1061242-46-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-47-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061242-49-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-50-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-53-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-56-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1061242-58-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-59-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-60-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-62-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-64-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-66-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B



RN 1061242-68-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-69-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-72-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-75-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-76-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-77-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-78-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-80-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1061242-81-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-83-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061242-84-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-87-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061242-90-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-91-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-92-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061242-93-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061242-95-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061242-97-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061243-00-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-01-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B



RN 1061243-04-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061243-06-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061243-08-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-10-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-13-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061243-15-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061243-18-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061243-21-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061243-23-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061243-26-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061243-27-3 HCAPLUS
 CN 2,4,8-Trioxa-9-aza-5-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno-
 xy]-2-pyridinyl]-5-hydroxy-10-oxo-, 1-(1-methylethyl) ester, 5-oxide (CA
 INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061243-30-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061243-31-9 HCAPLUS
CN 2,4,8-Trioxa-9-aza-5-phosphadecanoic acid,
10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]-10-oxo-5-phenoxy-, 1-methylethyl ester, 5-oxide (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061243-34-2 HCAPLUS
 CN 2,4,8-Trioxa-9-aza-5-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminol]phenoxy]-2-pyridinyl]-10-oxo-5-(phenylmethoxy)-, 1-methylethyl ester, 5-oxide
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-37-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-39-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1061243-40-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061243-41-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061243-42-2 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(carboxymethoxy)[(2,2-dimethyl-1-oxopropoxy)methoxy]phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-45-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-48-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-49-9 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(carboxymethoxy)(phenylmethoxy)phosphinyl]methyl]hydrazide] (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061243-50-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1061243-53-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061243-56-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-58-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-59-1 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(2-ethoxy-2-oxoethoxy) (phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-63-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-64-8 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(1-carboxyethoxy) [(2,2-dimethyl-1-oxopropoxy)methoxy]phosphinyl)methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-66-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-67-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

—Cl

RN 1061243-68-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminophenoxy]-, 2-[[[1-carboxyethoxy](phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—Cl

RN 1061243-71-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1061243-72-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061243-74-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-78-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-79-5 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(2-ethoxy-1-methyl-2-oxoethoxy) (phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-82-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-83-1 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(1-carboxypropoxy) [(2,2-dimethyl-1-oxopropoxy)methoxy]phosphinyl)methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-84-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-87-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B

—Cl

RN 1061243-88-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[1-carboxypropoxy] (phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 1061243-91-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-92-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-94-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-95-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061243-97-7 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminophenoxy]-, 2-[[[1-(ethoxycarbonyl)propoxy](phenylmethoxy)phosphinyl]methyl]hydrazide
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061243-99-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1061244-00-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061244-02-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-04-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-06-1 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(carboxymethyl)amino](phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 1061244-08-3 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[hydroxy(2-methoxy-2-oxoethyl)amino]phosphinyl]methyl]hydrazide (CA INDEX NAME)




RN 1061244-09-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-11-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-14-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B




RN 1061244-15-2 HCAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(2-methoxy-2-oxoethyl)amino] (phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)




RN 1061244-17-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-19-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061244-21-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-23-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-26-5 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[[(2-ethoxy-2-oxoethyl)amino](phenylmethoxy)phosphinyl]methyl]hydrazide
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061244-28-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-30-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-31-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-32-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-33-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-34-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B



RN 1061244-38-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061244-39-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-40-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-41-4 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[hydroxy(phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061244-45-8 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[[phenoxy(phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Cl

RN 1061244-46-9 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminophenoxy]-, 2-[[bis(phenylmethoxy)phosphinyl]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Cl

RN 1061244-49-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061244-53-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A




PAGE 1-B



RN 1061244-58-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061244-60-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-62-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-65-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061244-67-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061244-69-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-71-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-73-2 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[2-[(2-ethoxy-2-oxoethoxy)(phenylmethoxy)phosphinyl]ethyl]hydrazide (CA INDEX NAME)


PAGE 1-A





PAGE 1-B





RN 1061244-74-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1061244-77-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-80-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061244-81-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061244-85-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-88-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061244-90-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061244-93-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-94-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061244-96-9 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[2-[(2-ethoxy-1-methyl-2-oxoethoxy)(phenylmethoxy)phosphinyl]ethyl]hydrazide (CA INDEX NAME)


PAGE 1-A





PAGE 1-B





RN 1061245-00-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1061245-02-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-05-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-08-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-10-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061245-13-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-17-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-19-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061245-23-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061245-25-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B





RN 1061245-29-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-32-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-34-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-36-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-39-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-42-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061245-46-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-50-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-53-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-56-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[2-[(2-methoxy-2-oxoethyl)amino](phenylmethoxy)phosphinyl]ethyl]hydrazide (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 1061245-57-5 HCAPLUS



CN INDEX NAME NOT YET ASSIGNED





RN 1061245-61-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-65-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-68-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-71-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-72-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-74-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-75-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-78-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-81-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B





RN 1061245-84-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061245-85-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-86-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061245-89-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061245-92-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061245-93-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061245-94-0 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-[2-[bis(phenylmethoxy)phosphinyl]ethyl]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061245-96-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061245-99-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-01-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 1-B



RN 1061246-03-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1061246-04-5P 1061246-05-6P 1061246-08-9P
 1061246-09-0P 1061246-11-4P 1061246-13-6P
 1061246-14-7P 1061246-16-9P 1061246-18-1P
 1061246-19-2P 1061246-21-6P 1061246-24-9P
 1061246-26-1P 1061246-27-2P 1061246-29-4P
 1061246-31-8P 1061246-33-0P 1061246-34-1P
 1061246-36-3P 1061246-38-5P 1061246-40-9P
 1061246-41-0P 1061246-42-1P 1061246-45-4P
 1061246-47-6P 1061246-48-7P 1061246-49-8P
 1061246-51-2P 1061246-53-4P 1061246-56-7P
 1061246-57-8P 1061246-59-0P 1061246-60-3P
 1061246-62-5P 1061246-63-6P 1061246-65-8P
 1061246-66-9P 1061246-68-1P 1061246-70-5P
 1061246-72-7P 1061246-74-9P 1061246-76-1P
 1061246-77-2P 1061246-78-3P 1061246-79-4P
 1061246-82-9P 1061246-84-1P 1061246-86-3P
 1061246-87-4P 1061246-90-9P 1061246-93-2P
 1061246-94-3P 1061246-95-4P 1061246-96-5P
 1061246-98-7P 1061247-01-5P 1061247-04-8P
 1061247-05-9P 1061247-07-1P 1061247-08-2P
 1061247-11-7P 1061247-14-0P 1061247-15-1P
 1061247-16-2P 1061247-17-3P 1061247-18-4P
 1061247-20-8P 1061247-22-0P 1061247-25-3P
 1061247-28-6P 1061247-30-0P 1061247-31-1P
 1061247-32-2P 1061247-33-3P 1061247-35-5P
 1061247-36-6P 1061247-40-2P 1061247-42-4P
 1061247-43-5P 1061247-45-7P 1061247-46-8P
 1061247-48-0P 1061247-50-4P 1061247-53-7P
 1061247-54-8P 1061247-55-9P 1061247-56-0P
 1061247-58-2P 1061247-61-7P 1061247-63-9P
 1061247-64-0P 1061247-65-1P 1061247-66-2P
 1061247-67-3P 1061247-69-5P 1061247-72-0P
 1061247-75-3P 1061247-78-6P 1061247-80-0P
 1061247-81-1P 1061247-83-3P 1061247-84-4P
 1061247-87-7P 1061247-90-2P 1061247-92-4P
 1061247-93-5P 1061247-94-6P 1061247-95-7P
 1061248-01-8P 1061248-04-1P 1061248-06-3P


1061243-09-6P 1061248-11-0P 1061248-14-3P
 1061243-17-6P 1061248-20-1P 1061248-24-5P
 1061248-27-8P 1061248-29-0P 1061248-32-5P
 1061248-34-7P 1061248-37-0P 1061248-40-5P
 1061248-42-7P 1061248-45-0P 1061248-48-3P
 1061248-51-8P 1061248-54-1P 1061248-57-4P
 1061248-60-9P 1061248-62-1P 1061248-64-3P
 1061248-66-5P 1061248-68-7P 1061248-70-1P
 1061248-72-3P 1061248-75-6P 1061248-78-9P
 1061248-82-5P 1061248-84-7P 1061248-86-9P
 1061248-89-2P 1061248-92-7P 1061248-95-0P
 1061248-99-4P 1061249-02-2P 1061249-04-4P
 1061249-07-7P 1061249-09-9P 1061249-12-4P
 1061249-14-6P 1061249-17-9P 1061249-20-4P
 1061249-23-7P 1061249-26-0P 1061249-28-2P
 1061249-30-6P 1061249-32-8P 1061249-34-0P
 1061249-36-2P 1061249-38-4P 1061249-42-0P
 1061249-46-4P 1061249-49-7P 1061249-52-2P
 1061249-57-7P 1061249-59-9P 1061249-61-3P
 1061249-63-5P 1061249-65-7P 1061249-68-0P
 1061249-71-5P 1061249-74-8P 1061249-77-1P
 1061249-80-6P 1061249-82-8P 1061249-84-0P
 1061249-86-2P 1061249-89-5P 1061249-92-0P
 1061249-95-3P 1061249-99-7P 1061250-03-0P
 1061250-05-2P 1061250-07-4P 1061250-09-6P
 1061250-11-0P 1061250-13-2P 1061250-16-5P
 1061250-19-8P 1061250-22-3P 1061250-25-6P
 1061250-27-8P 1061250-30-3P 1061250-33-6P
 1061250-35-8P 1061250-37-0P 1061250-39-2P
 1061250-42-7P 1061250-45-0P 1061250-48-3P
 1061250-51-8P 1061250-54-1P 1061250-56-3P
 1061250-59-6P 1061250-62-1P 1061250-65-4P
 1061250-68-7P 1061250-71-2P 1061250-73-4P
 1061250-76-7P 1061250-79-0P 1061250-82-5P
 1061250-85-8P 1061250-87-0P 1061250-91-6P
 1061250-94-9P 1061250-97-2P 1061251-02-2P
 1061251-04-4P 1061251-07-7P 1061251-10-2P
 1061251-17-9P 1061251-19-1P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(preparation of phosphonate conjugates as kinase inhibitors useful as
 antitumor agents)

RN 1061246-04-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






PAGE 1-B

RN 1061246-05-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A





PAGE 1-B





RN 1061246-08-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1061246-09-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061246-11-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




PAGE 1-B



RN 1061246-13-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-14-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-16-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-18-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-19-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-21-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B





RN 1061246-24-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1061246-26-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-27-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-29-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-31-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-33-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-34-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-36-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-38-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-40-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B



RN 1061246-41-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-42-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-45-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-47-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-48-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-49-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-51-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-53-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-56-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-57-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B



RN 1061246-59-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-60-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061246-62-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-66-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-68-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-70-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-72-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-74-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061246-76-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-77-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061246-78-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-79-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-82-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-84-1 HCAPLUS
 CN 2,4,7-Trioxa-9-aza-5-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminolpheno-
 xy]-2-pyridinyl]-5-hydroxy-10-oxo-, 1-(1-methylethyl) ester, 5-oxide (CA
 INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061246-86-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-87-4 HCAPLUS

CN 2,4,7-Trioxa-9-aza-5-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]-10-oxo-5-phenoxy-, 1-methylethyl ester, 5-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061246-90-9 HCAPLUS

CN 2,4,7-Trioxa-9-aza-5-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]-10-oxo-5-(phenylmethoxy)-, 1-methylethyl ester, 5-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 1061246-93-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-94-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061246-95-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-96-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061246-98-7 HCAPLUS
 CN 3,7-Dioxa-9-aza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno-
 xy]-2-pyridinyl]-4-[(2,2-dimethyl-1-oxopropoxy)methoxy]-10-oxo-, 4-oxide
 (CA INDEX NAME)



PAGE 1-A





PAGE 1-B



RN 1061247-01-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1061247-04-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-05-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-07-1 HCAPLUS
 CN 3,7-Dioxa-9-aza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-4-hydroxy-10-oxo-, 1-ethyl ester, 4-oxide (CA INDEX
 NAME)

PAGE 1-A




PAGE 1-B




RN 1061247-08-2 HCAPLUS
 CN 3,7-Dioxa-9-aza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-4-[(2,2-dimethyl-1-oxopropoxy)methoxy]-10-oxo-, ethyl
 ester, 4-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061247-11-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-14-0 HCAPLUS
CN 3,7-Dioxa-9-aza-4-phosphadecanoic acid,
10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminopheno-
xy]-2-pyridinyl]-10-oxo-4-phenoxy-, ethyl ester, 4-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061247-15-1 HCAPLUS
 CN 3,7-Dioxa-9-aza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminolpheno
 xy]-2-pyridinyl]-10-oxo-4-(phenylmethoxy)-, ethyl ester, 4-oxide (CA
 INDEX NAME)



PAGE 1-A





PAGE 1-B



RN 1061247-16-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1061247-17-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-18-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-25-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-28-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-30-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-31-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-32-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A




PAGE 1-B



RN 1061247-33-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-40-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-42-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061247-43-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B




RN 1061247-45-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-46-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-48-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-50-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-53-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-56-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-58-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-61-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A



PAGE 1-B





RN 1061247-63-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-64-0 HCAPLUS

CN 2,4-Dioxa-6-aza-5-phosphaoctanedioic acid,
5-[2-[[[[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]carbonyl]amino]methoxy]ethyl]-, 8-methyl 1-(1-methylethyl) ester, 5-oxide (CA INDEX NAME)





RN 1061247-65-1 HCAPLUS



CN INDEX NAME NOT YET ASSIGNED





RN 1061247-66-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-67-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-69-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061247-72-0 HCAPLUS
CN 2,4-Dioxo-6-aza-5-phosphaoctanedioic acid,
5-[2-[[[[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]carbonyl]amino]methoxy]ethyl]-, 8-ethyl 1-(1-methylethyl) ester,
5-oxide (CA INDEX NAME)





RN 1061247-75-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-78-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-80-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061247-81-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-83-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-84-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-87-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-90-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061247-92-4 HCAPLUS
 CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid,
 5-[2-[[[[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]carbonyl]amino]methoxy]ethyl]-, 1,9-bis(1-methylethyl) ester,
 5-oxide (CA INDEX NAME)



PAGE 1-A





PAGE 1-B



RN 1061247-93-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1061247-94-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061247-95-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-01-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-04-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-06-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-09-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-11-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-14-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-17-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B





RN 1061248-20-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-24-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061248-27-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-29-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061248-32-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-34-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-37-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-40-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-42-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-45-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B





RN 1061248-48-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-51-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061248-54-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-57-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061248-60-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061248-62-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-64-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-66-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B




RN 1061248-68-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061248-70-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061248-72-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-75-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-78-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-82-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061248-84-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-86-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061248-89-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061248-92-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B





RN 1061248-95-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061248-99-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-02-2 HCAPLUS
CN 3,6,8-Triaza-4-phosphanonanoic acid,
9-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]-4-hydroxy-9-oxo-, 1-methyl ester, 4-oxide (CA INDEX NAME)





RN 1061249-04-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061249-07-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-09-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-12-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-14-6 HCAPLUS

CN 3,6,8-Triaza-4-phosphanonanoic acid,
9-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinyl]-4-hydroxy-9-oxo-, 1-ethyl ester, 4-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061249-17-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-20-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-23-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-26-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-28-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-30-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061249-32-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-34-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-36-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-38-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B





RN 1061249-42-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-46-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061249-49-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-52-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061249-57-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



RN 1061249-59-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-61-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-63-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B





RN 1061249-65-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-68-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-71-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-74-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-77-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061249-80-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061249-82-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-84-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-86-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061249-89-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061249-92-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-95-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061249-99-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-03-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-05-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-11-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A





PAGE 1-B





RN 1061250-13-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-16-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061250-19-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-22-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061250-25-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-27-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B



RN 1061250-30-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-33-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-35-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-37-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A





PAGE 1-B





RN 1061250-39-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-42-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061250-45-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-48-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-51-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-54-1 HCAPLUS
 CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-4-hydroxy-10-oxo-, 1-methyl ester, 4-oxide (CA INDEX
 NAME)

PAGE 1-A




PAGE 1-B




RN 1061250-56-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-59-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-62-1 HCAPLUS
 CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]aminol]pheno-
 xyl-2-pyridinyl]-10-oxo-4-phenoxy-, methyl ester, 4-oxide (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1061250-65-4 HCAPLUS
 CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-10-oxo-4-(phenylmethoxy)-, methyl ester, 4-oxide (CA
 INDEX NAME)



PAGE 1-A





PAGE 1-B



RN 1061250-68-7 HCAPLUS
 CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-4-hydroxy-10-oxo-, 1-ethyl ester, 4-oxide (CA INDEX
 NAME)




RN 1061250-71-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061250-73-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061250-76-7 HCAPLUS

CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-10-oxo-4-phenoxy-, ethyl ester, 4-oxide (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 1061250-79-0 HCAPLUS



CN 3,7,9-Triaza-4-phosphadecanoic acid,
 10-[4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]pheno
 xy]-2-pyridinyl]-10-oxo-4-(phenylmethoxy)-, ethyl ester, 4-oxide (CA
 INDEX NAME)





RN 1061250-82-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-85-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-87-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-91-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-94-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061250-97-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1061251-02-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1061251-04-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061251-07-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1061251-10-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1061251-17-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A



PAGE 1-B



RN 1061251-19-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 1012058-78-4

RL: PRPH (Prophetic); RCT (Reactant); RACT (Reactant or reagent)
 (preparation of phosphonate conjugates as kinase inhibitors useful as
 antitumor agents)

RN 1012058-78-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 138 THERE ARE 138 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L41 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1179520 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:469333

TITLE: Inhibition of raf kinase using substituted
 heterocyclic ureas

INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.;
 Paulsen, Holger; Riedl, Bernd; Scott, William
 J.; Smith, Roger A.; Wood, Jill E.;
 Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee,
 Wendy; Redman, Aniko; Sibley, Robert;
 Renick, Joel


PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 111pp., Div. of U.S. Ser. No.
 640,780.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070244120	A1	20071018	US 2007-768112	20070625 <--
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			US 2000-640780	A3 20000818 <--
MARPAT 147:469333				
ED Entered STN: 19 Oct 2007				
GI				



AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenoxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave 70% II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μ M.


IT 228999-89-1F 228999-90-4F 228999-91-5F
 228999-92-6F 229000-02-6F 229000-05-9F
 229000-12-8F 229000-13-9F 229000-14-0F
 229000-16-2F 229000-27-5F 229000-69-5F
 229000-74-2F 229001-03-0F 229001-05-2F
 229001-07-4F 229001-08-5F 229001-38-1F
 229001-50-7F 229001-51-8F 229002-35-1F
 229002-36-2F 229002-37-3F 229002-38-4F
 229002-39-5F 229002-40-8F 229002-41-9F
 229002-86-2F 229003-10-5F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)


RN 228999-89-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 228999-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-91-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-92-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-02-6 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-05-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229000-13-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 229000-27-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 229000-69-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[3-(1-methylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



PAGE 1-A


U

RN 229000-74-2 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[3-(1-methylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 229001-03-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)

PAGE 1-A




U

RN 229001-05-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




U

RN 229001-07-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 229001-08-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


U

RN 229001-38-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229001-50-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229001-51-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-35-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-36-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 229002-37-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229002-38-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-39-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-40-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-41-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-86-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[1-(methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 229003-10-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



PAGE 1-A

U

L41 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:691680 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:118041
 TITLE: Omega-carboxyaryl substituted diphenyl ureas as raf
 kinase inhibitors
 INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger,
 Timothy B.; Scott, William J.; Smith,
 Roger A.; Wood, Jill E.; Monahan, Mary-Katherine;
 Natero, Reina; Renick, Joel; Sibley, Robert N.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: U.S., 52pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7235576	B1	20070626	US 2002-42203	20020111 <--
US 20030144278	A1	20030731	US 2002-283248	20021030 <--
US 20080108672	A1	20080508	US 2007-768104	20070625 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P 20010112 <--
			US 2002-42203	A1 20020111 <--

OTHER SOURCE(S): MARPAT 147:118041

ED Entered STN: 27 Jun 2007

AB Aryl ureas A-NHCONH-B [A, B = C5-40 (poly)aryl, optionally containing 0-4 N, O, S heteroatoms, optionally substituted by (hetero)aryl, (hetero)aryloxy, halo, cyano, nitro, alkoxy, alkylthio, amino, hydroxyalkyl, sulfo, acyl, carboxamido-groups], useful as Raf-kinase inhibitors for treatment and inhibition of cancerous cell growth, were prepared by standard synthetic procedures by reactions of the corresponding isocyanates with aromatic amines and tested for inhibition of Raf kinase and growth of human tumor cell lines HCT116 and DLD-1, exhibiting IC50 values of 1 nM to 10 µM. In an example, N-(4-chloro-3-trifluoromethylphenyl)-N'-[4-(2-methylaminocarbonyl-4-pyridinyloxy)phenyl]urea was prepared by reaction of 65.9 mmol of 4-chloro-3-trifluoromethylphenyl isocyanate with 65.77 mmol of 4-(2-methylaminocarbonyl-4-pyridinyloxy)aniline in CH2Cl2 at room temperature for 22 h with 93% yield.

IT 943024-26-8P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors
 for treatment and inhibition of cancerous cell growth)


RN 943024-26-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]phenoxy]-N-methyl-,
 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-44-5


CMF C22 H19 F3 N4 O4



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



IT 475207-59-1P 943024-27-9P 943024-28-0P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase
 inhibitors
 for treatment and inhibition of cancerous cell growth)


RN 475207-59-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-,
 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0


CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 943024-27-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-74-1


CMF C20 H14 Cl F3 N4 O3



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 943024-28-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284462-31-3


CMF C22 H18 Cl F3 N4 O4



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




IT 284461-44-5P 284462-71-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)


RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-71-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-42-3P 284461-43-4P 284461-45-6P
 284461-47-8P 284461-48-9P 284461-49-0P
 284461-50-3P 284461-51-4P 284461-55-8P
 284461-58-1P 284461-60-5P 284461-61-6P
 284461-62-7P 284461-63-8P 284461-64-9P
 284461-73-0P 284461-74-1P 284461-75-2P
 284461-76-3P 284461-78-5P 284461-80-9P
 284461-81-0P 284461-82-1P 284461-83-2P
 284461-88-7P 284461-91-2P 284461-97-8P
 284461-98-9P 284462-01-7P 284462-02-8P
 284462-03-9P 284462-04-0P 284462-05-1P
 284462-17-5P 284462-18-6P 284462-19-7P
 284462-20-0P 284462-22-2P 284462-23-3P
 284462-24-4P 284462-25-5P 284462-26-6P
 284462-27-7P 284462-28-8P 284462-29-9P
 284462-30-2P 284462-31-3P 284462-32-4P
 284462-35-7P 284670-98-0P 447457-08-1P
 447457-09-2P 573673-43-5P 943011-56-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);


BIOL (Biological study); PREP (Preparation)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors

for treatment and inhibition of cancerous cell growth)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-64-9 HCAPLUS


CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-73-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-82-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-88-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284462-26-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-31-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)]




RN 447457-08-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




RN 447457-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 573673-43-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 943011-56-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-ethyl- (CA INDEX NAME)



IT 284462-06-2 284462-76-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors

for treatment and inhibition of cancerous cell growth)

RN 284462-06-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Cl

RN 284462-76-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L41 ANSWER 4 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:962905 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:211873
 TITLE: Preparation of substituted heterocyclic ureas for
 inhibition of raf kinase
 INVENTOR(S): Scott, William J.; Redman, Aniko;
 Johnson, Jeffrey; Wood, Jill E.; Paulsen, Holger;
 Khire, Uday; Dumas, Jacques; Smith, Roger A.
 ; Lee, Wendy; Hatoum-Mokdad, Holia; Riedl,
 Bernd; Lowinger, Timothy Bruno
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: Aust. Pat. Appl., 148 pp., Division of Austl. 2003
 204708.
 CODEN: AUXXCM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2006201959	A1	20060601	AU 2006-201959	20060511 <--
AU 2006201959	B2	20080904		
AU 2003204708	A1	20030717	AU 2003-204708	20030613 <--
AU 2003204708	B2	20060525		
AU 2008252068	A1	20090108	AU 2008-252068	20081204
PRIORITY APPLN. INFO.:			AU 2003-204708	A3 20030613 <--
			AU 1999-21989	A3 19981222 <--
			WO 1998-US26078	W 19981222 <--
			AU 2006-201959	A3 20060511

OTHER SOURCE(S): CASREACT 147:211873; MARPAT 147:211873

ED Entered SIN: 19 Sep 2006


GI




- AB The title compds. ANHC(O)NHB [I; A = (un)substituted pyrazolyl, isoxazolyl, thienyl, etc.; B = (un)substituted Ph, pyridinyl, indolyl, isoquinolyl, etc.], useful in treating raf mediated diseases such as cancer, were prepared Thus, reacting 5-tert-butyl-3-thiophene-ammonium chloride with 4-phenoxyphenyl isocyanate in DMF afforded II. All exemplified compds. I displayed IC₅₀ of between 1 nM and 10 μM when tested in in vitro raf kinase assay. Pharmaceutical composition comprising the compound I is disclosed.
- IT 228999-89-1P 228999-90-4P 228999-91-5P
 228999-92-6P 229000-02-6P 229000-05-9P
 229000-12-8P 229000-13-9P 229000-14-0P
 229000-16-2P 229000-27-5P 229000-69-5P
 229000-74-2P 229001-03-0P 229001-05-2P

(preparation of substituted heterocyclic ureas for inhibition of raf


CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




CN 2-Pyridinecarboxamide, 4-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-02-6 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-05-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 229000-13-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



U


RN 229000-74-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[3-(1-methylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 229001-03-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229001-05-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)






RN 229001-07-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 229001-08-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




U


RN 229001-38-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 229001-50-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229001-51-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-35-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-36-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 229002-37-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229002-38-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-39-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-40-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-41-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-86-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[1-(methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 229003-10-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[2-chloro-4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



PAGE 1-A

U


L41 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:99470 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:197889
 TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for
 treatment of raf, VEGFR, PDGFR, p38 and flt-3
 kinase-mediated diseases
 INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl,
 Bernd; Wilhelm, Scott
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722 <--
WO 2005009961	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004259760	A1	20050203	AU 2004-259760	20040722 <--
CA 2532865	A1	20050203	CA 2004-2532865	20040722 <--
US 20050038080	A1	20050217	US 2004-895985	20040722 <--
EP 1663978	A2	20060607	EP 2004-786091	20040722 <--
EP 1663978	B1	20071128		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004012219	A	20060822	BR 2004-12219	20040722 <--
CN 1856469	A	20061101	CN 2004-80021091	20040722 <--
JP 2006528196	T	20061214	JP 2006-521221	20040722 <--
ES 2297490	T3	20080501	ES 2004-786091	20040722 <--
KR 2006052866	A	20060519	KR 2006-701558	20060123 <--
MX 2006000860	A	20060720	MX 2006-860	20060123 <--
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123 <--
NO 2006000870	A	20060407	NO 2006-870	20060222 <--
PRIORITY APPLN. INFO.:			US 2003-489102P	P 20030723 <--
			US 2004-540326P	P 20040202
			WO 2004-US23500	W 20040722

OTHER SOURCE(S): CASREACT 142:197889

ED Entered STN: 04 Feb 2005

GI




AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

IT 755037-03-7P, 4-[4-[N'-(4-Chloro-3-trifluoromethylphenyl)ureido]-3-fluorophenoxy]pyridine-2-carboxylic acid methylamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

RN 755037-03-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)



IT 835621-07-3P 835621-08-4P 835621-09-5P


835621-11-9P 835621-12-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

RN 835621-07-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)




RN 835621-08-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 755037-03-7

CMF C21 H15 Cl F4 N4 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 835621-09-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 755037-03-7

CMF C21 H15 Cl F4 N4 O3



CM 2


CRN 98-11-3

CMF C6 H6 O3 S




RN 835621-11-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 835621-12-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-, 1-oxide (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:14200 HCAPLUS Full-text

DOCUMENT NUMBER: 142:86701

TITLE: Diaryl ureas for treatment of diseases mediated by PDGFR

INVENTOR(S): Wilhelm, Scott; Dumas, Jacques; Ladouceur, Gaetan; Lynch, Mark; Scott, William J.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000284	A2	20050106	WO 2004-US15653	20040519 <--
WO 2005000284	A3	20050310		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2526636	A1	20050106	CA 2004-2526636	20040519 <--
US 20050059703	A1	20050317	US 2004-848567	20040519 <--
EP 1626714	A2	20060222	EP 2004-776037	20040519 <--
EP 1626714	B1	20070704		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2006528986	T	20061228	JP 2006-533210	20040519 <--
AT 366108	T	20070715	AT 2004-776037	20040519 <--
ES 2288694	T3	20080116	ES 2004-776037	20040519 <--
AT 384264	T	20080215	AT 2004-752642	20040519 <--
ES 2305808	T3	20081101	ES 2004-752642	20040519 <--
MX 2005012486	A	20060703	MX 2005-12486	20051118 <--
PRIORITY APPLN. INFO.:			US 2003-471735P	P 20030520 <--
			US 2003-520399P	P 20031117 <--
			US 2004-556062P	P 20040325
			WO 2004-US15653	W 20040519


OTHER SOURCE(S): MARPAT 142:86701

ED Entered STN: 07 Jan 2005


AB The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR), especially PDGFR- β , by administering diaryl ureas. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other implantable device comprises an effective amount

of diaryl ureas. For example, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]-2-fluorophenyl] urea, and N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]-2-chlorophenyl]urea showed an IC50 of less than 10 µM in a pPDGFR-β sandwich ELISA in AoSMC cells.


IT 284461-73-0 284461-74-1 284461-80-9
 284462-18-6 284462-19-7 475207-59-1
 583840-03-3 583840-04-4 755037-03-7
 755037-03-7D, salts 819792-84-2 819792-85-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (diaryl ureas for prevention and/or treatment of diseases mediated by
 platelet-derived growth factor receptor)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX
 NAME)



RN 284461-74-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX
 NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 475207-59-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0


CMF C21 H16 Cl F3 N4 O3



CM 2


CRN 104-15-4

CMF C 7 H 8 O 3 S




RN 583840-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



RN 755037-03-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-

(CA INDEX NAME)




RN 755037-03-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
(CA INDEX NAME)




RN 819792-84-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
(CA INDEX NAME)



RN 819792-85-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[4-fluoro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:1154653 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:93545
 TITLE: Preparation of diaryl ureas with kinase inhibiting activity
 INVENTOR(S): Wilhelm, Scott; Dumas, Jacques; Ladouceur, Gaetan; Lynch, Mark; Scott, William J.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113274	A2	20041229	WO 2004-US15655	20040519 <--
WO 2004113274	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2526617	A1	20041229	CA 2004-2526617	20040519 <--
US 20050059703	A1	20050317	US 2004-848567	20040519 <--
EP 1636585	A2	20060322	EP 2004-752642	20040519 <--
EP 1636585	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007511203	T	20070510	JP 2006-533211	20040519 <--
AT 366108	T	20070715	AT 2004-776037	20040519 <--
ES 2288694	T3	20080116	ES 2004-776037	20040519 <--
AT 384264	T	20080215	AT 2004-752642	20040519 <--
ES 2305808	T3	20081101	ES 2004-752642	20040519 <--
MX 2005012491	A	20060929	MX 2005-12491	20051118 <--
US 20070020704	A1	20070125	US 2006-571100	20060728 <--
PRIORITY APPLN. INFO.:			US 2003-471735P	P 20030520 <--
			US 2003-520399P	P 20031117 <--

US 2004-556062P
WO 2004-US15655P 20040325
W 20040519OTHER SOURCE(S): MARPAT 142:93545
ED Entered STN: 30 Dec 2004
GI

AB Diaryl ureas B-NH-CO-NH-L-(CH₂)_m-X-(CH₂)_p-L₁-(Q)₁₋₃ [I; B = (un)substituted Ph, naphthyl, or heteroaryl; L, = (un)substituted Ph, naphthyl, or heteroaryl; X = bond, O, CO, NR₃, NR₃CO, S, CONR₃, CF₂, CC₁₂, CHF, CH(OH), C.tplbond.C, CH:CH, CR₄R₅; m, p = independently 0-4; L₁ = any group L, 5-6 membered cyclic structure; Q = independently COR₄, CO₂R₄, CONR₄R₅; each R₃-R₅ = independently H, (un)substituted C₁₋₅ alkyl, C₃₋₅ cycloalkyl, Ph, C₁₋₃ alkylphenyl, C₀₋₄ alkylheteroaryl], useful to treat diseases and conditions associated with signal transduction pathways comprising of at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. E.g., a multi-step synthesis of the urea II which produced dose-dependent 45-68% inhibition of tumor growth in a staged HCT 116 colon (mutant k-Ras) xenograft model.


IT 284461-42-3P 284461-43-4P 284461-44-5P
284461-45-6P 284461-47-8P 284461-48-9P
284461-49-0P 284461-50-3P 284461-51-4P
284461-55-8P 284461-58-1P 284461-60-5P
284461-61-6P 284461-62-7P 284461-63-8P
284461-64-9P 284461-73-0P 284461-74-1P
284461-75-2P 284461-76-3P 284461-78-5P
284461-80-9P 284461-81-0P 284461-82-1P
284461-83-2P 284461-86-5P 284461-88-7P
284461-91-2P 284461-97-8P 284461-98-9P
284462-01-7P 284462-02-8P 284462-03-9P
284462-04-0P 284462-05-1P 284462-06-2P
284462-17-5P 284462-18-6P 284462-19-7P
284462-20-0P 284462-21-1P 284462-22-2P
284462-23-3P 284462-24-4P 284462-25-5P
284462-26-6P 284462-27-7P 284462-28-8P
284462-29-9P 284462-30-2P 284462-31-3P
284462-32-4P 284462-33-5P 284462-35-7P
755037-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl ureas with kinase inhibiting activity)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284461-61-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-06-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


Cl

RN 284462-17-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-20-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-30-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-31-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-33-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 755037-03-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
 (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:756711 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:277641

TITLE: Preparation of bicyclic (hetero)aryl- and pyridine-containing diaryl ureas as Raf kinase and angiogenesis inhibitors useful in the treatment of cancer and other disorders

INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Verma, Sharad; Adnane, Lila; Chen, Yuanwei; Lee, Wendy; Phillips, Barton; Smith, Roger A.; Scott, William J.; Burke, Jennifer; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Miranda, Karl; Raudenbush, Brian; Redman, Aniko; Shao, Jianxing; Su, Ning; Wang, Gan; Yi, Lin; Zhu, Qingming

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078748	A2	20040916	WO 2004-US6287	20040301 <--
WO 2004078748	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516931	A1	20040916	CA 2004-2516931	20040301 <--
EP 1608639	A2	20051228	EP 2004-716166	20040301 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 JP 2006519265 T 20060824 JP 2006-508978 20040301 <--
 MX 2005009104 A 20060531 MX 2005-9104 20050826 <--
 PRIORITY APPLN. INFO.: US 2003-450348P P 20030228 <--
 WO 2004-US6287 W 20040301

OTHER SOURCE(S): MARPAT 141:277641
 ED Entered STN: 16 Sep 2004
 GI



- AB Title compds. I [wherein A = benzimidazolyl, 2,3-dihydro-1H-indolyl, 2,3-dihydro-1H-indenyl, 1H- or 2H-indazolyl, 1,3-benzodioxin-6-yl, quinoxaliny, etc.; B = (un)substituted Ph, naphthyl, pyridinyl, quinolinyl; L = (CH₂)_m-D-(CH₂)_n; m, n = independently 0-4; D = O, C(:O), NH and derivs., NHCO and derivs., S, CONH and derivs.; M = (un)substituted pyridine ring; Q = C(:O)H and derivs., CO₂H and derivs., CONH₂ and derivs.; and their pharmaceutically acceptable salts, prodrugs, and metabolites] were prepared as Raf kinase inhibitors for treating hyper-proliferative and angiogenesis disorders, alone or in combination with cytotoxic therapies. For example, urea II was prepared from 4-(4-Amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide (preparation given), triphosgene, 2-aminoquinoxaline, in the presence of DIPEA/anhydrous DMF at 75°. Selected I showed 80% inhibition of c-Raf kinase at 1 μM. Thus, I are useful for treating cancer and other Raf kinase-mediated diseases.
- IT 757249-67-5P, 4-[3-Fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757249-68-6P, Methyl 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxylate 757249-69-7P, 1-[4-[(2-Acetylpyridin-4-yl)oxy]phenyl]-3-(1-methyl-1H-indazol-5-yl)urea 757249-70-0P, 4-[4-[[[(1,3-Benzothiazol-6-ylamino)carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757249-71-1P, 4-[4-[[[(1-Methyl-1H-indazol-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757249-72-2P 757249-73-3P 757249-74-4P 757249-75-5P 757249-76-6P 757249-77-7P 757249-78-8P 757249-79-9P 757249-80-2P 757249-81-3P 757249-82-4P 757249-83-5P 757249-84-6P 757249-85-7P

757249-86-8P 757249-87-9P 757249-88-0P
 757249-89-1P 757249-90-4P 757249-91-5P
 757249-92-6P 757249-93-7P 757249-94-8P
 757249-95-9P 757249-96-0P 757249-97-1P
 757249-98-2P 757249-99-3P 757250-00-3P
 757250-01-4P 757250-02-5P 757250-03-6P
 757250-04-7P 757250-05-8P 757250-06-9P
 757250-07-0P 757250-08-1P 757250-09-2P
 757250-10-5P 757250-11-6P 757250-12-7P
 757250-13-8P 757250-14-9P 757250-15-0P
 757250-16-1P 757250-17-2P 757250-18-3P
 757250-19-4P 757250-20-7P 757250-21-8P
 757250-22-9P 757250-23-0P 757250-24-1P
 757250-25-2P 757250-26-3P 757250-27-4P,
 N-Methyl-4-[[[(2-methyl-1,3-benzothiazol-5-yl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide 757250-28-5P,
 4-[3-Chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-29-6P,
 4-[3-Chloro-4-[[[(1-oxo-2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-30-9P, 4-[3-Chloro-4-[[[quinoxalin-6-ylamino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-31-0P, 4-[3-Chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-32-1P, 4-[3-Chloro-4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-33-2P, 4-[3-Chloro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-34-3P,
 4-[2-Chloro-4-[[[(1-oxo-2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-35-4P, 4-[2-Chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-36-5P, 4-[2-Chloro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-37-6P,
 4-[2-Chloro-4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-38-7P, 4-[2-Chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-39-8P, 4-[2,4-Dichloro-5-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-40-1P,
 4-[2,4-Dichloro-5-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-41-2P, 4-[2,4-Dichloro-5-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-42-3P, 4-[4-Chloro-3-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-43-4P, 4-[4-Chloro-3-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-44-5P,
 4-[4-Chloro-3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 757250-45-6P,
 N-Methyl-4-[3-methyl-4-[[[(4-methyl-2-oxo-2H-chromen-7-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide 757250-46-7P, N-Methyl-4-[3-methyl-4-[[[(2-methyl-1,3-benzothiazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide 757250-47-8P, N-Methyl-4-[2-methyl-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-

carboxamide 757250-48-9P,
N-Methyl-4-[3-nitro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-53-6P, 4-[4-[[[(2-Methyl-1,3-benzothiazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-54-7P, 4-[4-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-55-8P, 4-[3-Fluoro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-56-9P, 4-[3-Chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-57-0P, 4-[3-Chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-58-1P, 4-[3-Chloro-4-[[[(1-oxo-2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-59-2P, 4-[2-Chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-60-5P, Methyl 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxylate
757250-61-6P, 4-[3-Fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)pyridine-2-carboxamide
757250-62-7P, N-[2-(Dimethylamino)-2-oxoethyl]-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-63-8P, 4-[3-Fluoro-4-[[[(6-nitro-1,3-benzothiazol-2-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-64-9P, N-Methyl-4-[4-[[[(6-nitro-1,3-benzothiazol-2-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-65-0P, 4-[4-[[[(4,6-Difluoro-1,3-benzothiazol-2-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-70-7P, 4-[3-Fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-71-8P, 4-[2,3-Difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-72-9P, 4-[3,5-Difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-73-0P, 4-[2,5-Difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-74-1P, N-Methyl-4-[3-methyl-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-77-4P, 4-[3-Chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-79-6P, 4-[4-Chloro-3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-81-0P, N-Methyl-4-[2-methyl-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-82-1P, N-Methyl-4-[3-nitro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-83-2P 757250-84-3P,
N-Methyl-5-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]nicotinamide 757250-85-4P,
4-[2,4-Dichloro-5-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
757250-87-6P, 4-[3-Fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-88-7P, 4-[3-Chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
757250-89-8P, 4-[2-Chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-

benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757250-90-1P, N-[2-(Methylamino)-2-oxoethyl]-4-[4-[[[(2,2,4,4-
 tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-
 2-carboxamide 757250-91-2P,
 N-[2-(Dimethylamino)-2-oxoethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-
 benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757250-92-3P 757250-93-4P,
 4-[3-[[[(1,3-Benzodioxol-5-ylamino)carbonyl]amino]phenoxy]-N-methylpyridine-
 2-carboxamide 757250-94-5P,
 4-[3-[[[(1,3-Benzodioxol-5-ylamino)carbonyl]amino]-4-chlorophenoxy]-N-
 methylpyridine-2-carboxamide 757250-95-6P,
 4-[4-[[[(1,3-Benzodioxol-5-ylamino)carbonyl]amino]phenoxy]-N-methylpyridine-
 2-carboxamide 757250-96-7P,
 4-[4-[[[(1,3-Benzodioxol-5-ylamino)carbonyl]amino]-3-chlorophenoxy]-N-
 methylpyridine-2-carboxamide 757250-97-8P,
 4-[4-[[[(1,3-Benzodioxol-5-ylamino)carbonyl]amino]-3-fluorophenoxy]pyridine-
 2-carboxamide 757250-98-9P,
 4-[3-[[[(2,3-Dihydro-1,4-benzodioxin-6-ylamino)carbonyl]amino]phenoxy]-N-
 methylpyridine-2-carboxamide 757250-99-0P,
 4-[4-Chloro-3-[[[(2,3-dihydro-1,4-benzodioxin-6-
 yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
 757251-00-6P, 4-[3-[[[(7-Fluoro-2,3-dihydro-1,4-benzodioxin-5-
 yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
 757251-01-7P, 4-[4-Chloro-3-[[[(6-fluoro-4H-1,3-benzodioxin-8-
 yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
 757251-02-8P, 4-[3-Chloro-4-[[[(6-fluoro-4H-1,3-benzodioxin-8-
 yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide
 757251-03-9P, 4-[3-Fluoro-4-[[[(6-fluoro-4H-1,3-benzodioxin-8-
 yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-05-1P, N-[3-(1H-Imidazol-1-yl)propyl]-4-[4-[[[(2,2,4,4-
 tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-
 2-carboxamide 757251-06-2P,
 N-[2-(Pyrrolidin-1-yl)ethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-
 benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-07-3P, N-Cyclopropyl-4-[4-[[[(1-methyl-1H-indazol-5-
 yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-08-4P, 4-[3-[[[(1-Methyl-1H-indazol-5-
 yl)amino]carbonyl]amino]phenoxy]-N-[2-(piperidin-1-yl)ethyl]pyridine-2-
 carboxamide 757251-09-5P,
 4-[3-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-pyridin-
 3-ylpyridine-2-carboxamide 757251-10-6P,
 4-[3,5-Difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-
 yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-11-9P, 4-[3-[[[(2,2,4,4-Tetrafluoro-4H-1,3-benzodioxin-6-
 yl)amino]carbonyl]amino]phenoxy]-N-oxo-2-(methylaminocarbonyl)pyridine
 757251-12-0P, N-Methyl-4-[3-(methylsulfonyl)-4-[[[(2,2,4,4-
 tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-
 2-carboxamide 757251-13-1P,
 N-[2-(Piperidin-1-yl)ethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-
 benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-14-2P, N-[2-(Piperazin-1-yl)ethyl]-4-[4-[[[(2,2,4,4-
 tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-
 2-carboxamide 757251-15-3P,
 N-Pyridin-2-yl-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-
 yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-16-4P, 4-[4-[[[(1-Methyl-1H-indazol-5-
 yl)amino]carbonyl]amino]phenoxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-
 carboxamide 757251-17-5P,
 4-[4-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-
 (piperazin-1-yl)ethyl]pyridine-2-carboxamide 757251-18-6P,


4-[4-[[[(2,3-Dihydro-1,4-benzodioxin-6-ylamino)carbonyl]amino]phenoxy]-N-[3-(1H-imidazol-1-yl)propyl]pyridine-2-carboxamide 757251-19-7P,
 4-[4-[[[(2,3-Dihydro-1,4-benzodioxin-6-ylamino)carbonyl]amino]phenoxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 757251-20-0P,
 N-[3-(1H-Imidazol-1-yl)propyl]-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-21-1P, 4-[4-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(piperidin-1-yl)ethyl]pyridine-2-carboxamide 757251-22-2P,
 N-(Cyclopropylmethyl)-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-23-3P, N-Cyclobutyl-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-24-4P, Methyl N-[[4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridin-2-yl]carbonyl]glycinate
 757251-25-5P, 4-[3-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 757251-26-6P,
 N-[3-(1H-Imidazol-1-yl)propyl]-4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-27-7P, N-[2-(Piperidin-1-yl)ethyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide 757251-28-8P,
 N-[2-(Pyrrolidin-1-yl)ethyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-29-9P, N-Pyridin-3-yl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-30-2P, N-[3-(1H-Imidazol-1-yl)propyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide 757251-31-3P,
 4-[2,5-Difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-32-4P, 4-[3-(Aminocarbonyl)-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-33-5P, 4-[2-Methoxy-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-34-6P, 4-[4-[[[(2,3-Dihydro-1H-inden-5-yl)amino]carbonyl]amino]-2-methoxyphenoxy]pyridine-2-carboxamide
 757251-80-2P, 4-[4-[[[(1,1-Dioxido-2,3-dihydrobenzo[b]thien-6-yl)amino]carbonyl]amino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
 757251-81-3P, N-Methyl-4-[3-[[[(1-methyl-1H-indazol-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 757251-82-4P, 5-[3-Fluoro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylnicotinamide
 757251-83-5P, N-Methyl-4-[4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide
 trifluoroacetate 757251-84-6P, Methyl
 4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-7-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxylate
 757251-85-7P, 5-[2-Fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methylnicotinamide
 757251-86-8P, 4-[2-Chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-7-yl)amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Raf kinase inhibitor; preparation of (hetero)aryl- and pyridine-containing diaryl ureas for treating cancer and other disorders)


RN 757249-67-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-68-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757249-69-7 HCAPLUS

CN Urea, N-[4-[(2-acetyl-4-pyridinyl)oxy]phenyl]-N'-(1-methyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 757249-70-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[(6-benzothiazolylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757249-71-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(1-methyl-1H-indazol-6-

yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757249-72-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2-methyl-6-benzoxazolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757249-73-3 HCAPLUS



CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1H-inden-4-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A






RN 757249-74-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2,2-difluoro-1,3-benzodioxol-4-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-75-5 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2-methyl-2H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757249-76-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-77-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(6-chloro-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-78-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(6-(trifluoromethoxy)-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-79-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(6-fluoro-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-80-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[6-methoxy-2-benzothiazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-81-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-chloro-2-benzoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-82-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2-methyl-1H-indol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757249-83-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(6-quinoxalinylamino)carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757249-84-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2-methyl-5-

benzothiazolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757249-85-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-86-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-87-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-88-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-89-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757249-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-5-benzofuranyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757249-91-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[(1H-benzotriazol-6-ylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757249-92-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[(1H-indazol-6-ylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)

ylamino)carbonylamino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-93-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[2-(trifluoromethyl)-1H-benzimidazol-6-yl]amino]carbonylamino]phenoxy]- (CA INDEX NAME)




RN 757249-94-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[1-ethyl-2-methyl-1H-benzimidazol-5-yl]amino]carbonylamino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-95-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[2-methyl-6-benzoxazolyl]amino]carbonylamino]phenoxy]- (CA INDEX NAME)




RN 757249-96-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]amino]carbonylamino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-97-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757249-98-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757249-99-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-00-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(2,3-dihydro-5-benzofuranyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-01-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[2-(trifluoromethyl)-1H-benzimidazol-6-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-02-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[1H-benzotriazol-6-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-03-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[6-fluoro-2-benzothiazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-04-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[6-(trifluoromethoxy)-2-benzothiazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-05-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[6-chloro-2-benzothiazolyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-06-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4,6-difluoro-2-benzothiazolyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-07-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[6-methoxy-2-benzothiazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757250-08-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[1-[2-(diethylamino)ethyl]-1H-indol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)



RN 757250-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[1-[2-(diethylamino)ethyl]-1H-indazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Net₂


RN 757250-10-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-11-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-12-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[6-(quinoxalinylamino)carbonyl]amino]phenoxy]]-N-methyl- (CA INDEX NAME)




RN 757250-13-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[2-methyl-5-benzothiazolyl]amino]carbonyl]amino]phenoxy]]-N-methyl- (CA INDEX NAME)




RN 757250-14-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[1,3-dihydro-2,2-dioxido-5-benzothienyl]amino]carbonyl]amino]-3-fluorophenoxy]]-N-methyl- (CA INDEX NAME)




RN 757250-15-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl]amino]carbonyl]amino]phenoxy]]-N-methyl- (CA INDEX NAME)




RN 757250-16-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-17-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-18-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2,4-difluoro-5-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-19-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-fluoro-3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-20-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-fluoro-5-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-21-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-6-fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-22-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-23-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-24-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 757250-25-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(6-quinoxalinylamino)carbonyl]amino]-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 757250-26-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 757250-27-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2-methyl-5-benzothiazolyl)amino]carbonyl]amino]-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 757250-28-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-29-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-30-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(6-quinoxalinyloxy)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-31-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-32-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-33-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-34-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-35-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-36-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-37-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-38-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-39-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2,4-dichloro-5-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-40-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2,4-dichloro-5-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757250-41-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2,4-dichloro-5-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-42-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-methyl-4-[[[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-46-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[3-methyl-4-[[[(2-methyl-5-benzothiazolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-47-8 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[2-methyl-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-48-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[3-nitro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757250-53-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methyl-5-benzothiazolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-54-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]amino]-3-fluorophenoxy]- (CA INDEX NAME)




RN 757250-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-56-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-57-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-58-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-59-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757250-60-5 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 757250-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (CA INDEX NAME)


PAGE 1-A






RN 757250-62-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)-2-oxoethyl]-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-63-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(6-nitro-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-64-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(6-nitro-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-65-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(4,6-difluoro-2-benzothiazolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-70-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-71-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2,3-difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-72-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3,5-difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2,5-difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-methyl-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-77-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-79-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[2-methyl-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-nitro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-83-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757250-84-3 HCAPLUS

CN 3-Pyridinecarboxamide, N-methyl-5-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-85-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2,4-dichloro-5-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-87-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-89-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-90-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(methylamino)-2-oxoethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757250-91-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-((dimethylamino)-2-oxoethyl)-4-[[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-92-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)


PAGE 1-A






RN 757250-93-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-94-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-4-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-95-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-96-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-3-fluorophenoxy]- (CA INDEX NAME)




RN 757250-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757250-99-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757251-00-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(7-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757251-01-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-chloro-3-[[[(6-fluoro-4H-1,3-benzodioxin-8-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 757251-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[(6-fluoro-4H-1,3-benzodioxin-8-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 757251-03-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[(6-fluoro-4H-1,3-benzodioxin-8-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)


PAGE 1-A






RN 757251-05-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-06-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-07-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-cyclopropyl-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-08-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 757251-09-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-3-pyridinyl- (CA INDEX NAME)




RN 757251-10-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3,5-difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-11-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



RN 757251-12-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[3-(methylsulfonyl)-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-13-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1-piperidinyl)ethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—F


RN 757251-14-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1-piperazinyl)ethyl]-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 757251-15-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-2-pyridinyl-4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-16-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 757251-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 757251-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 757251-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 757251-20-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 757251-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-(cyclopropylmethyl)-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-23-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-cyclobutyl-4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-24-4 HCAPLUS


CN Glycine, N-[[4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-2-pyridinyl]carbonyl]-, methyl ester (CA

INDEX NAME)




RN 757251-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 757251-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1-piperidinyl)ethyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

INDEX NAME)

PAGE 1-A




PAGE 1-B

—F


RN 757251-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-3-pyridinyl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-30-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-31-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2,5-difluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-(aminocarbonyl)-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-33-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-methoxy-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757251-34-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 757251-80-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,3-dihydro-1,1-dioxidobenzo[b]thien-6-yl)amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 757251-81-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[(1-methyl-1H-indazol-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-82-4 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[3-fluoro-4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757251-83-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]carbonyl]amino]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 757250-92-3

CMF C22 H16 F4 N4 O5

PAGE 1-A



PAGE 2-A



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 757251-84-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-7-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757251-85-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[2-fluoro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 757251-86-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-7-yl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 757251-77-7F, 1-[1-(tert-Butoxycarbonyl)indazol-5-yl]-3-[3-[[2-(methylaminocarbonyl)-4-pyridinyl]oxy]phenyl]urea 757251-79-9F,

4-[3-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxylic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of (hetero)aryl- and pyridine-containing diaryl

ureas

for treating cancer and other disorders)


RN 757251-77-7 HCAPLUS

CN 1H-Indazole-1-carboxylic acid, 5-[[[3-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 757251-79-9 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 757250-78-5, N-Methyl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide

757250-86-5, Methyl 4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxylate

757251-04-0, N-Methyl-4-[3-(methylthio)-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide 757251-78-8,

4-[4-[[[(1-Methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]pyridine-2-carboxamide


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (hetero)aryl- and pyridine-containing diaryl ureas for treating

cancer and other disorders)


RN 757250-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 757250-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757251-04-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-(methylthio)-4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 757251-78-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L41 ANSWER 9 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:756710 HCAPLUS Full-text


DOCUMENT NUMBER: 141:277628

TITLE: Preparation of ureidophenoxycyanopyridines as

INVENTOR(S): anticancer drugs.
 Scott, William J.; Dumas, Jacques;
 Boyer, Stephen; Lee, Wendy;
 Chen, Yuanwei; Phillips, Barton;
 Verma, Sharad; Chen, Jianqing; Chen,
 Zhi; Fan, Jianmei; Raudenbush, Brian
 ; Redman, Aniko; Yi, Lin;
 Zhu, Qingming
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078747	A1	20040916	WO 2004-US6286	20040301 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040235829	A1	20041125	US 2004-788029	20040227 <--
AU 2004217977	A1	20040916	AU 2004-217977	20040301 <--
CA 2517361	A1	20040916	CA 2004-2517361	20040301 <--
US 20040229937	A1	20041118	US 2004-789446	20040301 <--
US 20050032798	A1	20050210	US 2004-788405	20040301 <--
US 20050038031	A1	20050217	US 2004-788426	20040301 <--
EP 1599467	A1	20051130	EP 2004-716144	20040301 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007897	A	20060301	BR 2004-7897	20040301 <--
JP 2006519264	T	20060824	JP 2006-508977	20040301 <--
CN 1839126	A	20060927	CN 2004-80011547	20040301 <--
IN 2005DN03802	A	20070824	IN 2005-DN3802	20050826 <--
PRIORITY APPLN. INFO.:			US 2003-450323P	P 20030228 <--
			US 2003-450324P	P 20030228 <--
			US 2003-450348P	P 20030228 <--
			WO 2004-US6286	A 20040301

OTHER SOURCE(S): CASREACT 141:277628; MARPAT 141:277628
 ED Entered SIN: 16 Sep 2004
 GI




AB Title compds. [I; A = (substituted) pyridinyl, naphthyl, 8-10 membered bicyclic heteroaryl, heterocyclyl, carbocyclyl; B = (substituted) phenylene, naphthylenediyl; L = O, S; m = 0-3; R2 = alkyl, haloalkyl, alkoxy, N-oxo, N-hydroxy], were prepared. Thus, 2-trifluoromethyl-4-pyridylamine was stirred 20 h with carbonyldiimidazole in CH₂Cl₂; 4-(4-amino-3-fluorophenoxy)pyridine-2-carbonitrile (preparation given) was added followed by stirring for 1 day to give 75% title compound (II). I inhibited c-RAF-1 kinase with IC₅₀ = 7.86 nM to >1600 nM.

IT 284461-73-G, Bay 43-9006
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 10 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:756709 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:260780

TITLE: Preparation of 2-oxo-1,3,5-perhydrotriazapine derivatives for treatment of hyper-proliferative, angiogenesis, and inflammatory disorders

INVENTOR(S): Boyar, Stephen; Dumas, Jacques; Phillips, Barton; Scott, William J.; Smith, Roger A.; Chen, Jianqing; James, Benjamin; Wang, Gan

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078746	A2	20040916	WO 2004-US6283	20040301 <--
WO 2004078746	A3	20041202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2516624 A1 20040916 CA 2004-2516624 20040301 <--
 EP 1599466 A2 20051130 EP 2004-716136 20040301 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 JP 2006519182 T 20060824 JP 2006-501213 20040301 <--
 MX 2005009103 A 20060418 MX 2005-9103 20050826 <--
 ZA 2005006861 A 20060628 ZA 2005-6861 20050826 <--
 PRIORITY APPLN. INFO.: US 2003-450323P P 20030228 <--
 WO 2004-US6283 W 20040301


OTHER SOURCE(S): CASREACT 141:260780; MARPAT 141:260780
 ED Entered STN: 16 Sep 2004
 GI



I



III




II

- AB The title compds. I [A, B = 5-10 membered cyclic moieties which optionally substituted with 1-4 substituents selected from the group consisting of R1, OR1, NR1R2, etc.; L = a bridging group selected from -(CH2)m-O-(CH2)n-, -(CH2)m-(CH2)n-, -(CH2)m-C(O)-(CH2)n-, etc.; m, n = 0-4; M = Ph, naphthyl, 5- or 6- membered monocyclic heteroaryl consisting 1-3 heteroatoms selected from O, N, S, etc.; R1, R2 = H, alkyl, Ph, etc.] were prepared for treating hyperproliferative and angiogenesis disorders. For example, reaction of 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide with methylamine hydrochloride and formaldehyde furnished compound II. As prodrugs, compds. I will release diaryl ureas of the formula III when administrated.
- IT 284461-73-0, N-(4-Chloro-3(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea 755037-03-7
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (preparation of diaryl 2-oxo-1,3,5-perhydropyridazine derivs. for treatment

of hyper-proliferative, angiogenesis, and inflammatory disorders)


RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 755037-03-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:754414 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:277492

TITLE: Preparation of pyridine-containing diaryl ureas useful in the treatment of cancer and other disorders

INVENTOR(S): Dumas, Jacques; Lee, Wendy; Chen, Yuanwei; Adnane, Lila; Scott, William J.; Verma, Sharad; Chen, Jiangang; Chen, Zhi; Yi, Lin
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078128	A2	20040916	WO 2004-US6295	20040301 <--
WO 2004078128	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2516627 A1 20040916 CA 2004-2516627 20040301 <--
 EP 1603879 A2 20051214 EP 2004-716142 20040301 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 JP 2006519266 T 20060824 JP 2006-508981 20040301 <--
 MX 2005009102 A 20060531 MX 2005-9102 20050826 <--
 PRIORITY APPLN. INFO.: US 2003-450324P P 20030228 <--
 WO 2004-US6295 W 20040301

OTHER SOURCE(S): MARPAT 141:277492
 ED Entered STN: 16 Sep 2004
 GI




AB The title novel pyridine-containing diaryl ureas ANHC(O)NHBLMQ [A = (un)substituted Ph, naphthyl, heteroaryl, etc.; B = (un)substituted Ph, naphthyl, pyridyl; L = (CH₂)_mO(CH₂)_l, (CH₂)_m(CH₂)_l, (CH₂)_mC(O)(CH₂)_l, etc.; m, l = 0-4; M = (un)substituted pyridine; Q = tetrazolyl, imidazolyl, thiazolyl, etc.], useful for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies, were prepared and formulated. E.g., a multi-step synthesis of I, was given.

IT 758709-49-8P 758709-51-2P 758709-53-4P
 758709-55-6P 758709-57-8P 758709-59-0P
 758709-61-4P 758709-63-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridine-containing diaryl ureas for treating cancer and other disorders)
 RN 758709-49-8 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, hydrazide (CA INDEX NAME)




RN 758709-51-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-, hydrazide (CA INDEX NAME)




RN 758709-53-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2,2-dimethylhydrazide (CA INDEX NAME)



RN 758709-55-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-1-piperidinyl- (CA INDEX NAME)



RN 758709-57-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-4-morpholinyl-
(CA INDEX NAME)




RN 758709-59-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-1-piperidiny-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 758709-61-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-4-morpholinyl-4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 758709-63-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-N-4-morpholinyl- (CA INDEX NAME)



IT 758709-96-5

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of pyridine-containing diaryl ureas for treating cancer and

other

disorders)

RN 758709-96-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 573673-43-5P 757249-68-6P 757250-67-2P

757251-79-9P 758709-93-2P 758709-94-3P

758709-95-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyridine-containing diaryl ureas for treating cancer and

other

disorders)


RN 573673-43-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757249-68-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757250-67-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 757251-79-9 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(1-methyl-1H-indazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 758709-93-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-7-yl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 758709-94-3 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 758709-95-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[3-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:874973 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:364831

TITLE: Preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase using
 INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan, Mary-Katherine; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030207914	A1	20031106	US 2002-125369	20020419 <--
US 20060019990	A1	20060126	US 2005-158048	20050622 <--
US 7371763	B2	20080513		
US 20080194580	A1	20080814	US 2007-932269	20071031 <--
PRIORITY APPLN. INFO.:			US 2001-367376P	P 20010420 <--
			US 2002-125369	A1 20020419 <--
			US 2005-158048	A3 20050622

OTHER SOURCE(S): MARPAT 139:364831

ED Entered STN: 07 Nov 2003

AB Urea derivs. of general formula A-NHCONH-B, A'-CONH-B', and A''-NHCONH-B" or pharmaceutically acceptable salts thereof [wherein A = each (un)substituted tert-butylpyridyl, (trifluoromethyl)pyridyl, isopropylpyridyl, 2-methyl-2-butylpyridyl, or 3-methyl-3-pentylpyridyl; A' = each (un)substituted isoquinolinyl or isoquinolinyl; A" = substituted quinolinyl group; B, B' = independently, (un)substituted bridged cyclic structure of up to 30 carbon atoms of the formula -L-(ML)q (wherein L comprises a cyclic moiety having at least 5 members and is bound directly to D; L1 comprises a cyclic moiety having at least 5 members; M is a bridging group having at least one atom, q is an integer of from 1-3, and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B" = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with a cyclic structure bound directly to D containing at least 5 members with 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared These compds. are useful in treating raf-mediated diseases, in particular cancerous cell growth mediated by a raf kinase. All compds. exemplified, e.g. N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea, displayed IC50 of between 10 nM and 10 μ M against ref kinase.

IT 432050-22-1P, N-(2-Methoxy-3-quinolinyl)-N'-[4-[2-(N-Methylcarbonyl)-4-pyridyloxy]phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)
 RN 432050-22-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L41 ANSWER 13 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:874965 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 139:364958
 TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
 INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 60 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030207872	A1	20031106	US 2002-42226	20020111 <--
PRIORITY APPLN. INFO.:			US 2002-42226	20020111 <--
OTHER SOURCE(S):	MARPAT 139:364958			
ED	Entered STN: 07 Nov 2003			
AB	<p>Urea derivs. of formula A-NHCONH-B or pharmaceutically acceptable salts thereof [A = a substituted moiety of up to 40 carbon atoms of the formula -L-(M-L1)q; where L = a 5 or 6 membered cyclic structure bound directly to D; L1 = a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur; B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared. These compds. are useful for raf mediated diseases, in particular a cancerous cell growth mediated by raf kinase. All compds. exemplified, e.g. N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbonyl)-4-pyridyloxy]phenyl]urea, displayed IC50 of between 1 mM and 10 µM.</p>			
IT	694813-15-2P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-			


methoxycarbonylpyridyl]oxy]phenyl]urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; preparation of ω -carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 604813-15-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




IT 284461-86-5P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(methoxycarbonyl)-5-pyridyloxy]phenyl]urea 284462-06-2P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-[N-(2-triisopropylsilyloxyethyl)carbonyl]-4-pyridyl]oxy]phenyl]urea 284671-00-7P, N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of ω -carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)


RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)



RN 284462-06-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)



PAGE 1-B

Cl

RN 284671-00-7 HCAPLUS
 CN 3-Pyridinecarboxylic acid, 6-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




IT 284461-42-3P 284461-43-4P 284461-44-5P
 284461-45-6P 284461-47-8P 284461-48-9P
 284461-49-0P 284461-50-3P 284461-51-4P
 284461-55-8P 284461-58-1P 284461-60-5P
 284461-61-6P 284461-62-7P 284461-63-8P
 284461-64-9P 284461-73-0P 284461-74-1P
 284461-75-2P 284461-76-3P 284461-78-5P
 284461-80-9P 284461-81-0P 284461-82-1P
 284461-83-2P 284461-88-7P 284461-91-2P
 284461-97-8P 284462-01-7P 284462-02-8P
 284462-03-9P 284462-04-0P 284462-05-1P
 284462-17-5P 284462-18-6P 284462-19-7P
 284462-20-0P 284462-21-1P 284462-22-2P
 284462-23-3P 284462-24-4P 284462-25-5P
 284462-26-6P 284462-27-7P 284462-28-8P
 284462-29-9P 284462-30-2P 284462-31-3P
 284462-35-7P, N-[5-(tert-Butyl)-2-(2,5-dimethylpyrrolyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284670-98-0P,
 N,N'-Bis[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
 447457-08-1P 573673-43-5P 604813-02-7P
 604813-04-9P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-[5-(2-dimethylaminoethyl)carbamoyl]pyridyl]oxy]phenyl]urea
 620962-98-3P 620962-99-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of α -carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284462-26-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-31-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)




RN 447457-08-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




RN 573673-43-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 604813-02-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-(1-methylethyl)- (CA INDEX NAME)




RN 604813-04-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 620962-98-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 620962-99-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)-
(CA INDEX NAME)




IT 573673-47-9P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-carboxypyridyl)oxy]phenyl]urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(reactant; preparation of ω -carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 573673-47-9 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L41 ANSWER 14 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:757329 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:276918

TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 61 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030181442	A1	20030925	US 2001-993647	20011127 <--
PRIORITY APPLN. INFO.:			US 2001-993647	20011127 <--

OTHER SOURCE(S): MARPAT 139:276918

ED Entered STN: 26 Sep 2003


AB Aryl ureas of formula A-NHCONH-B [A = a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L1)q (where L = a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of from 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared. These urea derivs. are useful for treating raf mediated diseases, in particular cancerous cell growth mediated by raf kinase. Thus, N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. Thus, a solution of 4-bromo-3-(trifluoromethyl)phenyl isocyanate (8.0 g, 30.1 mmol) in CH₂Cl₂ (80 mL) was added dropwise to a solution of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (7.0 g, 28.8 mmol) in CH₂Cl₂ (40 mL) at 0°, stirred at room temperature for 16 h, and filtered to give, after washing the yellow solids, washing with CH₂Cl₂ (2 + 50 mL), and drying under reduced pressure (approx. 1 mmHg) at 40° to give N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. All compds. exemplified showed IC₅₀ between 1 nM to 10 µM against raf kinase.

IT 284670-98-0P, N,N'-Bis[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)

RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)]




IT 284461-86-5P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(methoxycarbonyl)-5-pyridyl]oxy]phenyl]urea 284462-06-2P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-[N-(2-triisopropylsilyloxyethyl)carbamoyl]-4-pyridyloxy]phenyl]urea 284462-71-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(5-carboxy-3-pyridyloxy)phenyl]urea 284462-76-6P,

Serial No.:10/788,426

N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(5-methoxycarbonyl-3-pyridyloxy)phenyl]urea 284671-60-7P,
 N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea 573673-59-3P,
 N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-(5-methoxycarbonyl-3-pyridyloxy)phenyl]urea 604813-15-2P,
 N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)


RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 284462-06-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)



PAGE 1-B


RN 284462-71-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-76-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284671-00-7 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 573673-59-3 HCAPLUS


CN 3-Pyridinecarboxylic acid, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 604813-15-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)

INDEX NAME)




IT 284461-42-3P 284461-43-4P,
 N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-44-5P,
 N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[4-[(2-(methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284461-45-6P,
 N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl]oxy]phenyl]urea 284461-47-8P 284461-48-9P
 284461-49-0P, N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[3-[(2-carbamoyl-4-pyridyl]oxy]-4-methylphenyl]urea 284461-50-3P
 284461-51-4P 284461-55-8P 284461-58-1P
 284461-60-5P, N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[3-[(2-(methylcarbamoyl)-4-pyridyl]thio]phenyl]urea 284461-61-6P
 284461-62-7P 284461-63-8P 284461-64-9P
 284461-73-0P 284461-74-1P,
 N-(4-Chloro-3-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl]oxy]phenyl]urea 284461-75-2P,
 N-(4-Chloro-3-trifluoromethylphenyl)-N'-[3-[(2-carbamoyl-4-pyridyl]oxy]phenyl]urea 284461-76-3P,
 N-(4-Chloro-3-trifluoromethylphenyl)-N'-[3-[(2-methylcarbamoyl-4-pyridyl]oxy]phenyl]urea 284461-78-5P 284461-80-9P
 284461-81-0P 284461-82-1P 284461-83-2P
 284461-88-7P 284461-91-2P 284461-97-8P
 284462-01-7P 284462-02-8P 284462-03-9P
 284462-04-0P 284462-05-1P 284462-17-5P
 284462-18-6P 284462-19-7P 284462-20-0P
 284462-21-1P 284462-22-2P 284462-23-3P
 284462-24-4P 284462-25-5P 284462-26-6P
 284462-27-7P 284462-28-8P 284462-29-9P
 284462-30-2P 284462-31-3P 284462-32-4P
 284462-35-7P, N-[2-(2,5-Dimethyl-1-pyrrolyl)-5-tert-butylphenyl]-N'-[4-[(2-methylcarbamoyl-4-pyridyl]oxy]phenyl]urea 447457-08-1P
 447457-09-2P 573673-43-5P 604813-02-7P
 604813-04-9P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-[5-[[2-(dimethylamino)ethyl]carbamoyl]pyridyl]oxy]phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)
 RN 284461-42-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284461-61-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284462-26-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-31-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 447457-08-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




RN 447457-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)-
(CA INDEX NAME)




RN 573673-43-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 604813-02-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-(1-methylethyl)- (CA INDEX NAME)



RN 604813-04-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



L41 ANSWER 15 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:656745 HCAPLUS Full-text

DOCUMENT NUMBER: 139:197377

TITLE: Preparation of aryl ureas for therapeutic use as kinase inhibitors

INVENTOR(S): Dumas, Jacques; Scott, William J.; Chien, Du-Schieng; Lee, Wendy; Bjorge, Susan;

PATENT ASSIGNEE(S): Musza, Laszlo L.; Nassar, Ala; Riedl, Bernd
Bayer Corporation, USA; Bayer Pharmaceuticals Corporation

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068746	A1	20030821	WO 2003-US4109	20030211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2475818	A1	20030821	CA 2003-2475818	20030211 <--
AU 2003209118	A1	20030904	AU 2003-209118	20030211 <--
US 20030216446	A1	20031120	US 2003-361859	20030211 <--
EP 1474393	A1	20041110	EP 2003-707848	20030211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1630638	A	20050622	CN 2003-803705	20030211 <--
CN 1318404	C	20070530		
JP 2005523278	T	20050804	JP 2003-567877	20030211 <--
EP 1580188	A1	20050928	EP 2005-7027	20030211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
MX 2004007830	A	20050701	MX 2004-7830	20040811 <--
HK 1079774	A1	20071221	HK 2005-111827	20051222 <--
PRIORITY APPLN. INFO.:			US 2002-354937P	P 20020211 <--
			EP 2003-707848	A3 20030211 <--
			WO 2003-US4109	W 20030211 <--


OTHER SOURCE(S): MARPAT 139:197377

ED Entered STN: 22 Aug 2003


GI



- AB Aryl ureas, such as I [R = Cl, Br; R₂ = OH, NH₂, NHMe, NHCH₂OH, alkoxy; n = 0, 1], were prepared for use in pharmaceutical compns. for the treatment of raf kinase and p38 kinase mediated diseases. These ureas are useful for the treatment of inflammation, osteoporosis, angiogenesis disorders and hyperproliferative disorders, such as cancer. Thus, urea I (R = Cl, R₂ = NHMe, n = 1) was prepared with 57% yield by N-oxidation of I (R = Cl, R₂ = NHMe, n = 0) using 3-chloroperbenzoic acid in CH₂Cl₂ and THF. The prepared ureas were assayed for inhibition of p38 kinase and raf kinase, as well as for cancer cell growth inhibition in human cancer cell lines, such as HCT116 and DLD-1.
- IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl(4-pyridyloxy)phenyl)urea 284462-18-6P
583840-03-3P 583840-04-4P 583840-09-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
- RN 284461-74-1 HCAPLUS
- CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




- RN 284462-18-6 HCAPLUS
- CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 583840-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide
(CA INDEX NAME)




RN 583840-04-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



RN 583840-09-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-05-5P 583840-06-6P 583840-07-7P


583840-08-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl ureas for therapeutic use as kinase inhibitors)


RN 583840-05-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (CA INDEX NAME)




RN 583840-06-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide
(CA INDEX NAME)




RN 583840-07-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (CA INDEX NAME)



RN 583840-08-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)




IT 284461-73-QP, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)(4-pyridyloxy)phenyl]urea

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl ureas for therapeutic use as kinase inhibitors)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 16 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:656581 HCAPLUS Full-text

DOCUMENT NUMBER: 139:197370

TITLE: Preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors

INVENTOR(S): Dumas, Jacques; Scott, William J.; Riedl, Bernd

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068229	A1	20030821	WO 2003-US4110	20030211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003209119	A1	20030904	AU 2003-209119	20030211 <--
US 20030216396	A1	20031120	US 2003-361850	20030211 <--
US 20070265315	A1	20071115	US 2007-775457	20070710 <--
PRIORITY APPLN. INFO.:			US 2002-354935P	P 20020211 <--
			US 2003-361850	BI 20030211 <--
			WO 2003-US4110	W 20030211 <--

OTHER SOURCE(S): MARPAT 139:197370

ED Entered STN: 22 Aug 2003

GI




IT 583840-03-3P 583840-04-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline
N-oxide functionality as kinase inhibitors)


RN 583840-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide
(CA INDEX NAME)



RN 583840-04-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:656580 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:197369

TITLE: Preparation of aryl ureas with angiogenesis inhibiting activity

INVENTOR(S): Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia

PATENT ASSIGNEE(S): Bayer Corporation, USA


SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068228	A1	20030821	WO 2003-US4103	20030211 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2475703	A1	20030821	CA 2003-2475703	20030211 <--
AU 2003209116	A1	20030904	AU 2003-209116	20030211 <--
US 20030207870	A1	20031106	US 2003-361858	20030211 <--
EP 1478358	A1	20041124	EP 2003-707846	20030211 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005522448	T	20050728	JP 2003-567410	20030211 <--
MX 2004007832	A	20050908	MX 2004-7832	20040811 <--
JP 2007302687	A	20071122	JP 2007-183948	20070713 <--
US 20080227828	A1	20080918	US 2007-932626	20071031 <--
PRIORITY APPLN. INFO.:			US 2002-354950P	P 20020211 <--
			JP 2003-567410	A3 20030211 <--
			US 2003-361858	A3 20030211 <--
			WO 2003-US4103	W 20030211 <--

OTHER SOURCE(S): MARPAT 139:197369
 ED Entered STN: 22 Aug 2003
 GI




I

AB The title compds. ANHCONHB [A, B = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, etc.], useful for treating diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Preps. of three title ureas are described. E.g., a 3-step synthesis of the urea I (starting from Me 4-chloro-2-pyridinecarboxylate hydrochloride), was given. The KDR (VEGFR2) assay for testing the title ureas is described.

IT 284461-44-5P 284461-73-0P 284461-74-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryl ureas with angiogenesis inhibiting activity)


RN 284461-44-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:590832 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:149528

TITLE: Preparation of diphenylureas as RAF kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger,

Timothy B.; Scott, William J.; Smith,

Roger A.; Wood, Jill E.; Monahan, Mary-katherine;

Serial No.:10/788,426

PATENT ASSIGNEE(S): Natero, Reina; Renick, Joel; Sibley, Robert N.
 SOURCE: Bayer Corporation, USA
 U.S. Pat. Appl. Publ., 62 pp., Cont. of U. S. Ser. No. 42,203.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030144278	A1	20030731	US 2002-283248	20021030 <--
US 7235576	B1	20070626	US 2002-42203	20020111 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P 20010112 <--
			US 2002-42203	A1 20020111 <--

OTHER SOURCE(S): MARPAT 139:149528

ED Entered STN: 01 Aug 2003

AB ADB [I; D = NHCONH; A = L(ML1)q; L = 5-6 membered cyclic structure bound directly to D; L1 = substituted cyclic moiety having ≥5 members, M = bridging group having ≥1 atom; q = 1-3; L, L1 contain 0-4 N, O, S; B = (substituted) up to tricyclic aryl, heteroaryl of ≤30 C atoms with ≥1 6-membered cyclic structure bound directly to D containing 0-4 N, O, S], were prepared. Thus, 4-chloro-3-(trifluoromethyl)phenyl isocyanate in CH2Cl2 was added dropwise to a suspension of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (preparation given) in CH2Cl2 at 0°; the resulting mixture was stirred at room temperature for 22 h. to afford N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. I inhibited RAF kinase in the range 1 nM-1 μM. I pharmaceutical comps. are claimed.

IT 284461-42-3P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea 284461-43-4P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl] urea 284461-44-5P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea 284461-45-6P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl] urea 284461-47-8P 284461-48-9P 284461-49-0P 284461-50-3P 284461-51-4P 284461-55-8P 284461-58-1P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridylthio]phenyl] urea 284461-60-5P 284461-61-6P 284461-62-7P 284461-63-8P 284461-64-9P 284461-73-0P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-75-2P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl] urea 284461-76-3P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284461-78-5P 284461-80-9P 284461-81-0P 284461-82-1P 284461-83-2P 284461-88-7P 284461-91-2P 284461-97-8P 284461-98-9P 284462-01-7P 284462-02-8P 284462-03-9P 284462-04-0P 284462-05-1P 284462-17-5P 284462-18-6P, N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284462-19-7P, N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[2-chloro-4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl]urea 284462-20-0P,

Serial No.:10/788,426


N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[3-chloro-4-[2-(N-methylcarbamoyl)(4-pyridyloxy)phenyl]urea 284462-21-1P
 284462-22-2P, N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284462-23-3P
 284462-24-4P 284462-25-5P 284462-26-6P
 284462-27-7P 284462-28-8P,
 N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea 284462-29-9P
 284462-30-2P 284462-31-3P,
 N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea 284462-32-4P
 284462-35-7P 284670-98-0P 447457-08-1P
 447457-09-2P 474642-55-2P 573673-43-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diphenylureas as RAF kinase inhibitors)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284461-60-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-64-9 HCAPLUS


CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-73-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-82-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-88-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)-
(CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-29-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-31-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)]




RN 447457-08-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)



RN 447457-09-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 474642-55-2 HCAPLUS


CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)-
(CA INDEX NAME)



RN 573673-43-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



IT 284461-86-5 284462-06-2 284462-71-1


284462-76-6 573673-53-7 573673-59-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of diphenylureas as RAF kinase inhibitors)

RN 284461-86-5 HCAPLUS


CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 284462-06-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl


RN 284462-71-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-76-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 573673-53-7 HCAPLUS

CN 3-Pyridinecarboxylic acid, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 573673-59-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




IT 573673-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diphenylureas as RAF kinase inhibitors)

RN 573673-47-9 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L41 ANSWER 19 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:454119 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:17567

TITLE: Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases
Carter, Christopher A.; Dumas, Jacques; Gibson, Neil; Hibner, Barbara; Humphrey, Rachel W.; Trail, Pamela; Vincent, Patrick W.; Zhai, Yifan; Riedl, Bernd; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley,

Serial No.:10/788,426

PATENT ASSIGNEE(S): Robert N.
 SOURCE: Bayer Corporation, USA; Bayer AG
 PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047579	A1	20030612	WO 2002-US38439	20021203 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2468463	A1	20030612	CA 2002-2468463	20021203 <--
AU 2002351196	A1	20030617	AU 2002-351196	20021203 <--
US 20030232765	A1	20031218	US 2002-308187	20021203 <--
EP 1450799	A1	20040901	EP 2002-786842	20021203 <--
EP 1450799	B1	20061115		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005511658	T	20050428	JP 2003-548834	20021203 <--
AT 345130	T	20061215	AT 2002-786842	20021203 <--
EP 1769795	A2	20070404	EP 2006-23696	20021203 <--
EP 1769795	A3	20080312		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, AL, LT, LV, MK, RO			
ES 2275931	T3	20070616	ES 2002-786842	20021203 <--
RU 2316326	C2	20080210	RU 2004-120785	20021203 <--
IN 2004DN01420	A	20070316	IN 2004-DN1420	20040526 <--
MX 2004005137	A	20050603	MX 2004-5137	20040528 <--
ZA 2004004225	A	20050829	ZA 2004-4225	20040528 <--
US 20060247186	A1	20061102	US 2006-480360	20060705 <--
IN 2008DN07086	A	20080926	IN 2008-DN7086	20080820 <--
PRIORITY APPLN. INFO.:			US 2001-334609P	P 20011203 <--
			EP 2002-786842	A3 20021203 <--
			US 2002-308187	B1 20021203 <--
			WO 2002-US38439	W 20021203 <--
			IN 2004-DN1420	A3 20040526
OTHER SOURCE(S):	MARPAT 139:17567			
ED	Entered STN: 13 Jun 2003			
AB	The invention discloses aryl urea compds. in combination with cytotoxic or cytostatic agents for use in treating raf kinase-mediated diseases, e.g. cancer.			
IT	475207-59-1			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(aryl urea compds. in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases)			
RN	475207-59-1 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-			

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-,
4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0


CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 20 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:850357 HCAPLUS Full-text

DOCUMENT NUMBER: 137:352907

TITLE: Preparation of quinolyl, isoquinolyl or pyridyl-ureas
as inhibitors of raf kinase for the treatment of
tumors and/or cancerous cell growth

INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill
E.; Robert, Sibley N.; Monahan, Mary-Katherine;
Renick, Joel; Gunn, David E.; Lowinger, Timothy B.;
Scott, William J.; Smith, Roger A.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S.
Ser. No. 758,548.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020165394	A1	20021107	US 2001-777920	20010207 <--

Serial No.:10/788,426

CA 2549558	A1	20000720	CA 2000-2549558	20000112 <--
CN 1721397	A	20060118	CN 2005-10089504	20000112 <--
EP 1690853	A1	20060816	EP 2005-28442	20000112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 556598	A	20081128	NZ 2000-556598	20000112 <--
ZA 2001005751	A	20030714	ZA 2001-5751	20010712 <--
US 20020137774	A1	20020926	US 2001-907970	20010719 <--
WO 2002062763	A2	20020815	WO 2002-US3361	20020207 <--
WO 2002062763	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002238042	A1	20020819	AU 2002-238042	20020207 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
JP 2006328075	A	20061207	JP 2006-190034	20060711 <--
US 20080032979	A1	20080207	US 2007-845595	20070827 <--
PRIORITY APPLN. INFO.:				
			US 1999-115877P	P 19990113 <--
			US 1999-257266	B2 19990225 <--
			US 1999-425228	B2 19991022 <--
			US 2001-758548	A2 20010112 <--
			US 1999-115878P	P 19990113 <--
			AU 2000-25016	A3 20000112 <--
			CA 2000-2359510	A3 20000112 <--
			CN 2000-802685	A3 20000112 <--
			EP 2000-903239	A3 20000112 <--
			JP 2000-593580	A3 20000112 <--
			NZ 2000-544840	A3 20000112 <--
			US 2001-777920	A 20010207 <--
			US 2001-948915	A1 20010910 <--
			WO 2002-US3361	W 20020207 <--
OTHER SOURCE(S): MARPAT 137:352907				
ED Entered STN: 08 Nov 2002				
GI				



II



III

AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepared. For example, coupling of aniline II, e.g., prepared from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 µM. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.


IT 284461-42-3P 284461-43-4P 284461-44-5P
 284461-45-6P 284461-47-8P 284461-48-9P
 284461-49-0P 284461-50-3P 284461-51-4P
 284461-55-9P 284461-58-1P 284461-60-5P
 284461-61-6P 284461-62-7P 284461-63-8P
 284461-64-9P 284461-73-0P 284461-74-1P
 284461-75-2P 284461-76-3P 284461-78-5P
 284461-80-9P 284461-81-0P 284461-82-1P
 284461-86-5P 284461-88-7P 284461-91-2P
 284461-97-8P 284461-98-9P 284462-01-7P
 284462-02-8P 284462-03-9P 284462-04-0P
 284462-05-1P 284462-17-5P 284462-18-6P
 284462-19-7P 284462-20-0P 284462-21-1P
 284462-22-2P 284462-23-3P 284462-24-4P
 284462-25-5P 284462-26-6P 284462-27-7P
 284462-28-8P 284462-29-9P 284462-30-2P
 284462-31-3P 284462-32-4P 284462-35-7P
 284670-98-0P 432050-22-1P 432050-24-3P
 432050-25-4P 432050-26-5P 447457-08-1P
 447457-09-2P 474642-44-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)



RN 284461-50-3 HCAPLUS
 CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy)-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenylthio)-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenylthio)-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)-
(CA INDEX NAME)


RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)


RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenylthio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 284462-03-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]thio]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-30-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-31-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)]




RN 432050-22-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)]



RN 432050-24-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)]



RN 432050-25-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)]

quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 432050-26-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-3-(quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 447457-08-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




RN 447457-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 474642-44-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284462-71-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 284462-71-1 HCAPLUS


CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 474642-55-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 474642-55-2 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



L41 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:832761 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:337791

TITLE: Preparation of quinolyl, isoquinolyl or pyridyl-ureas

Serial No.:10/788,426

as inhibitors of raf kinase

INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan, Mary-Katherine; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085857	A2	20021031	WO 2002-US12066	20020418 <--
WO 2002085857	A3	20030116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2443950	A1	20021031	CA 2002-2443950	20020418 <--
AU 2002256260	A1	20021105	AU 2002-256260	20020418 <--
EP 1379505	A2	20040114	EP 2002-725710	20020418 <--
EP 1379505	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005501813	T	20050120	JP 2002-583384	20020418 <--
AT 355272	T	20060315	AT 2002-725710	20020418 <--
ES 2283543	T3	20071101	ES 2002-725710	20020418 <--
MX 2003009648	A	20051005	MX 2003-9648	20031020 <--
PRIORITY APPLN. INFO.:			US 2001-838285	A 20010420 <--
			WO 2002-US12066	W 20020418 <--

OTHER SOURCE(S): MARPAT 137:337791

ED Entered STN: 01 Nov 2002

AB Title compds. A-D-B (I) [D = NHCONH; A = (un)substituted t-butylpyridyl, etc.; B = (un)substituted bridged cyclic structure, etc.] and analogs were prepared. For instance, 4-tert-butyl-2-aminopyridine was coupled to 4-(4-pyridylmethyl)aniline (CH₂Cl₂, CDI, 0°) to give N-(4-tert-butylpyridyl)-N'-[4-(4-pyridylmethyl)phenyl]urea as a white solid. Example compds. had IC₅₀ between 10nM and 10µM for raf kinase. I are useful for the treatment of cancerous cell growth mediated by raf kinase.


IT 432050-22-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 432050-22-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:615574 HCAPLUS Full-text

DOCUMENT NUMBER: 137:169425

TITLE: Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors
 INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062763	A2	20020815	WO 2002-US3361	20020207 <--
WO 2002062763	A3	20021010		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20020165394	A1	20021107	US 2001-777920	20010207 <--
AU 2002238042	A1	20020819	AU 2002-238042	20020207 <--
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
PRIORITY APPLN. INFO.:			US 2001-777920	A 20010207 <--
			US 1999-115877P	P 19990113 <--
			US 1999-257266	B2 19990225 <--
			US 1999-425228	B2 19991022 <--
			AU 2000-25016	A3 20000112 <--
			US 2001-758548	A2 20010112 <--
			WO 2002-US3361	W 20020207 <--

OTHER SOURCE(S): MARPAT 137:169425

ED Entered STN: 16 Aug 2002

GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C₆H₄(CMe₃)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R₁ = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepared. Thus, 4-(H₂N)C₆H₄OC₆H₄(CONHMe)-4 (preparation given) was condensed with 3-(Me₃C)C₆H₄NH₂ and CO(OCCl₃)₂ to give title compound II. Data for biol. activity of title compds. were given.


IT 284461-42-3P 284461-43-4P 284461-44-5P
 284461-45-6P 284461-47-8P 284461-48-9P
 284461-49-0P 284461-50-3P 284461-51-4P
 284461-55-8P 284461-58-1P 284461-60-5P
 284461-61-6P 284461-62-7P 284461-63-8P
 284461-64-9P 284461-73-0P 284461-74-1P
 284461-75-2P 284461-76-3P 284461-78-5P
 284461-80-9P 284461-81-0P 284461-82-1P
 284461-83-2P 284461-86-5P 284461-88-7P
 284461-91-2P 284461-97-8P 284461-98-9P
 284462-01-7P 284462-02-8P 284462-03-9P
 284462-04-0P 284462-05-1P 284462-17-5P
 284462-18-6P 284462-19-7P 284462-20-0P
 284462-21-1P 284462-22-2P 284462-23-3P
 284462-24-4P 284462-25-5P 284462-26-6P
 284462-27-7P 284462-28-8P 284462-29-9P
 284462-30-2P 284462-31-3P 284462-32-4P
 284462-35-7P 284670-98-0P 432050-22-1P
 432050-24-3P 432050-25-4P 432050-26-5P
 447457-08-1P 447457-09-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([3-chloro-4-([2-methoxy-5-(trifluoromethyl)phenyl]amino)carbonyl]amino)phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-([2-methoxy-5-(trifluoromethyl)phenyl]amino)carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-ethyl-4-[4-([2-methoxy-5-(trifluoromethyl)phenyl]amino)carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 284461-58-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenylthio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-31-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrolo-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284670-98-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)]




RN 432050-22-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 432050-24-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 432050-25-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 432050-26-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 447457-08-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-

methylethyl)silyloxy]ethyl]- (CA INDEX NAME)



RN 447457-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




IT 284462-71-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 284462-71-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:409267 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:6098

TITLE: Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors

INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan, Mary-katherine; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.

Serial No.:10/788,426

PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U. S. Ser. No. 778,039.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020065296	A1	20020530	US 2001-838286	20010420 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
CA 2443952	A1	20021031	CA 2002-2443952	20020417 <--
WO 2002085859	A1	20021031	WO 2002-US12064	20020417 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256259	A1	20021105	AU 2002-256259	20020417 <--
EP 1379507	A1	20040114	EP 2002-725709	20020417 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004537511	T	20041216	JP 2002-583386	20020417 <--
MX 2003009649	A	20051005	MX 2003-9649	20031020 <--
AU 2004200566	A1	20040311	AU 2004-200566	20040213 <--
AU 2004200566	B2	20060817		
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
US 20080027061	A1	20080131	US 2007-845597	20070827 <--
PRIORITY APPLN. INFO.:			US 1999-115878P	P 19990113 <--
			US 1999-257265	B1 19990225 <--
			US 1999-425229	A2 19991022 <--
			US 2001-778039	A2 20010207 <--
			US 1999-115877P	P 19990113 <--
			US 1999-257266	B2 19990225 <--
			US 1999-425228	B1 19991022 <--
			AU 2000-25016	A3 20000112 <--
			AU 2000-27250	A3 20000113 <--
			US 2001-838286	A 20010420 <--
			US 2001-948915	A1 20010910 <--
			US 2002-86417	B3 20020304 <--
			WO 2002-US12064	W 20020417 <--

OTHER SOURCE(S): MARPAT 137:6098

ED Entered STN: 31 May 2002

AB This invention relates to the use of a group of heteroaryl ureas (I; for example, N-(2-methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea) containing N in treating p38 mediated diseases, and pharmaceutical compns. for use in such therapy. I is A-NHC(O)NH-B or a pharmaceutically acceptable salt thereof, wherein A is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group, B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 50 C atoms with a cyclic structure bound directly to N, containing at least 5 cyclic members with 0-4 members of groups consisting of N, O and S. Information about the substituents for A and B are given in the claims.

Although the methods of preparation are not claimed, 37 example preps. are included as well as examples of preparation of intermediates. No pharmacol. data is included.


- IT 284670-98-0P, N,N'-Bis[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-22-1P,
N-(2-Methoxy-3-quinolyl)-N'-[4-(2-(N-Methylcarbamyl)-4-pyridyloxy)phenyl]urea 432050-24-3P,
N-(2-Methoxy-3-quinolyl)-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-25-4P, N-(2-Methoxy-3-quinolyl)-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-26-5P,
N-(2-Methoxy-3-quinolyl)-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-29-8P, N-(3-Isoquinolyl)-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38

kinase
inhibitors)


RN 284670-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-methyl- (CA INDEX NAME)




RN 432050-22-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 432050-24-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 432050-25-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 432050-26-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 432050-29-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(3-isoquinolinylamino)carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L41 ANSWER 24 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:493516 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 133:120157

TITLE: Preparation of o-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042012	A1	20000720	WO 2000-US648	20000112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359510	A1	20000720	CA 2000-2359510	20000112 <--
CA 2359510	C	20070213		
CA 2549558	A1	20000720	CA 2000-2549558	20000112 <--
AU 2000025016	A	20000801	AU 2000-25016	20000112 <--
EP 1140840	A1	20011010	EP 2000-903239	20000112 <--
EP 1140840	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EE 200100368	A	20030415	EE 2001-368	20000112 <--
EE 4913	B1	20071015		
HU 2003000866	A2	20030728	HU 2003-866	20000112 <--
HU 2003000866	A3	20060428		
HU 225780	B1	20070828		
JP 2003526613	T	20030909	JP 2000-593580	20000112 <--
JP 3845792	B2	20061115		
BR 2000007487	A	20030923	BR 2000-7487	20000112 <--
CN 1219764	C	20050921	CN 2000-802685	20000112 <--
CN 1721397	A	20060118	CN 2005-10089504	20000112 <--
AT 321027	T	20060415	AT 2000-903239	20000112 <--
PT 1140840	T	20060531	PT 2000-903239	20000112 <--
ES 2255971	T3	20060716	ES 2000-903239	20000112 <--
EP 1690853	A1	20060816	EP 2005-28442	20000112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
SK 285532	B6	20070301	SK 2001-988	20000112 <--
RU 2319693	C2	20080320	RU 2001-122818	20000112 <--
CZ 299125	B6	20080430	CZ 2001-2489	20000112 <--
NZ 556598	A	20081128	NZ 2000-556598	20000112 <--
TW 269791	B	20070101	TW 2000-89100575	20000407 <--
US 20010011135	A1	20010802	US 2001-773659	20010202 <--
US 20010011136	A1	20010802	US 2001-773675	20010202 <--
US 20010016659	A1	20010823	US 2001-773672	20010202 <--
US 20010027202	A1	20011004	US 2001-773658	20010202 <--
US 20010034447	A1	20011025	US 2001-773604	20010202 <--
IN 2001MN00799	A	20050304	IN 2001-MN799	20010705 <--
NO 2001003463	A	20010912	NO 2001-3463	20010712 <--
NO 321059	B1	20060306		
MX 2001007118	A	20021023	MX 2001-7118	20010712 <--
ZA 2001005751	A	20030714	ZA 2001-5751	20010712 <--
US 20020137774	A1	20020926	US 2001-907970	20010719 <--
BG 105763	A	20020329	BG 2001-105763	20010801 <--
BG 65158	B1	20070430		
BG 109688	A	20070531	BG 2001-109688	20010801 <--
HR 2001000580	A1	20020831	HR 2001-580	20010802 <--
US 20020042517	A1	20020411	US 2001-948915	20010910 <--
US 7351834	B1	20080401	US 2002-889227	20020108 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
HK 1045504	A1	20060407	HK 2002-106872	20020920 <--

AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
NO 2005005863	A	20010912	NO 2005-5863	20051209 <--
JP 2006328075	A	20061207	JP 2006-190034	20060711 <--
KR 2007020158	A	20070216	KR 2007-702656	20070201 <--
US 20080032979	A1	20080207	US 2007-845595	20070827 <--
IN 2007MN01633	A	20071214	IN 2007-MN1633	20071005 <--
US 20080153823	A1	20080626	US 2007-956111	20071213 <--
PRIORITY APPLN. INFO.:			US 1999-115877P	P 19990113 <--
			US 1999-257266	A2 19990225 <--
			US 1999-425228	A2 19991022 <--
			US 1999-115878P	P 19990113 <--
			AU 2000-25016	A3 20000112 <--
			CA 2000-2359510	A3 20000112 <--
			CN 2000-802685	A3 20000112 <--
			EP 2000-903239	A3 20000112 <--
			JP 2000-593580	A3 20000112 <--
			NZ 2000-544840	A3 20000112 <--
			WO 2000-US648	W 20000112 <--
			IN 2001-MN799	A3 20010705 <--
			KR 2001-708847	A3 20010712 <--
			US 2001-948915	A1 20010910 <--
			US 2002-889227	A1 20020108 <--

OTHER SOURCE(S): MARPAT 133:120157
 ED Entered STN: 21 Jul 2000
 GI



AB This invention relates to the preparation and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML)q; L = 5- or 6-membered (hetero)aryl, especially Ph or pyridinyl; M = bridging group; Ll = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepared For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addition of 4-(3-N-methylcarbamoylphenoxy)aniline (preparation given) to afford the urea II.

IT 284461-42-3P 284461-43-4P,
 N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-44-5P 284461-45-6P,
 N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-51-4P 284461-58-1P,
 N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyl]thio]phenyl]urea 284461-74-1P,
 N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-75-2P,
 N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[3-(2-carbamoyl-4-

pyridyloxy)phenyl]urea 284461-78-5P 284461-86-5P

284462-05-1P 284462-06-2P 284462-17-5P

284462-18-6P 284462-19-7P,

N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[2-chloro-4-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284462-20-6P,

N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[3-chloro-4-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284462-22-2P,

N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[3-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284462-26-6P 284462-28-8P,

N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[4-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284462-30-2P

284462-31-3P, N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[3-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea 284462-35-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of o-carboxy(hetero)aryl substituted di-Ph urea raf

kinase inhibitors by reacting arylisocyanates with arylamines)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]thio]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-86-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-06-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Cl


RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-30-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-31-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-35-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




IT 284461-47-8P 284461-49-0P 284461-50-3P
 284461-55-8P 284461-60-5P 284461-61-6P
 284461-62-7P 284461-63-8P 284461-64-9P
 284461-80-9P 284461-81-0P 284461-82-1P
 284461-83-2P 284461-88-7P 284461-91-2P
 284461-97-8P 284461-98-9P 284462-01-7P
 284462-02-8P 284462-03-9P 284462-04-0P
 284462-21-1P 284462-23-3P 284462-24-4P
 284462-25-5P 284462-27-7P 284462-32-4P
 284462-33-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ω -carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)


RN 284461-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-60-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio)-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenylthio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284462-33-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



IT 284461-48-9 284461-76-3,

N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-(3-((2-(N-Methylcarbamoyl)-4-pyridyl)oxy)phenyl)urea 284462-29-9 284462-76-6


284671-00-7, N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of ω -carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)


RN 284461-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-29-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-76-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 284671-00-7 HCAPLUS


CN 3-Pyridinecarboxylic acid, 6-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)




IT 284461-73-0P 284462-71-1P 284670-98-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of α -carboxy(hetero)aryl substituted di-Ph urea raf
 kinase inhibitors by reacting arylisocyanates with arylamines)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX
 NAME)



RN 284462-71-1 HCAPLUS
 CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284670-98-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4,4'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[N-
 methyl- (CA INDEX NAME)]



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:493376 HCAPLUS Full-text
 DOCUMENT NUMBER: 133:120155

TITLE: Preparation of α -carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041698	A1	20000720	WO 2000-US768	20000113 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359244	A1	20000720	CA 2000-2359244	20000113 <--
EP 1158985	A1	20011205	EP 2000-905597	20000113 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
MX 2001007120	A	20011101	MX 2001-7120	20010712 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
US 20030105091	A1	20030605	US 2002-86417	20020304 <--
AU 2004200566	A1	20040311	AU 2004-200566	20040213 <--
AU 2004200566	B2	20060817		
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
US 20080027061	A1	20080131	US 2007-845597	20070827 <--
PRIORITY APPLN. INFO.:			US 1999-115878P	P 19990113 <--
			US 1999-257265	A2 19990225 <--
			US 1999-425229	A2 19991022 <--
			US 1999-115877P	P 19990113 <--
			US 1999-257266	B2 19990225 <--
			US 1999-425228	B1 19991022 <--
			AU 2000-25016	A3 20000112 <--
			AU 2000-27250	A3 20000113 <--
			WO 2000-US768	W 20000113 <--
			US 2001-948915	A1 20010910 <--
			US 2002-86417	B3 20020304 <--

OTHER SOURCE(S): MARPAT 133:120155


ED Entered STIN: 21 Jul 2000

GI




II

- AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepared E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 μ M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).
- IT 284461-86-5P 284462-06-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of *o*-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
- RN 284461-86-5 HCAPLUS
- CN 2-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



- RN 284462-06-2 HCAPLUS
- CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (CA INDEX NAME)



PAGE 1-A

C1


IT 284461-42-3P 284461-43-4P 284461-44-5P
 284461-45-6P 284461-47-8P 284461-48-9P
 284461-49-0P 284461-50-3P 284461-51-4P
 284461-55-8P 284461-58-1P 284461-60-5P
 284461-61-6P 284461-62-7P 284461-63-8P
 284461-64-9P 284461-73-0P 284461-74-1P
 284461-75-2P 284461-76-3P 284461-78-5P
 284461-80-9P 284461-81-0P 284461-82-1P
 284461-83-2P 284461-88-7P 284461-91-2P
 284461-97-8P 284461-98-9P 284462-01-7P
 284462-02-8P 284462-03-9P 284462-04-0P
 284462-05-1P 284462-17-5P 284462-18-6P
 284462-19-7P 284462-20-0P 284462-21-1P
 284462-22-2P 284462-23-3P 284462-24-4P
 284462-25-5P 284462-26-6P 284462-27-7P
 284462-28-8P 284462-29-9P 284462-30-2P
 284462-31-3P 284462-32-4P 284462-33-5P
 284462-35-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of *o*-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)


RN 284461-42-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-43-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-44-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-45-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-47-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-48-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]- (CA INDEX NAME)




RN 284461-50-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-51-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-55-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-58-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 284461-60-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-61-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284461-62-7 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284461-63-8 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-64-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-80-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-81-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284461-83-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284461-97-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284461-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 284462-01-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-03-9 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-04-0 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-05-1 HCAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 284462-17-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 284462-18-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-19-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-20-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-chlorophenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-21-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-22-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-23-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[5-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-2-methylphenoxy]-N-methyl-
(CA INDEX NAME)




RN 284462-24-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 284462-25-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-26-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)




RN 284462-27-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 284462-28-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-29-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-30-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[4-chloro-2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-31-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284462-32-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 284462-33-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 284462-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




IT 284462-76-6 284462-90-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ω -carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)


RN 284462-76-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 284462-90-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




IT 284462-71-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ω -carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 284462-71-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:425/45 HCAPLUS Full-text

DOCUMENT NUMBER: 131:87909

TITLE: Inhibition of p38 kinase activity using substituted heterocyclic ureas

INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	A1	19990701	CA 1998-2315720	19981222 <--
AU 9919971	A	19990712	AU 1999-19971	19981222 <--
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526223	T	20011218	JP 2000-525102	19981222 <--
IL 170201	A	20061231	IL 1998-170201	19981222 <--
IL 136738	A	20070617	IL 1998-136738	19981222 <--
MX 200006233	A	20020918	MX 2000-6233	20000622 <--
PRIORITY APPLN. INFO.:			US 1997-995750	A 19971222 <--
			IL 1998-136738	A3 19981222 <--
			WO 1998-US26080	W 19981222 <--

OTHER SOURCE(S): MARPAT 131:87909

ED Entered STN: 09 Jul 1999
GI



AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compound II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 μ M.


IT 228999-89-1P 228999-90-4P 228999-91-5P
228999-92-6P 229155-71-9P 229155-81-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)


RN 228999-89-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 228999-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-91-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-92-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229155-71-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[3-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenyl]thio]- (CA INDEX NAME)



RN 229155-81-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-5-[4-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT:


1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial No.:10/788,426

L41 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 1999:425740 HCAPLUS Full-text
 DOCUMENT NUMBER: 131:73648
 TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
 INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 163 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315717	A1	19990701	CA 1998-2315717	19981222 <--
AU 9921989	A	19990712	AU 1999-21989	19981222 <--
EP 1047418	A1	20001102	EP 1998-965981	19981222 <--
EP 1047418	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002618	T2	20010420	TR 2000-2618	19981222 <--
JP 2001526220	T	20011218	JP 2000-525097	19981222 <--
HU 2001001704	A2	20011228	HU 2001-1704	19981222 <--
HU 2001001704	A3	20021228		
BR 9814374	A	20020514	BR 1998-14374	19981222 <--
CN 1149085	C	20040512	CN 1998-813623	19981222 <--
RU 2232015	C2	20040710	RU 2000-120184	19981222 <--
CN 1544420	A	20041110	CN 2004-10028655	19981222 <--
CN 100360507	C	20080109		
AT 300299	T	20050815	AT 1998-965981	19981222 <--
ES 2153340	T3	20060201	ES 1998-965981	19981222 <--
IL 136767	A	20070724	IL 1998-136767	19981222 <--
SK 286213	B6	20080506	SK 2000-963	19981222 <--
CZ 299156	B6	20080507	CZ 2000-2350	19981222 <--
NO 2000003232	A	20000821	NO 2000-3232	20000621 <--
NO 326150	B1	20081006		
MX 2000006226	A	20020311	MX 2000-6226	20000622 <--
IN 193672	A1	20040731	IN 2000-MN153	20000704 <--
BG 104597	A	20010228	BG 2000-104597	20000712 <--
BG 64984	B1	20061130		
HK 1029052	A1	20051118	HK 2000-107684	20001130 <--
AU 2003204708	A1	20030717	AU 2003-204708	20030613 <--
AU 2003204708	B2	20060525		
IN 2003MN00990	A	20050429	IN 2003-MN990	20031024 <--
PRIORITY APPLN. INFO.:			US 1997-996343	A 19971222 <--

AU 1999-21989
WO 1998-US26078A3 19981222 <--
W 19981222 <--OTHER SOURCE(S): MARPAT 131:73648
ED Entered STN: 09 Jul 1999
GI


AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave title compound II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μ M.

IT 228999-89-1P 228999-90-4P 228999-91-5P
228999-92-6P 229000-02-6P 229000-05-9P
229000-12-8P 229000-13-9P 229000-14-0P
229000-16-2P 229000-27-5P 229000-69-5P
229000-74-2P 229001-03-0P 229001-05-2P
229001-07-4P 229001-08-5P 229001-38-1P
229001-50-7P 229001-51-8P 229002-35-1P
229002-36-2P 229002-37-3P 229002-38-4P
229002-39-5P 229002-40-8P 229002-41-9P
229002-86-2P 229003-10-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)


RN 228999-89-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 228999-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-91-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 228999-92-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-02-6 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-05-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229000-13-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 229000-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 229000-27-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 229000-69-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[3-(1-methylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


RN 229000-74-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[[3-(1-methylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 229001-03-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



PAGE 1-A


U

PAGE 2-A

RN 229001-05-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 229001-07-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



RN 229001-08-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)


PAGE 1-A




U

PAGE 2-A

RN 229001-38-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229001-50-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 229001-51-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[3-(1,1-dimethylpropyl)-5-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 229002-35-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[3-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-36-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 229002-37-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 229002-38-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-39-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-chloro-4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-40-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]-3-methylphenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-41-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 229002-86-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[1-methyl-3-phenyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 229003-10-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-chloro-4-[[[3-(1,1-dimethylethyl)-5-isoxazolyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



U


REFERENCE COUNT:

7


THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Structure Search

=> D STAT QUE L17
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 STR



G1 [01], [02], [03]

Structure attributes must be viewed using STN Express query preparation.

L5 SCR 1840
L13 2810 SEA FILE=REGISTRY SSS FUL L5 AND (L1 AND L3)
L16 814 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L13
L17 75 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L16 AND (PRY<=2003 OR
AY<=2003 OR PY<=2003)

=> S L17 NOT L41
L42 48 L17 NOT L41

=> D IBIB ED ABS HITSTR L42 1-48

L42 ANSWER 1 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:207399 HCAPLUS [Full-text](#)
DOCUMENT NUMBER: 150:229703
TITLE: Methods using non-peptide thrombopoietin (TPO)
receptor agonists for treating cardiovascular
diseases/injuries
INVENTOR(S): Erickson-Miller, Connie; Jenkins, Julian
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S.

Serial No.:10/788,426

Ser. No. 554,811.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090048318	A1	20090219	US 2008-256669	20081023 <--
WO 2004096154	A2	20041111	WO 2004-US13468	20040429 <--
WO 2004096154	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070105824	A1	20070510	US 2006-554811	20061110 <--
PRIORITY APPLN. INFO.:				
			US 2003-466540P	P 20030429 <--
			US 2003-471554P	P 20030519 <--
			US 2003-495034P	P 20030814 <--
			US 2004-549977P	P 20040304
			US 2004-554581P	P 20040319
			US 2004-556390P	P 20040325
			WO 2004-US13468	W 20040429
			US 2006-554811	A2 20061110
ED	Entered STN: 20 Feb 2009			
AB	The invention discloses a method for treating cardiovascular disease/injury in a mammal (including a human) in need thereof, which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist.			
IT	475207-59-1, Nexavar			
	RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (non-peptide TPO receptor agonists for treatment of cardiovascular diseases/injuries)			
RN	475207-59-1 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)			
CM	1			
CRN	284461-73-0			
CMF	C21 H16 C1 F3 N4 O3			



CM 2

CRN 104-15-4

CMF C / H8 O3 S



L42 ANSWER 2 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1223087 HCAPLUS Full-text

DOCUMENT NUMBER: 149:440342

TITLE: DR5-binding agonist antibodies for induction of apoptosis in DR5 expressing cells and for treatment of cancer and hepatitis C virus infections

INVENTOR(S): Ni, Jian; Gentz, Reiner L.; Yu, Guo-Liang; Rosen, Craig A.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 138pp., Cont.-in-part of U.S. Ser. No. 9/9,831.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080248046	A1	20081009	US 2008-10106	20080118 <--
CA 2644454	A1	19980924	CA 1998-2644454	19980317 <--
EP 1788086	A1	20070523	EP 2007-1405	19980317 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6872568	B1	20050329	US 2000-565009	20000504 <--
US 20020098550	A1	20020725	US 2001-5842	20011207 <--
US 20040136951	A1	20040715	US 2003-648825	20030827 <--
US 20050233958	A1	20051020	US 2004-979831	20041103 <--
AU 2006246525	A1	20061221	AU 2006-246525	20061201 <--
JP 2008081503	A	20080410	JP 2007-260427	20071003 <--
PRIORITY APPLN. INFO.:		US 1997-40846P	P	19970317 <--
		US 1997-54021P	P	19970729 <--
		US 1998-42583	A2	19980317 <--

US 1999-132498P	P 19990504 <--
US 1999-133238P	P 19990507 <--
US 1999-148939P	P 19990813 <--
US 2000-565009	A2 20000504 <--
US 2002-406307P	P 20020828 <--
US 2002-413747P	P 20020927 <--
US 2003-648825	A2 20030827 <--
US 2004-551811P	P 20040311
US 2004-608429P	P 20040910
US 2004-979831	A2 20041103
US 2007-885944P	P 20070122
US 2007-990701P	P 20071128
AU 1998-67635	A 19980317 <--
CA 1998-2285040	A3 19980317 <--
EP 1998-912966	A3 19980317 <--
JP 1998-540790	A3 19980317 <--
AU 2002-300603	A3 20020809 <--

ED Entered STN: 10 Oct 2008


AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, antibodies with bind DR5 and act as agonists may be used to induce apoptosis in DR5-expressing cells. The DR5 agonist antibodies are used in combination with another agent, e.g., an alkylating agent, a PPAR γ antagonist, a proteasome inhibitor, etc., to treat cancer. Addnl., they may be used in treating hepatitis C virus infections. Thus, human DR5 cDNA was cloned, sequenced, and expressed in E. coli, CHO and COS cells and the extracellular domain was produced in a baculovirus expression system. This extracellular domain bound to TRAIL and blocked TRAIL-induced apoptosis of MCF7 cells. Overexpression of DR5 in MCF7 breast carcinoma cells and in HeLa epitheloid carcinoma cells induced apoptosis in these cells.

IT 284461-73-0, BAY 43-9006

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination chemotherapy with; DR5-binding agonist antibodies for
induction of apoptosis in DR5 expressing cells and for treatment of
cancer and hepatitis C virus infections)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L42 ANSWER 3 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1191409 HCAPLUS Full-text

DOCUMENT NUMBER: 149:417697

TITLE: Death domain containing receptor DR4 and methods for
inducing apoptosis and treating cancer with DR4

agonist antibodies
 INVENTOR(S): Ni, Jian; Rosen, Craig A.; Pan, James G.; Gentz, Reiner L.; Dixit, Vishva M.
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; The Regents of the University of Michigan
 SOURCE: U.S. Pat. Appl. Publ., 146pp., Cont.-in-part of U.S. Ser. No. 76,187.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080241155	A1	20081002	US 2008-10108	20080118 <--
US 6342363	B1	20020129	US 1998-13895	19980127 <--
EP 1862548	A1	20071205	EP 2007-9954	19980127 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6461823	B1	20021008	US 1999-448868	19991124 <--
US 6433147	B1	20020813	US 2000-565918	20000505 <--
US 20030036168	A1	20030220	US 2002-226296	20020823 <--
US 6943020	B2	20050913		
US 20030073187	A1	20030417	US 2002-226318	20020823 <--
US 7060272	B2	20060613		
US 20040136950	A1	20040715	US 2003-648786	20030827 <--
US 20050112090	A9	20050526		
US 7452538	B2	20081118		
US 20050244857	A1	20051103	US 2005-76187	20050310 <--
US 7476384	B2	20090113		
JP 2007326879	A	20071220	JP 2007-230847	20070905 <--
PRIORITY APPLN. INFO.:				
			US 1997-35722P	P 19970128 <--
			US 1997-37829P	P 19970205 <--
			US 1998-13895	A2 19980127 <--
			US 1999-132922P	P 19990506 <--
			US 2000-565918	A2 20000505 <--
			US 2002-406922P	P 20020830 <--
			US 2002-413861P	P 20020927 <--
			US 2003-648786	A2 20030827 <--
			US 2004-551768P	P 20040311
			US 2004-608469P	P 20040910
			US 2005-76187	A2 20050310
			US 2007-885971P	P 20070122
			US 2007-990687P	P 20071128
			EP 1998-904690	A3 19980127 <--
			JP 1998-532198	A3 19980127 <--
			US 1999-448868	A1 19991124 <--


ED Entered STN: 03 Oct 2008

AB The present invention relates to death domain-containing receptor 4 (DR4) proteins which are members of the tumor necrosis factor receptor family. A method for inducing apoptosis and treating cancer of a DR4-expressing cell comprising contacting the cell with an agonist antibody which binds to the extracellular domain of DR4 is disclosed. Thus, expts. are described which indicate that DR4 is an apoptosis-inducing receptor which binds TRAIL.

IT 284461-73-0, BAY 43-9006

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination chemotherapy with; death domain containing receptor DR4 and methods for inducing apoptosis and treating cancer with DR4 agonist antibodies)

RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L42 ANSWER 4 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1314363 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 144:57544
 TITLE: Antibody drug conjugates and uses for cancer therapy
 INVENTOR(S): Ebens, Allen J., Jr.; Jacobson, Frederic S.; Polakis, Paul; Schwall, Ralph H.; Sliwowski, Mark X.; Spencer, Susan D.
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 163
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117986	A2	20051215	WO 2005-US18829	20050531
WO 2005117986	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AT 310810	T	20051215	AT 2001-127791	19980916 <--
ES 2253320	T3	20060601	ES 2001-127791	19980916 <--
NZ 528704	A	20050225	NZ 1999-528704	19990308 <--
CA 2450824	A1	20000420	CA 1999-2450824	19991005 <--
EP 1466977	A1	20041013	EP 2004-7618	19991202 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NZ 523206	A	20041224	NZ 2000-523206	20000211 <--
NZ 523207	A	20041224	NZ 2000-523207	20000211 <--
NZ 523208	A	20041224	NZ 2000-523208	20000211 <--

Serial No.:10/788,426

NZ 523209	A	20041224	NZ 2000-523209	20000211 <--
CA 2481685	A1	20010308	CA 2000-2481685	20000824 <--
CA 2481691	A1	20010308	CA 2000-2481691	20000824 <--
CA 2481731	A1	20010308	CA 2000-2481731	20000824 <--
CA 2481756	A1	20010308	CA 2000-2481756	20000824 <--
CA 2481788	A1	20010308	CA 2000-2481788	20000824 <--
EP 1657253	A1	20060517	EP 2005-24024	20010601 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY, AL, TR				
EP 1657254	A2	20060517	EP 2005-24029	20010601 <--
EP 1657254	A3	20060607		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY, TR				
EP 1657251	A2	20060517	EP 2005-24036	20010601 <--
EP 1657251	A3	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY, AL, TR				
CN 1210696	C	20050713	CN 2001-811390	20010613 <--
AU 758921	B2	20030403	AU 2001-57764	20010801 <--
AU 759004	B2	20030403	AU 2001-57765	20010801 <--
CA 2420193	A1	20020228	CA 2001-2420193	20010823 <--
JP 2004520810	T	20040715	JP 2002-522275	20010823 <--
US 20030073129	A1	20030417	US 2001-946374	20010904 <--
US 20030207803	A1	20031106	US 2001-143026	20011019 <--
US 20030199021	A1	20031023	US 2001-13924	20011025 <--
EP 1397383	A2	20040317	EP 2001-990229	20011213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 772759	B2	20040506	AU 2002-14767	20020201 <--
AU 772723	B2	20040506	AU 2002-14769	20020201 <--
AU 772734	B2	20040506	AU 2002-14771	20020201 <--
AU 778585	B2	20041209	AU 2002-14753	20020201 <--
CA 2449602	A1	20021219	CA 2002-2449602	20020403 <--
WO 2002101069	A2	20021219	WO 2002-US10513	20020403 <--
WO 2002101069	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZA, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,				
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,				
GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002303231	A1	20021223	AU 2002-303231	20020403 <--
AU 2002303231	B2	20080306		
EP 1402260	A2	20040331	EP 2002-731246	20020403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500030	T	20050106	JP 2003-503819	20020403 <--
US 20030207351	A1	20031106	US 2002-140473	20020506 <--
US 20030148438	A1	20030807	US 2002-145821	20020514 <--
US 20030170788	A1	20030911	US 2002-145634	20020514 <--
US 20030207371	A1	20031106	US 2002-145749	20020514 <--
US 20030166084	A1	20030904	US 2002-146793	20020515 <--
US 20030134380	A1	20030717	US 2002-147509	20020516 <--
US 20040214269	A1	20041028	US 2002-147518	20020516 <--
US 20030180875	A1	20030925	US 2002-147505	20020517 <--
US 20030199027	A1	20031023	US 2002-152396	20020520 <--

Serial No.:10/788,426

US 20050074837	A1	20050407	US 2002-158788	20020530 <--
US 20030064446	A1	20030403	US 2002-194460	20020711 <--
US 20030153037	A1	20030814	US 2002-194457	20020711 <--
US 20030059879	A1	20030327	US 2002-194456	20020712 <--
US 20030064448	A1	20030403	US 2002-194484	20020712 <--
US 20030049747	A1	20030313	US 2002-195899	20020715 <--
US 20030064449	A1	20030403	US 2002-195884	20020715 <--
US 20030063112	A1	20030403	US 2002-195896	20020715 <--
US 20030068705	A1	20030410	US 2002-195886	20020715 <--
US 20030071834	A1	20030417	US 2002-195898	20020715 <--
US 20030049748	A1	20030313	US 2002-196748	20020716 <--
US 20030059880	A1	20030327	US 2002-196758	20020716 <--
US 20030064451	A1	20030403	US 2002-196755	20020716 <--
US 20030068710	A1	20030410	US 2002-196761	20020716 <--
US 20030162250	A1	20030828	US 2002-196747	20020716 <--
US 20030215910	A1	20031120	US 2002-199463	20020718 <--
US 20030180881	A1	20030925	US 2002-202475	20020723 <--
US 20030049777	A1	20030313	US 2002-202939	20020724 <--
US 20030054482	A1	20030320	US 2002-205902	20020725 <--
US 20030064462	A1	20030403	US 2002-206919	20020726 <--
US 20030064463	A1	20030403	US 2002-206922	20020726 <--
US 20030068754	A1	20030410	US 2002-206910	20020726 <--
US 20030068756	A1	20030410	US 2002-206912	20020726 <--
US 20030068759	A1	20030410	US 2002-206920	20020726 <--
US 20030068760	A1	20030410	US 2002-206921	20020726 <--
US 20030073183	A1	20030417	US 2002-206917	20020726 <--
US 20030096359	A1	20030522	US 2002-205910	20020726 <--
US 20040048334	A1	20040311	US 2002-205890	20020726 <--
US 20030064467	A1	20030403	US 2002-207921	20020729 <--
US 20030064468	A1	20030403	US 2002-207922	20020729 <--
US 20030064469	A1	20030403	US 2002-208027	20020729 <--
US 20030068766	A1	20030410	US 2002-207917	20020729 <--
US 20030068767	A1	20030410	US 2002-207918	20020729 <--
US 20030068768	A1	20030410	US 2002-207919	20020729 <--
US 20030068769	A1	20030410	US 2002-207920	20020729 <--
US 20030068770	A1	20030410	US 2002-207925	20020729 <--
US 20030068771	A1	20030410	US 2002-208021	20020729 <--
US 20030068772	A1	20030410	US 2002-208022	20020729 <--
US 20030068773	A1	20030410	US 2002-208023	20020729 <--
US 20030068774	A1	20030410	US 2002-208026	20020729 <--
US 20030068776	A1	20030410	US 2002-208030	20020729 <--
US 20030073184	A1	20030417	US 2002-207923	20020729 <--
US 20030073185	A1	20030417	US 2002-207924	20020729 <--
US 20030073186	A1	20030417	US 2002-208028	20020729 <--
US 20030215912	A1	20031120	US 2002-207915	20020729 <--
US 20040048335	A1	20040311	US 2002-208024	20020729 <--
AU 2002301608	A1	20030306	AU 2002-301608	20021023 <--
AU 2002301608	B2	20041118		
AU 2002301732	A1	20030306	AU 2002-301732	20021024 <--
AU 2002301732	B2	20050414		
AU 2002301730	A1	20030306	AU 2002-301730	20021025 <--
AU 2002301730	B2	20041014		
AU 2002301731	A1	20030306	AU 2002-301731	20021025 <--
AU 2002301731	B2	20050526		
AU 2002301722	A1	20030306	AU 2002-301722	20021028 <--
AU 2002301722	B2	20040916		
AU 2002301723	A1	20030313	AU 2002-301723	20021028 <--
AU 2002301723	B2	20041118		
US 20030120056	A1	20030626	US 2002-289498	20021105 <--
US 20030144498	A1	20030731	US 2002-289527	20021105 <--

Serial No.:10/788,426

US 20040249141	A1	20041209	US 2002-289490	20021105 <--
US 20030211576	A1	20031113	US 2002-298993	20021118 <--
US 20030224984	A1	20031204	US 2002-305654	20021126 <--
AU 2002313838	A1	20030327	AU 2002-313838	20021202 <--
AU 2002313838	B2	20050526		
AU 2002330288	A1	20030417	AU 2002-330288	20021202 <--
AU 2002330288	B2	20050505		
AU 2002317529	A1	20030410	AU 2002-317529	20021205 <--
AU 2002317529	B2	20050526		
AU 2002318894	A2	20030410	AU 2002-318894	20021213 <--
AU 2002318894	A1	20030410		
AU 2002318894	B2	20050512		
AU 2002363307	A1	20030710	AU 2002-363307	20021216 <--
AU 2002363307	B2	20050526		
AU 2002323928	A1	20030403	AU 2002-323928	20021220 <--
AU 2002323928	B2	20050811		
AU 2003200137	A1	20030417	AU 2003-200137	20030115 <--
AU 2003200204	A1	20030410	AU 2003-200204	20030120 <--
AU 2003200204	B2	20050512		
AU 2003200585	A1	20030501	AU 2003-200585	20030213 <--
AU 2003200585	B2	20060713		
AU 2003200721	A1	20030501	AU 2003-200721	20030225 <--
AU 2003200721	B2	20051208		
AU 2003200722	A1	20030501	AU 2003-200722	20030225 <--
AU 2003200722	B2	20060202		
AU 2003200731	A1	20030501	AU 2003-200731	20030225 <--
AU 2003200731	B2	20060413		
AU 2003200740	A1	20030612	AU 2003-200740	20030226 <--
AU 2003200740	B2	20051215		
AU 2003201315	A1	20030612	AU 2003-201315	20030228 <--
US 20030186306	A1	20031002	US 2003-410374	20030408 <--
AU 2003203679	A1	20030612	AU 2003-203679	20030411 <--
AU 2003203679	B2	20070405		
AU 2003204018	A1	20030612	AU 2003-204018	20030505 <--
AU 2003204018	B2	20050428		
AU 2003204357	A1	20030619	AU 2003-204357	20030526 <--
AU 2003204357	B2	20060330		
AU 2003257515	A1	20031120	AU 2003-257515	20031023 <--
AU 2003257515	B2	20051201		
AU 2003259607	A1	20031127	AU 2003-259607	20031031 <--
AU 2003259607	B2	20051103		
US 20040258710	A1	20041223	US 2004-791618	20040302 <--
US 20050019823	A1	20050127	US 2004-931886	20040831 <--
US 20050187382	A1	20050825	US 2004-950374	20040923 <--
US 20050153396	A1	20050714	US 2004-955952	20040929 <--
US 20050153348	A1	20050714	US 2004-20604	20041221 <--
US 20050176041	A1	20050811	US 2004-26279	20041230 <--
US 20050214819	A1	20050929	US 2005-30464	20050105 <--
US 20050164266	A1	20050728	US 2005-36582	20050113 <--
US 20050170396	A1	20050804	US 2005-36869	20050114 <--
US 20050202475	A1	20050915	US 2005-38328	20050118 <--
US 20050176046	A1	20050811	US 2005-46650	20050128 <--
US 20050176104	A1	20050811	US 2005-52503	20050204 <--
US 20050136515	A1	20050623	US 2005-56802	20050211 <--
US 20050136475	A1	20050623	US 2005-60652	20050216 <--
US 20050158830	A1	20050721	US 2005-80062	20050314 <--
US 20050214846	A1	20050929	US 2005-117757	20050427 <--
AU 2005249490	A1	20051215	AU 2005-249490	20050531
CA 2567520	A1	20051215	CA 2005-2567520	20050531
EP 1753463	A2	20070221	EP 2005-804852	20050531

Serial No.:10/788,426

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1993146	A	20070704	CN 2005-80026066	20050531
BR 2005010883	A	20071226	BR 2005-10883	20050531
JP 2008051029	T	20080117	JP 2007-515417	20050531
AU 2005205752	A1	20050922	AU 2005-205752	20050831 <--
AU 2005205752	B2	20070607		
AU 2005205754	A1	20050922	AU 2005-205754	20050831 <--
AU 2005205754	B2	20070920		
AU 2005205755	A1	20050922	AU 2005-205755	20050831 <--
AU 2005205755	B2	20071004		
AU 2005205758	A1	20050922	AU 2005-205758	20050831 <--
AU 2005205758	B2	20070913		
US 20070191270	A1	20070816	US 2005-234694	20050922 <--
US 20080166294	A1	20080710	US 2006-461752	20060801 <--
JP 2007037551	A	20070215	JP 2006-221327	20060814 <--
JP 4166254	B2	20081015		
IN 2006DN07052	A	20070713	IN 2006-DN7052	20061123
US 20070269446	A1	20071122	US 2006-564171	20061128 <--
MX 2006014065	A	20070131	MX 2006-14065	20061130
KR 2007037575	A	20070405	KR 2006-725240	20061130
AU 2006252290	A1	20070125	AU 2006-252290	20061229 <--
NO 2006006075	A	20070228	NO 2006-6075	20061229
US 20070219350	A1	20070920	US 2007-801111	20070507
AU 2007203155	A1	20070726	AU 2007-203155	20070705 <--
AU 2007203291	A1	20070802	AU 2007-203291	20070717 <--
AU 2007214325	A1	20070920	AU 2007-214325	20070830 <--
AU 2008201807	A1	20080515	AU 2008-201807	20080424
AU 2008201995	A1	20080529	AU 2008-201995	20080506 <--
AU 2008201996	A1	20080529	AU 2008-201996	20080506 <--
AU 2008201998	A1	20080529	AU 2008-201998	20080506 <--
AU 2008202000	A1	20080529	AU 2008-202000	20080506 <--
AU 2008202004	A1	20080529	AU 2008-202004	20080506 <--
AU 2008202007	A1	20080529	AU 2008-202007	20080506 <--
US 20090075278	A1	20090319	US 2008-156160	20080529
US 20090075279	A1	20090319	US 2008-156180	20080529
PRIORITY APPLN. INFO.:			US 2004-576517P	P 20040601
			US 2004-616098P	P 20041005
			US 1997-63128P	P 19971024 <--
			US 1998-83742P	P 19980430 <--
			US 1998-84366P	P 19980505 <--
			US 1998-85339P	A1 19980513 <--
			US 1998-87106P	P 19980528 <--
			US 1998-88326P	P 19980604 <--
			US 1998-88217P	P 19980605 <--
			US 1998-88655P	P 19980609 <--
			US 1998-89947P	P 19980619 <--
			US 1998-90676P	P 19980625 <--
			US 1998-91982P	P 19980707 <--
			AU 1998-84850	A3 19980714 <--
			US 1998-94651P	A1 19980730 <--
			US 1998-96012P	P 19980810 <--
			US 1998-97022P	P 19980818 <--
			US 1998-97954P	P 19980826 <--
			US 1998-97974P	P 19980826 <--
			US 1998-97979P	P 19980826 <--
			AU 1998-93881	A3 19980914 <--
			AU 1998-93178	A3 19981002 <--
			AU 1999-10703	A3 19981007 <--
			US 1998-105169P	P 19981022 <--

Serial No.:10/788,426

US 1998-63561P	P 19981028 <--
AU 1999-11260	A3 19981029 <--
AU 1999-12883	A3 19981029 <--
WO 1998-US22992	W 19981029 <--
AU 1999-30721	A3 19990308 <--
US 1999-131293P	P 19990427 <--
US 1999-133459P	P 19990511 <--
US 1999-140650P	P 19990622 <--
US 1999-149395P	P 19990817 <--
US 1999-151689P	P 19990831 <--
AU 1999-55908	A3 19990901 <--
CA 1999-2344465	A3 19991005 <--
AU 2000-17482	A3 19991130 <--
AU 2000-17499	A3 19991202 <--
EP 1999-960644	A3 19991202 <--
AU 2000-28794	A3 20000211 <--
US 2000-189320P	P 20000314 <--
US 2000-189328P	P 20000314 <--
US 2000-190828P	P 20000321 <--
US 2000-191048P	P 20000321 <--
US 2000-191314P	P 20000321 <--
US 2000-193032P	P 20000329 <--
US 2000-193053P	P 20000329 <--
US 2000-194449P	P 20000404 <--
US 2000-194647P	P 20000404 <--
US 2000-195975P	P 20000411 <--
US 2000-196000P	P 20000411 <--
US 2000-196187P	P 20000411 <--
US 2000-196820P	XX 20000411 <--
US 2000-198121P	P 20000418 <--
US 2000-198585P	P 20000418 <--
US 2000-199397P	P 20000425 <--
US 2000-199550P	P 20000425 <--
US 2000-201516P	P 20000503 <--
US 2000-204675P	P 20000517 <--
US 2000-213087P	P 20000622 <--
US 2000-220893P	P 20000726 <--
US 2000-222425P	P 20000801 <--
US 2000-227133P	P 20000822 <--
CA 2000-2380355	A3 20000824 <--
US 2000-232887P	P 20000915 <--
US 2000-236009P	P 20000927 <--
US 2000-690189	A3 20001016 <--
JP 2002-576286	A3 20010322 <--
US 2001-816920	B1 20010322 <--
EP 2001-939834	A3 20010601 <--
EP 2004-5726	A3 20010601 <--
US 2001-880457	A 20010612 <--
US 2001-882636	B1 20010614 <--
AU 2001-271938	A3 20010710 <--
AU 2001-71938	T0 20010710 <--
US 2001-927796	B1 20010809 <--
WO 2001-US26626	W 20010823 <--
US 2001-990711	A1 20011114 <--
US 2001-992521	B1 20011114 <--
WO 2001-US48938	W 20011213 <--
US 2002-52586	A1 20020115 <--
WO 2002-US10513	W 20020403 <--
US 2002-123155	A1 20020415 <--
US 2002-127825	A1 20020422 <--

US	2002-127966	B1	20020423	<--
US	2002-141703	A1	20020508	<--
US	2002-145627	A1	20020514	<--
US	2002-145751	A	20020514	<--
US	2002-146793	A1	20020515	<--
US	2002-197703	B1	20020717	<--
US	2002-197708	A1	20020717	<--
US	2002-197942	B1	20020718	<--
US	2002-199666	A1	20020718	<--
US	2002-199464	B1	20020719	<--
US	2002-211858	A1	20020802	<--
AU	2002-330015	A3	20020911	<--
AU	2002-367318	A3	20021230	<--
AU	2003-200137	A3	20030115	<--
AU	2003-203679	A3	20030411	<--
AU	2003-261484	A	20031106	<--
US	2003-520842P	P	20031117	<--
US	2003-532426P	P	20031224	<--
US	2004-797366	A1	20040309	
US	2004-872972	A1	20040621	
US	2004-989826	A2	20041116	
WO	2004-US38262	A2	20041116	
AU	2005-200179	A3	20050114	
US	2005-141344	A2	20050531	
WO	2005-US18829	W	20050531	
US	2006-461752	A2	20060801	
US	2007-804045	A1	20070515	

OTHER SOURCE(S): MARPAT 144:57544

ED Entered SIN: 16 Dec 2005


AB The present invention relates to antibody-drug conjugate compds. with a formula of Ab-(L-D)_p where 1 to 8 (p) maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compds. may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

IT 284461-73-0, Sorafenib

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibody drug conjugates and uses for cancer therapy)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial No.:10/788,426

L42 ANSWER 5 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:641873 HCAPLUS Full-text

DOCUMENT NUMBER: 143:153299

TITLE: Preparation of substituted urea derivatives for use in treating heart failure

INVENTOR(S): Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-Ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of Appl. No. PCT/US04/001069.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050159416	A1	20050721	US 2004-890829	20040714 <--
US 7491826	B2	20090217		
WO 2004064730	A2	20040805	WO 2004-US1069	20040114 <--
WO 2004064730	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
PRIORITY APPLN. INFO.:				
			US 2003-440133P	P 20030114 <--
			US 2003-440183P	P 20030114 <--
			US 2003-476086P	P 20030604 <--
			US 2003-476517P	P 20030605 <--
			US 2003-501376P	P 20030908 <--
			WO 2004-US1069	A2 20040114

OTHER SOURCE(S): MARPAT 143:153299

ED Entered STN: 22 Jul 2005

AB The present invention provides substituted urea derivs., pharmaceutical compns. containing the derivs., and methods for the treatment of heart failure including congestive heart failure, particularly systolic heart failure. The compns. are selective modulators of the cardiac sarcomere, for example, potentiating cardiac myosin. The ureas of the invention are represented by the formula R1NHC(O)NHR2 wherein: R1 is optionally substituted aryl or heteroaryl; and R2 is optionally substituted aryl, aralkyl, cycloalkyl, heteroaryl, heteroaralkyl or heterocyclyl, including single stereoisomers, mixts. of stereoisomers, and the pharmaceutically acceptable salts, solvates, and solvates of pharmaceutically acceptable salts thereof.

IT 1055935-78-8 1055936-00-9 1055936-01-0
 1055936-02-1 1055936-06-5 1055936-11-2
 1055936-14-5 1055936-20-3 1055936-26-9
 1055936-75-8 1055936-78-1 1055936-79-2
 1055936-81-6 1055936-83-8 1055936-86-1
 1055936-87-2 1055936-89-4 1055936-92-9
 1055936-94-1 1055936-96-3 1055936-97-4
 1055937-00-2 1055937-09-1 1055937-12-6
 1055937-23-9 1055938-03-8 1055938-05-0
 1055938-22-1 1055938-53-8 1055938-55-0
 1055938-56-1 1055938-58-3 1055938-73-2
 1055938-88-9 1055939-04-2 1055939-18-8
 1055939-89-3 1055939-91-7 1055939-92-8
 1055939-95-1 1055939-98-4 1055940-01-6


1055940-02-7 1055940-03-8 1055940-04-9
 1055940-05-0 1055940-08-3 1055940-14-1
 1055940-20-9 1055940-34-5 1055940-35-6
 1055940-36-7 1055940-37-8 1055940-38-9
 1055940-39-0 1055940-40-3 1055940-41-4
 1055940-42-5 1055940-54-9 1055940-55-0
 1055940-56-1 1055940-59-4 1055940-81-2
 1055940-82-3 1055940-84-5 1055940-87-8
 1055941-01-9 1055941-17-7 1055941-18-8
 1055941-19-9 1055941-20-2 1055941-21-3
 1055941-38-2 1055941-39-3 1055941-47-3
 1055942-11-4 1055942-13-6 1055942-14-7
 1055942-15-8 1055942-45-4 1055942-50-1
 1055942-76-1 1055942-77-2 1055942-78-3
 1055942-80-7 1055942-85-2 1055942-88-5
 1055942-89-6 1055942-90-9 1055942-91-0
 1055943-09-3 1055943-10-6 1055943-11-7
 1055943-12-8 1055943-15-1 1055943-16-2
 1055943-17-3 1055943-18-4 1055943-19-5
 1055943-20-8 1055943-21-9 1055943-22-0
 1055943-23-1 1055943-25-3 1055943-28-6
 1056969-82-4 1056969-88-0 1056969-89-1
 1056969-90-4 1056969-93-7 1056969-94-8
 1056969-95-9 1056969-97-1 1056969-98-2
 1056969-99-3 1056970-00-3 1056970-01-4
 1056970-02-5 1056970-03-6 1056970-08-1
 1056970-09-2 1056970-10-5 1056970-11-6
 1056970-12-7 1056970-13-8 1056970-15-0
 1056970-16-1 1056970-17-2 1056970-18-3
 1056970-19-4 1056970-21-8 1056970-24-1
 1056970-42-3 1056970-43-4 1056970-44-5
 1067173-78-7 1067175-92-1

RL: PRPH (Prophetic)

(Preparation of substituted urea derivatives for use in treating heart failure)

RN 1055935-78-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[(3-pyridinylamino)carbonylamino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)



RN 1055936-00-9 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-01-0 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-02-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[6-(cyanomethyl)-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-06-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1055936-11-2 HCAPLUS

CN 2-Pyridinecarboxamide, 5-([3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl)amino]carbonyl]amino]-N-(aminoiminomethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-14-5 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-methoxy-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-20-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(1-methyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-26-9 HCAPLUS

CN 1-Piperidineacetic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-α-oxo-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-75-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-78-1 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-[6-(cyanomethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-79-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[[(2R)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-81-6 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-83-8 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-86-1 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[[[(3R)-1-[[[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-87-2 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(1H-imidazol-2-ylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055936-89-4 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1055936-92-9 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[(6-ethyl-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-94-1 HCAPLUS

CN Urea, N-[3-[[[(3R,5R)-1-acetyl-5-hydroxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-96-3 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-97-4 HCAPLUS

CN Urea, N-[3-[[[(3R,5R)-1-acetyl-5-hydroxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-00-2 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-09-1 HCAPLUS

CN Urea, N-[3-[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-chloro-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-12-6 HCAPLUS

CN Urea, N-[3-fluoro-5-[[(3R)-1-[(tetrahydro-2H-pyran-4-yl)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-23-9 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[3-(3-pyridinylamino)carbonyl]amino]phenoxy]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-03-8 HCAPLUS

CN Urea, N-[3-[[3R)-1-(1-azetidiny carbonyl)-3-piperidinyloxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-05-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-(3-pyridinylamino)carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-22-1 HCAPLUS

CN Urea, N-[3-[[[(3R,5S)-1-acetyl-5-methoxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-53-8 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[[[(3R)-1-[(tetrahydro-2-furanyl)carbonyl]-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-55-0 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-1H-imidazol-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-56-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[(3-pyridinylamino)carbonyl]amino]phenoxy]-, 2-methoxyethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-58-3 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-[6-(methoxymethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-73-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[(3R)-1-[(tetrahydro-2-furanyl)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-88-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[5-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-04-2 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-methoxy-, methyl ester, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055939-18-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[3-pyridinylamino]carbonyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 1055939-89-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-91-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[3-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-92-8 HCAPLUS


CN Urea, N-[3-[[3-(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-(5-fluoro-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055939-95-1 HCAPLUS
 CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055939-98-4 HCAPLUS
 CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055940-01-6 HCAPLUS
 CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-2-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055940-02-7 HCAPLUS
 CN Urea, N-[3-fluoro-5-[[[(3R)-1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055940-03-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1055940-04-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1055940-05-0 HCAPLUS
CN Urea, N-[3-fluoro-5-[[[(3R)-1-(2-methoxy-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055940-08-3 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 1055940-14-1 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-5-methoxy]-, methyl ester, (3R,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055940-20-9 HCAPLUS


CN Urea, N-[3-[(1-acetyl-3-piperidyl)oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 1055940-34-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-35-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-36-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-[6-(methoxymethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-37-8 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(phenylmethoxy)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-38-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[(1,6-dihydro-6-oxo-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-39-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[6-(cyanomethyl)-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-40-3 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(4-formyl-1-piperidinyl)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-41-4 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-42-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-54-9 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(4-piperidinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-55-0 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(1-pyrrolidinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-56-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[(5-chloro-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-59-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-81-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-82-3 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-aminomethyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-84-5 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(2R)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-87-8 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055941-01-9 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 1055941-17-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-18-8 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-19-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 1055941-20-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(2-methoxyacetyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-21-3 HCAPLUS

CN Urea, N-[3-[[1-[2-(dimethylamino)acetyl]-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-38-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 1055941-39-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)



RN 1055941-47-3 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 1055942-11-4 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-(6-formyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-13-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[4-(pyridazinylamino)carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-14-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[3R)-1-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-15-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 5-[3-fluoro-5-[[6-methyl-3-pyridinyl]amino]carbonyl]amino]phenoxy]-2-oxo-, 1,1-dimethylethyl ester, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-45-4 HCAPLUS

CN Urea, N-(1,6-dihydro-6-oxo-3-pyridinyl)-N'-[3-fluoro-5-[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-50-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, methyl ester, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-76-1 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-[[[1,6-dihydro-6-oxo-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055942-77-2 HCAPLUS


CN Urea, N-[3-[(1R)-1-(2-oxo-2-(methylamino)ethyl)piperidin-3-yl]oxy]-5-fluorophenyl]-N'-[2-(hydroxymethyl)-3-pyridinyl]- (CA INDEX NAME)



RN 1055942-78-3 HCAPLUS

CN Urea, N-[3-[(1R)-1-(2-oxo-2-(methylamino)ethyl)piperidin-3-yl]oxy]-5-fluorophenyl]-N'-[6-(1,3,4-oxadiazol-2-ylmethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-80-7 HCAPLUS

CN Urea, N-[6-(cyanomethyl)-3-pyridinyl]-N'-[3-fluoro-5-[(1R)-1-formyl-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-85-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-methoxy-, methyl ester, (3R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-88-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-89-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-4-methoxy-, methyl ester, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-90-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-91-0 HCAPLUS

CN Urea, N-[3-fluoro-5-[(1R)-1-(1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-09-3 HCAPLUS

CN Urea, N-[3-[(1S)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-10-6 HCAPLUS

CN Urea, N-[3-[(1R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-2-oxazolyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-11-7 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(2-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-12-8 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(6-ethyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-15-1 HCAPLUS


CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055943-16-2 HCAPLUS


CN Urea, N-[3-[(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 1055943-17-3 HCAPLUS

CN Urea, N-[3-fluoro-5-[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-18-4 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-19-5 HCAPLUS

CN Urea, N-[3-[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-20-8 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-ethynyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-21-9 HCAPLUS

CN Urea, N-[3-fluoro-5-[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-(6-(1-methylethyl)-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-22-0 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-(1-methylethyl)-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-23-1 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-5-oxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-25-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(4-pyridazinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-28-6 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(4-pyridazinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056969-82-4 HCAPLUS


CN Urea, N-[3-fluoro-5-[(1-formyl-3-piperidinyl)oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 1056969-88-0 HCAPLUS

CN 2-Pyridinesulfonamide, 3-[[[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]amino]carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-89-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[2-[(acetylamino)methyl]-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-90-4 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R)-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-piperidinyloxy]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-93-7 HCAPLUS

CN 2-Pyridinecarboxamide, 3-([3-[(3R)-1-[(dimethylamino)carbonyl]-3-piperidinyl]oxy]-5-fluorophenyl)amino]carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-94-8 HCAPLUS

CN 4-Morpholinecarboxamide, N-[2-[(2R)-2-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-95-9 HCAPLUS

CN 2-Pyridinecarboxamide, 3-([3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl)amino]carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-97-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-[2-(acetyloxy)ethyl]-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-98-2 HCAPLUS

CN 2-Pyridineacetamide, 3-[[[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]amino]carbonyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056969-99-3 HCAPLUS


CN 2-Pyridineacetamide, 3-[[[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]amino]carbonyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056970-00-3 HCAPLUS
 CN Acetamide, N-[3-[[[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]amino]carbonyl]amino]-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056970-01-4 HCAPLUS
 CN Acetamide, N-[3-[[[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]amino]carbonyl]amino]-2-pyridinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056970-02-5 HCAPLUS
 CN Acetamide, N-[3-[[[3-[[[3-fluoro-5-[[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]amino]carbonyl]amino]-2-pyridinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056970-03-6 HCAPLUS
 CN 1-Piperidinecarboxamide, 3-[3-[[[2-[(acetylamino)methyl]-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-08-1 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(2-[(formylmethylamino)methyl]-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-09-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[2-(aminoiminomethyl)-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-10-5 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(4-hydroxy-1-piperidinyloxy)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-11-6 HCAPLUS

CN 4-Piperidinecarboxamide, 1-[[[(3R)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-12-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-13-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1056970-15-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1056970-16-1 HCAPLUS

CN Acetamide, N-[2-[(2R)-2-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-17-2 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1056970-18-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1056970-19-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 2-methoxyethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056970-21-8 HCAPLUS
CN 1-Piperidinecarboxamide, 3-[3-[[[(5-chloro-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 1067173-78-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1067175-92-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 732246-14-9P, N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methoxypyridin-3-yl)urea 732246-15-0P,
N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(pyridin-3-yl)urea 732246-17-2P 732246-18-3P,
(R)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methoxypyridin-3-yl)urea 732246-19-4P, (R)-3-[3-Fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-1-piperidinecarboxylic acid methyl ester 732246-20-7P 732246-22-9P,
(R)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methylpyridin-3-yl)urea 732246-23-0P 732246-24-1P 732246-26-3P
732246-39-8P 732246-40-1P 732246-42-3P
859838-51-0P, (S)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methoxypyridin-3-yl)urea 859838-52-1P,
(S)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(pyridin-3-yl)urea 859838-53-2P 859838-55-4P,
(S)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methylpyridin-3-yl)urea 859838-60-1P 859838-67-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


Serial No.:10788,426

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted urea derivs. for use in treating heart failure)


RN 732246-14-9 HCAPLUS

CN Urea, N-[3-[(1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 732246-15-0 HCAPLUS

CN Urea, N-[3-[(1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)



RN 732246-17-2 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 732246-18-3 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-19-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[(3-methoxypyridin-2-ylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-20-7 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[(3-methoxypyridin-2-ylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-22-9 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-23-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-24-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-26-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-39-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-40-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[(3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-42-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-51-0 HCAPLUS

CN Urea, N-[3-[(3S)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-52-1 HCAPLUS

CN Urea, N-[3-[(3S)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-53-2 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-55-4 HCAPLUS

CN Urea, N-[3-[[(3S)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-60-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-87-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 732245-95-3P 732246-03-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted urea derivs. for use in treating heart failure)

RN 732245-95-3 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-03-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 732246-06-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted urea derivs. for use in treating heart failure)

RN 732246-06-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


105

THERE ARE 105 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L42 ANSWER 6 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:641861 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:146651
 TITLE: JAK/STAT inhibitors and MAPK/ERK inhibitors for
 respiratory syncytial virus (RSV) infection
 INVENTOR(S): Mohapatra, Shyam S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050159385	A1	20050721	US 2004-18954	20041220 <--
PRIORITY APPLN. INFO.:			US 2003-531052P	P 20031219 <--
ED Entered STN: 22 Jul 2005				
AB	The invention discloses a method for treating or reducing the likelihood of developing a RSV infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Also disclosed is a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Further disclosed is a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection.			
IT	284461-73-0, BAY 43-9006 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (JAK/STAT inhibitors and MAPK/ERK inhibitors for respiratory syncytial virus infection treatment)			
RN	284461-73-0 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)			




L42 ANSWER 7 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:470256 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:20052
 TITLE: Urea derivatives as kinase modulators
 INVENTOR(S): Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld,

Serial No.:10/788,426

Robert M.; Mehta, Shamal A.; Andiliy, Lai G.;
Lockhart, David J.PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
SOURCE: PCT Int. Appl., 350 pp.
CODEN: PIXXD2DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048948	A2	20050602	WO 2004-US38288	20041115 <--
WO 2005048948	A3	20050728		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004291147	A1	20050602	AU 2004-291147	20041115 <--
CA 2545711	A1	20050602	CA 2004-2545711	20041115 <--
US 20050148605	A1	20050707	US 2004-989745	20041115 <--
US 20050165031	A1	20050728	US 2004-989814	20041115 <--
US 20050165024	A1	20050728	US 2004-989824	20041115 <--
US 20050165074	A1	20050728	US 2004-990007	20041115 <--
US 20050171171	A1	20050804	US 2004-989766	20041115 <--
US 20050171172	A1	20050804	US 2004-989823	20041115 <--
US 20050192314	A1	20050901	US 2004-990195	20041115 <--
US 20050197371	A1	20050908	US 2004-990194	20041115 <--
US 20050261315	A1	20051124	US 2004-989623	20041115 <--
US 20050267182	A1	20051201	US 2004-989717	20041115 <--
EP 1684762	A2	20060802	EP 2004-811122	20041115 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
JP 2007512255	T	20070517	JP 2006-539991	20041115 <--
PRIORITY APPLN. INFO.:			US 2003-520273P	P 20031113 <--
			US 2003-527094P	P 20031203 <--
			US 2003-531082P	P 20031218 <--
			US 2003-531243P	P 20031218 <--
			WO 2004-US38288	W 20041115
OTHER SOURCE(S):	MARPAT 143:20052			
ED	Entered STN: 02 Jun 2005			
AB	The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.			
IT	228999-89-1 RL: PRPH (Prophetic) (Urea derivatives as kinase modulators)			
RN	228999-89-1 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[5-(1,1-dimethylethyl)-3- isoxazolyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)			



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 8 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:470251 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:19957

TITLE: Combination therapy comprising a cyclooxygenase 2 (COX-2) inhibitor and an antineoplastic agent for treatment or prevention of neoplasia

INVENTOR(S): Masferrer, Jaime L.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 317 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048942	A2	20050602	WO 2004-US38019	20041115 <--
WO 2005048942	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20050227929	A1	20051013	US 2004-989192	20041115 <--
PRIORITY APPLN. INFO.:			US 2003-519701P	P 20031113 <--

ED Entered STN: 02 Jun 2005


AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a COX-2 inhibitor and an antineoplastic agent.

IT 284461-73-0, BAY 439006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor-antineoplastic agent combination for treatment or prevention of neoplasia)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 9 OF 48 HCAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2005:409543 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:457053

TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy

INVENTOR(S): Lacasse, Eric; McManus, Daniel

PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042558	A1	20050512	WO 2004-CA1902	20041029 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050148535	A1	20050707	US 2004-975974	20041028 <--
CA 2542904	A1	20050512	CA 2004-2542904	20041029 <--
EP 1682565	A1	20060726	EP 2004-789809	20041029 <--
R: DE, FR, GB				
JP 2007510408	T	20070426	JP 2006-537024	20041029 <--
PRIORITY APPLN. INFO.:			US 2003-516192P	P 20031030 <--
			WO 2004-CA1902	W 20041029

ED Entered STN: 13 May 2005

AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The


invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).

IT 284461-73-0, BAY-43-9006

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 10 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:409357 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:457052

TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent

INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.

PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.

SOURCE: PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

Serial No.:10/788,426

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 20050119217	A1	20050602	US 2004-975790	20041028 <--
AU 2004284855	A1	20050512	AU 2004-284855	20041029 <--
CA 2542884	A1	20050512	CA 2004-2542884	20041029 <--
EP 1691842	A1	20060823	EP 2004-789807	20041029 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004015779	A	20061226	BR 2004-15779	20041029 <--
CN 1901939	A	20070124	CN 2004-80039601	20041029 <--
JP 2007509861	T	20070419	JP 2006-537023	20041029 <--
MX 2006004920	A	20070216	MX 2006-4920	20060502 <--
IN 2006MN00614	A	20070420	IN 2006-MN614	20060526 <--
NO 2006002420	A	20060731	NO 2006-2420	20060529 <--
KR 2006127393	A	20061212	KR 2006-710619	20060530 <--

PRIORITY APPLN. INFO.: US 2003-516263P P 20031030 <--
 WO 2004-CA1900 W 20041029


ED Entered STN: 13 May 2005

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

IT 284461-73-0, BAY-43-9006
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with chemotherapeutic agent)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 11 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:283363 HCAPLUS Full-text

DOCUMENT NUMBER: 142:329832

TITLE: Combination of a vegf receptor inhibitor with a chemotherapeutic agent

INVENTOR(S): Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry Min-Jian; Kinder, Frederick Ray, Jr.; Lane, Heidi; Latour, Elisabeth Jeanne; Manley, Paul William; Wood, Jeanette Marjorie

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027972	A2	20050331	WO 2004-EP10686	20040923 <--
WO 2005027972	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273615	A1	20050331	AU 2004-273615	20040923 <--
AU 2004273615	B2	20090115		
CA 2537991	A1	20050331	CA 2004-2537991	20040923 <--
EP 1682181	A2	20060726	EP 2004-765542	20040923 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856327	A	20061101	CN 2004-80027544	20040923 <--
BR 2004014698	A	20061128	BR 2004-14698	20040923 <--
JP 2007505938	T	20070315	JP 2006-527348	20040923 <--
MX 2006003163	A	20060605	MX 2006-3163	20060320 <--
IN 2006CN00982	A	20070615	IN 2006-CN982	20060322 <--
NO 2006001777	A	20060623	NO 2006-1777	20060421 <--
US 20080085902	A1	20080410	US 2007-573163	20070228 <--
PRIORITY APPLN. INFO.:				
			US 2003-505250P	P 20030923 <--
			WO 2004-EP10686	W 20040923

OTHER SOURCE(S): MARPAT 142:329832

ED Entered SIN: 01 Apr 2005

AB The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with: (a) a VEGF inhibitor compound; and (b) one or more chemotherapeutic agents selected from the group consisting of: an aromatase inhibitor; an anti-estrogen, an anti-androgen (especially in the case of prostate cancer) or a gonadorelin agonist; a topoisomerase I inhibitor or a topoisomerase II inhibitor; a microtubule active agent, an alkylating agent, an anti-neoplastic anti-metabolite or a platin compound; a compound

targeting/decreasing a protein or lipid kinase activity or a protein or lipid phosphatase activity, a further anti-angiogenic compound or a compound which induces cell differentiation processes. The patient is treated with : (a) a VEGF inhibitor compound; and (b) one or more chemotherapeutic agents selected from the group consisting of : a bradykinin 1 receptor or an angiotensin II antagonist ; a cyclooxygenase inhibitor , a bisphosphonate , a heparanase inhibitor (prevents heparan sulfate degradation) , e.g. , PI-88 , a biol. response modifier, preferably a lymphokine or interferons , e.g., interferon γ , an ubiquitination inhibitor, or an inhibitor which blocks anti-apoptotic pathways ; an inhibitor of Ras oncogenic isoforms or a farnesyl transferase inhibitor ; a telomerase inhibitor , e.g. , telomestatin ; a protease inhibitor, a matrix metalloproteinase inhibitor , a methionine aminopeptidase inhibitor , e.g. , bengamide or a derivative thereof , or a proteasome inhibitor , e.g. , PS-341. The patient is treated with : (a) a VEGF inhibitor compound (b) one or more chemotherapeutic agents selected from the group consisting of : agents used in the treatment of hematol. malignancies or FMS-like tyrosine kinase inhibitors ; an HSP90 inhibitors ; HDAC inhibitors ; mTOR inhibitors ; somatostatin receptor antagonists ; integrin antagonists ; anti-leukemic compds. ; tumor cell damaging approaches such as ionizing radiation EDG binders ; anthranilic acid amide class of kinase inhibitors ; ribonucleotide reductase inhibitors ; S-adenosylmethionine decarboxylase inhibitors ; antibodies against VEGF or VEGFR ; photodynamic therapy ; angiostatic steroids ; implants containing corticosteroids ; ATI receptor antagonists ; ACE inhibitors.


IT 284461-73-0, BAY43-9006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of vegf receptor inhibitor with chemotherapeutic agent)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 12 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:283298 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:349042

TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916 <--
WO 2005027842	A3	20051222		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004273910	A1	20050331	AU 2004-273910	20040916 <--
CA 2538570	A1	20050331	CA 2004-2538570	20040916 <--
EP 1670477	A2	20060621	EP 2004-788798	20040916 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014568	A	20061107	BR 2004-14568	20040916 <--
CN 1878556	A	20061213	CN 2004-80033294	20040916 <--
JP 2007505914	T	20070315	JP 2006-527024	20040916 <--
MX 2006003066	A	20060620	MX 2006-3066	20060317 <--
NO 2006001325	A	20060606	NO 2006-1325	20060323 <--
KR 2007012618	A	20070126	KR 2006-707244	20060414 <--
PRIORITY APPLN. INFO.:			US 2003-504310P	P 20030918 <--
			WO 2004-US30368	W 20040916

OTHER SOURCE(S): MARPAT 142:349042

ED Entered STN: 01 Apr 2005

AB The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.


IT 284461-73-0, BAY-43-9006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chlorpromazine compound-antiproliferative drug antitumor combination)


RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




L42 ANSWER 13 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:182644 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:280215
 TITLE: Preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors
 INVENTOR(S): Hoelzemann, Guenter; Ackermann, Karl-August; Staehle, Wolfgang; Jonczyk, Alfred; Rautenberg, Wilfried; Mitjans, Francesc; Rosell-Vives, Elisabet; Adan, Jaume; Soler, Marta; Crassier, Helene
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019192	A1	20050303	WO 2004-EP7224	20040702 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10334663	A1	20050310	DE 2003-10334663	20030730 <--
AU 2004266781	A1	20050303	AU 2004-266781	20040702 <--
CA 2533963	A1	20050303	CA 2004-2533963	20040702 <--
EP 1651626	A1	20060503	EP 2004-763077	20040702 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2007500136	T	20070111	JP 2006-521413	20040702 <--
US 20060241301	A1	20061026	US 2006-566351	20060130 <--
PRIORITY APPLN. INFO.:			DE 2003-10334663	A 20030730 <--
			WO 2004-EP7224	W 20040702
ED	Entered STN:	04 Mar 2005		
AB	Twenty-eight title compds. were claimed. Thus, 5-(4-aminophenoxy)benzo-1,2,5-thiadiazole (preparation given), 2-fluoro-5-(trifluoromethylphenyl) isocyanate, and Et3N were stirred in CH2Cl2 to give 1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-3-(2-fluoro-5- trifluoromethylphenyl)urea as the trifluoroacetate. The latter inhibited TIE-2 and RAF kinase with IC50 = 57 nM and 220 nM, resp.			
IT	847054-10-8P 847054-43-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (claimed compound; preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors)			
RN	847054-10-8 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)			



RN 847054-43-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[4-[[[2-fluoro-4-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 14 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:182263 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:259420
 TITLE: Detection of BRAF transversion mutation on fine needle aspiration biopsy specimens as diagnostic tool for malignant thyroid cancer in human
 INVENTOR(S): Sidransky, David; Cohen, Yoram; Zhao, Ming
 PATENT ASSIGNEE(S): The Johns Hopkins University, USA
 SOURCE: U.S. Pat. Appl. Publ., 16 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050048533	A1	20050303	US 2004-821203	20040409 <--
US 7378233	B2	20080527		
US 20080241132	A1	20081002	US 2008-124504	20080521 <--
PRIORITY APPLN. INFO.:			US 2003-462046P	P 20030412 <--
			US 2004-821203	A3 20040409

ED Entered STN: 04 Mar 2005

AB The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme anal. of BRAF exon 15. In 24 (69%) of the 35


papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas. The presence of the transversion T1796A indicates a higher risk of neck lymph node metastasis. BRAF mutation was found only in PTC (papillary thyroid carcinoma), but not in the follicular thyroid cancers, Hurthle cell thyroid cancers, medullary thyroid cancers, and benign thyroid neoplasms.

IT 284461-73-G, BAY 43-9006

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(detection of BRAF transversion mutation for diagnosis of malignant thyroid cancer and uses of Ras-Raf-MAPK or Raf/MEK/ERK signaling pathway inhibitor in treating thyroid cancer)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 15 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:141055 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:240466

TITLE: Preparation of piperazinylbenzocycloheptapyridines as farnesyl protein transferase inhibitors useful as antitumor agents.

INVENTOR(S): Zhu, Hugh Y.; Cooper, Alan B.; Desai, Jagdish A.; Wang, James J.-S.; Rane, Dinanath F.; Doll, Ronald J.; Njoroge, F. George; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014577	A1	20050217	WO 2004-US25042	20040804 <--
WO 2005014577	A9	20060323		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

Serial No.:10/788,426

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004263493	A1	20050217	AU 2004-263493	20040804 <--
CA 2535210	A1	20050217	CA 2004-2535210	20040804 <--
US 20050059672	A1	20050317	US 2004-911340	20040804 <--
EP 1660477	A1	20060531	EP 2004-779960	20040804 <--
EP 1660477	B1	20081210		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004013384	A	20061017	BR 2004-13384	20040804 <--
CN 1863792	A	20061115	CN 2004-80029384	20040804 <--
JP 2007501791	T	20070201	JP 2006-522672	20040804 <--
AT 417041	T	20081215	AT 2004-779960	20040804 <--
IN 2006CN00459	A	20070518	IN 2006-CN459	20060203 <--
KR 2006057599	A	20060526	KR 2006-702512	20060206 <--
MX 2006001483	A	20060515	MX 2006-1483	20060207 <--
NO 2006001077	A	20060505	NO 2006-1077	20060306 <--


PRIORITY APPLN. INFO.:

US 2003-493269P	P	20030807 <--
US 2003-498509P	P	20030828 <--
WO 2004-US25042	W	20040804


OTHER SOURCE(S): CASREACT 142:240466; MARPAT 142:240466

ED Entered SIN: 18 Feb 2005

GI



I



II

AB Title compds. [I; R1 = R9X(CR6R7)nCO, R10O2C; n = 1-6; X = O, S, N; R2-R5 = H, Br, Cl, F; R5a = H, alkyl, cycloalkyl; R6, R7 = H, alkyl; R6R7C = C3-7 cycloalkyl; R8 = R10O2C, R11SO2, R12R11aNCO, R21R22R46CO; R9 = alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, etc.; R10 = substituted aryl, heteroaryl, cycloalkyl, alkenyl, alkynyl, etc.; R11 = (substituted) alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl; R11a = H, OH, (substituted) alkyl, aryl, cycloalkyl, heteroaryl,

heterocycloalkyl, etc.; R12 = H, alkyl, (substituted) piperidinyl, alkylpiperidinyl; R21, R22, R46 = H, alkyl, (substituted) aryl, cycloalkyl, heteroaryl, piperidinyl, etc.), were prepared. Thus, title compound (II) was prepared in several steps from 8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one. I inhibited FPTase with IC50 in the range of <0.5 nM to 5 nM.


IT 284461-73-G, Bay 43-9006

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration; preparation of piperazinylbenzocycloheptapyridines as farnesyl protein transferase inhibitors useful as antitumor agents)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 16 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:99319 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:172181

TITLE: Novel targets of protein kinase-inhibiting drugs for novel disease therapies

INVENTOR(S): Biggs, William H., III; Carter, Todd; Fabian, Miles A.; Lockhart, David J.; Zarrinkar, Patrick Parvis; Treiber, Daniel Kelly; Edeen, Phillip

PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009367	A2	20050203	WO 2004-US23325	20040719 <--
WO 2005009367	A3	20050512		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TGUS 20060234931 A1 20061019 US 2004-894877 20040719 <--
PRIORITY APPLN. INFO.: US 2003-488513P P 20030717 <--

ED Entered STN: 04 Feb 2005

AB The invention is directed to the identification and use of addnl. targets of BIRB 796, imatinib mesylate, and BAY 43-9006. The new targets of BIRB 796, imatinib mesylate, and BAY 43-9006 can be used to screen for suitable therapeutic compds. Novel therapeutic and prophylactic uses for BIRB 796, imatinib mesylate, and BAY 43-9006 are disclosed. Protein targets of the drugs were identified using a phage-based competition assay using a panel of 69 proteins including 48 kinases.


IT 284461-73-0, BAY 43-9006

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel targets of protein kinase-inhibiting drugs for novel disease therapies)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L42 ANSWER 17 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1016023 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:6557

TITLE: Preparation of nitrogenous heterocyclic compounds as p38 MAP kinase inhibitors

INVENTOR(S): Takahashi, Kanji; Sumino, Naoki; Yamamoto, Shingo; Sugitani, Masafumi; Uegaki, Akihiko; Nakatani, Shingo; Matsunaga, Naoki; Inukai, Takayuki

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101529	A1	20041125	WO 2004-JP7070	20040518 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

Serial No.:10/788,426

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 20070010529 A1 20070111 US 2005-557352 20051230 <--
 PRIORITY APPLN. INFO.: JP 2003-141042 A 20030519 <--
 JP 2003-338389 A 20030929 <--
 JP 2004-110572 A 20040402
 WO 2004-JP7070 W 20040518

OTHER SOURCE(S): MARPAT 142:6557
 ED Entered STN: 25 Nov 2004
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = H, (un)substituted cycle, etc.; B = (un)substituted cycle; E = spacer; K = C, N; Z = O, etc.; C:T = carbonyl, etc.; D = (un)substituted heterocycle containing at least one nitrogen] were prepared For example, EDCI-mediated acylation of compound II·2HCl [X = H] with 4-(N-methylpiperazinyl)methylbenzoic acid afforded compound II [X = 4-(N-methylpiperazinyl)methylbenzoyl]. In p38 MAP (mitogen activated protein) kinase inhibition assays, the IC50 value of compound II [X = 4-(N-methylpiperazinyl)methylbenzoyl] was 2.5 nM. Compound I are claimed useful for the treatment of inflammation, cancer, etc. Formulations are given.

IT 797792-67-7P 797792-93-9P, Benzyl
 4-([4-([([3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl)amino]phenyl)amino)piperidine-1-carboxylate
 797792-95-1P, N-[4-[(1-Benzoylpiperidin-4-yl)aminophenyl]-N'-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of nitrogenous heterocyclic compds. as p38 MAP kinase inhibitors for treatment of inflammation, circulatory disease, etc.)


RN 797792-67-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-3-methylphenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 797792-93-9 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[[3-(1,1-dimethylethyl)-1-(4-

methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]amino]-,
phenylmethyl ester (CA INDEX NAME)



RN 797792-95-1 HCAPLUS

CN Urea, N-[4-[(1-benzoyl-4-piperidinyl)amino]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)





IT 797792-68-8P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-methyl-4-[(1-[4-[(4-methylpiperazin-1-yl)methyl]benzoyl]piperidin-4-yl)oxy]phenyl]urea 797792-90-6P,
N-[4-[(1-Benzoyl-4-piperidinyl)oxy]-2-methylphenyl]-N'-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea 797792-96-2P
797792-97-3P 797792-98-4P,
N-(4-[(1-Benzoylpiperidin-4-yl)(methyl)amino]phenyl)-N'-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrogenous heterocyclic compds. as p38 MAP kinase inhibitors for treatment of inflammation, circulatory disease, etc.)


RN 797792-68-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-methyl-4-[[1-[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]-4-piperidinyl]oxy]phenyl]- (CA INDEX NAME)




RN 797792-90-6 HCAPLUS

CN Urea, N-[4-[(1-benzoyl-4-piperidinyl)oxy]-2-methylphenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 797792-96-2 HCAPLUS

CN Acetamide, N-(1-benzoyl-4-piperidinyl)-N-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 797792-97-3 HCAPLUS

CN Methanesulfonamide, N-(1-benzoyl-4-piperidinyl)-N-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 797792-98-4 HCAPLUS

CN Urea, N-[4-[(1-benzoyl-4-piperidinyl)methylamino]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 18 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1015876 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:23273

TITLE: Preparation of pyrazolyl phenyl urea derivatives as inhibitors of p38 kinase and/or tumor necrosis factor (TNF) inhibitors for the treatment of inflammations

INVENTOR(S): Borchering, David R.; Gross, Alexandre; Shum, Patrick Wai-Kwok; Willard, Nicole; Freed, Brian S.

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004100946	A1	20041125	WO 2004-US13875	20040505 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004238241 A1 20041125 AU 2004-238241 20040505 <--
 CA 2524043 A1 20041125 CA 2004-2524043 20040505 <--
 EP 1622610 A1 20060208 EP 2004-751319 20040505 <--
 EP 1622610 B1 20061220

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR


BR 2004009991 A 20060509 BR 2004-9991 20040505 <--
 AT 348610 T 20070115 AT 2004-751319 20040505 <--
 JP 2007502324 T 20070208 JP 2006-532565 20040505 <--
 ES 2277271 T3 20070701 ES 2004-751319 20040505 <--
 US 20060063796 A1 20060323 US 2005-264063 20051101 <--
 US 2003-468285P P 20030506 <--
 WO 2004-US13875 W 20040505

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 142:23273

ED Entered SIN: 25 Nov 2004

GI



AB Title compds. I [wherein R1 = (cyclo)alkyl, (un)substituted aryl or pyridyl; R2 = (un)substituted (cyclo)alkyl; X = C(O), C(O)CH2, S(O)2, or NHC(O); A = (un)substituted alk(en/yn)yl; B = (CH2)n; n = 0 or 2; et al., or pharmaceutically acceptable salts, solvates or ester prodrugs thereof; or ester prodrugs of such salts or solvates], useful as inhibitors of p38 kinase and/or tumor necrosis factor (TNF), were prepared Thus, condensation of 4-methylenepiperidine hydrochloride with 2,4-dimethoxybenzoyl chloride followed by addition reaction with 9-BBN and subsequent Pd-catalyzed coupling with m-bromoaniline gave an aniline derivative This compound underwent addition reaction with 5-isocyanato-3-tert-butyl-1-(4-methylphenyl)pyrazole to afford

urea II. Compds. I were tested in several biol. assays. E.g., I showed 50% inhibition at the concns. of 0.3-10000 nM in the p38 cascade assay, at the concns. of 10-50000 nM in the murine p38 assay, and at the concns. of 10-50000 nM in the LPS-induced TNF α assay. Pharmaceutical compns. comprising I are useful in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma and joint inflammation.

IT 1082347-60-1 1082347-62-3 1082347-63-4
 1082347-64-5 1082347-66-9 1082347-71-4
 1082347-73-6 1082347-74-7 1082347-77-0
 1082347-79-2 1082347-81-6 1082347-82-7
 1082347-84-9 1082347-87-2 1082347-90-7
 1082347-92-9 1082347-93-0 1082348-02-4
 1082348-05-7 1082348-08-0 1082348-09-1
 1082348-11-5 1082348-13-7 1082348-27-3
 1082348-29-5 1082348-32-0 1082348-35-3
 1082348-36-4 1082348-37-5 1082348-40-0
 1082349-16-3 1082349-18-5 1082349-20-9
 1082349-21-0 1082349-27-6 1082349-30-1
 1082349-31-2 1082349-35-6 1082349-38-9
 1082349-43-6 1082349-44-7 1082349-47-0
 1082349-49-2 1082349-97-0 1082350-00-2
 1082350-03-5 1082350-15-9 1082350-21-7
 1082350-26-2 1082350-27-3 1082350-30-8
 1082350-34-2 1082350-40-0 1082350-67-1
 1082350-71-7 1082350-72-8 1082350-74-0
 1082351-33-4 1082351-34-5 1082351-35-6
 1082351-36-7 1082351-37-8 1082351-38-9
 1082351-39-0 1082351-40-3 1082351-42-5
 1082351-43-6 1082351-44-7 1082351-48-1
 1082351-56-1 1082351-57-2 1082351-59-4
 1082351-62-9 1082351-65-2 1082351-67-4
 1082351-68-5 1082351-70-9 1082351-74-3
 1082351-75-4 1082351-77-6 1082351-83-4
 1082351-85-6 1082351-86-7 1082351-87-8
 1082351-91-4 1082351-93-6 1082351-95-8
 1082351-96-9 1082352-04-2 1082352-06-4
 1082352-07-5 1082352-08-6 1082352-14-4
 1082352-25-7 1082352-26-8 1082352-28-0
 1082353-03-4 1082353-05-6 1082353-07-8
 1082353-12-5 1082353-13-6 1082353-14-7
 1082353-15-8 1082353-16-9 1082353-17-0
 1082353-18-1 1082353-19-2 1082353-20-5
 1082353-21-6 1082353-22-7 1082353-23-8
 1082353-24-9 1082353-25-0 1082353-26-1
 1082353-27-2 1082353-28-3 1082353-29-4
 1082353-30-7 1082353-31-8 1082353-32-9
 1082353-33-0 1082353-35-2 1082353-36-3
 1082353-44-3 1082353-45-4 1082354-66-2
 1082354-69-5 1082354-70-8 1082354-71-9
 1082354-84-4 1082354-88-8 1082354-89-9
 1082354-93-5 1082354-97-9 1082354-99-1
 1082355-01-8 1082355-02-9 1082355-06-3
 1082355-08-5 1082355-10-9 1082355-11-0
 1082355-15-4 1082355-18-7 1082355-19-8
 1082355-21-2 1082355-23-4 1082355-27-8
 1082355-29-0 1082355-30-3 1082355-32-5
 1082355-36-9 1082355-38-1 1082355-53-0
 1082356-39-5 1082356-41-9 1082356-42-0
 1082356-43-1 1082356-48-6 1082356-50-0


1082356-51-1 1082356-58-8 1082356-60-2
 1082356-61-3 1082356-64-6 1082356-80-6
 1082356-81-7 1082356-84-0 1082356-86-2
 1082356-88-4 1082356-90-8 1082356-98-6
 1082357-02-5 1082357-76-3 1082357-77-4
 1082357-78-5 1082357-79-6 1082357-80-9
 1082357-82-1 1082357-83-2 1082357-84-3
 1082357-85-4 1082357-86-5 1082357-87-6
 1082357-88-7 1082357-89-8 1082357-91-2
 1082357-92-3 1082357-93-4 1082357-94-5
 1082357-95-6 1082357-96-7 1082357-97-8
 1082357-98-9 1082357-99-0 1082358-00-6
 1082358-01-7 1082358-10-8 1082358-24-4
 1082358-27-7 1082358-28-8 1082358-33-5
 1082358-35-7 1082359-35-0 1082359-37-2
 1082359-38-3 1082359-44-1 1082359-46-3
 1082359-47-4 1082359-52-1 1082359-55-4
 1082359-56-5 1082359-59-8 1082359-63-4
 1082359-64-5 1082359-66-7 1082359-70-3
 1082359-72-5 1082359-73-6 1082359-77-0
 1082359-78-1 1082359-80-5 1082359-81-6
 1082359-86-1 1082359-88-3 1082359-89-4
 1082359-91-8 1082359-92-9 1082359-93-0
 1082360-04-0 1082360-05-1 1082360-06-2
 1082360-07-3 1082360-08-4 1082360-09-5
 1082361-25-8 1082361-50-9 1082361-52-1
 1082361-53-2 1082361-60-1

RL: PRPH (Prophetic)

(Preparation of pyrazolyl phenyl urea derivatives as inhibitors of p38 kinase and/or tumor necrosis factor (TNF) inhibitors for the treatment of inflammations)


RN 1082347-60-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082347-62-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082347-63-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(6-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082347-64-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082347-68-9 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082347-71-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-73-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(3-quinolinylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082347-74-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-77-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-79-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-81-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-82-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-84-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(2,2-dimethyl-1-oxopropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082347-87-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-90-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-92-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082347-93-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-02-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-05-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-08-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-09-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-11-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-13-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-27-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-36-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082348-37-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082348-40-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082349-16-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1H-imidazol-5-ylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)



RN 1082349-18-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082349-20-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-


[[1-[(2S)-1,4-dioxo-2-phenylpentyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1082349-21-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(2,2-dimethyl-1-oxopropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082349-27-6 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(2H-indazol-3-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082349-30-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-31-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-35-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-38-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-43-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-44-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082349-47-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082349-49-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082349-97-0 HCAPLUS
CN Urea, N-[4-[[1-[(2S)-2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1082350-00-2 HCAPLUS
CN Acetamide, N-[(1R)-2-[4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]phenyl]methyl]-1-piperidinyl]-1-

methyl-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1082350-03-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1082350-15-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082350-21-7 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-

Serial No.:10788,426


methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]-,
2-methoxyphenyl ester (CA INDEX NAME)




RN 1082350-26-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-27-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-30-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-34-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-40-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-67-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082350-71-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-72-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082350-74-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A




RN 1082351-33-4 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[1-(1H-indol-5-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

RN 1082351-34-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082351-35-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-36-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082351-37-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1H-indol-6-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082351-38-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-39-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-40-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-42-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-43-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-44-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-48-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-56-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-57-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082351-59-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-62-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-65-2 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-
 [[1-(2,4,6-trimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
 NAME)


PAGE 1-A




PAGE 2-A




RN 1082351-67-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082351-68-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-70-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-74-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-75-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-77-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-83-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082351-85-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082351-86-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




PAGE 1-A


PAGE 2-A




RN 1082351-87-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
 [[1-(2-furanylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082351-91-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082351-93-6 HCAPLUS
 CN Urea, N-[2-[[1-(2-cyclohexylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 1082351-95-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082351-96-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082352-04-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1082352-06-4 HCAPLUS
CN Benzamide, 4-amino-N-[2-[4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—NH₂

RN 1082352-07-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




—Bu-t

RN 1082352-08-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082352-14-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082352-25-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082352-26-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082352-28-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, cyclopentyl ester (CA INDEX NAME)




RN 1082353-03-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(3-methyl-2-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 1082353-05-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(1H-indol-3-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082353-07-8 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082353-12-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-13-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-14-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-15-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-16-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-17-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-18-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-19-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-20-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-21-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082353-22-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(1-oxo-2-heptyn-1-yl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082353-23-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-24-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-
[[1-(3-pyridinylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082353-25-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082353-26-1 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082353-27-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-28-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-29-4 HCAPLUS
CN Urea, N-[2-[[1-(2,3-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082353-30-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-31-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-32-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082353-33-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-35-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082353-36-3 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(2,4,6-trimethylbenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)

PAGE 1-A





PAGE 2-A




RN 1082353-44-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A






RN 1082353-45-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082354-66-2 HCAPLUS
CN Acetamide, N-[(1S)-2-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-1-methyl-2-oxoethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1082354-69-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082354-70-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082354-71-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082354-84-4 HCAPLUS
CN 1-Piperidinecarboxamide, N-(2,4-dimethoxyphenyl)-4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]aminophenyl]methyl]- (CA INDEX NAME)




RN 1082354-88-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082354-89-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 1082354-93-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082354-97-9 HCAPLUS

CN Urea, N-[2-[[1-(6-benzothiazolylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082354-99-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082355-01-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082355-02-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(4-methoxy-2-methylbenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 1082355-06-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082355-08-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082355-10-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-11-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-15-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(3-furanylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 1082355-18-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-19-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082355-21-2 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1082355-23-4 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082355-27-8 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082355-29-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-30-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-32-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-36-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082355-38-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082355-53-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082356-39-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082356-41-9 HCAPLUS

CN Urea, N-[3-[[1-[2-(4-aminophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082356-42-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(4-pyridinyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082356-43-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082356-48-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[1-oxo-3-(1-piperidinyl)propyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 1082356-50-0 HCAPLUS


CN Urea, N-[3-[[1-(cycloheptylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082356-51-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(2S)-1-oxo-2-phenylpropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1082356-58-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082356-60-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082356-61-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082356-64-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082356-80-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1082356-81-7 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1082356-84-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1082356-86-2 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082356-88-4 HCAPLUS


CN Urea, N-[4-[[1-[4-(aminomethyl)benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082356-90-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082356-98-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-02-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 4-methylphenyl ester (CA INDEX NAME)



RN 1082357-76-3 HCAPLUS


CN Urea, N-[3-[[1-[(2S)-2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1082357-77-4 HCAPLUS

CN Urea, N-[3-[[1-[4-(aminomethyl)benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082357-78-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082357-79-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082357-80-9 HCAPLUS
CN Urea, N-[3-[[1-(4-amino-5-chloro-2-methoxybenzoyl)-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1082357-82-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1H-pyrrol-3-ylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082357-83-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-84-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-85-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082357-86-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-87-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082357-88-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-
[[1-(1-isoquinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX

NAME)


PAGE 1-A



PAGE 2-A




RN 1082357-89-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(2-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


RN 1082357-91-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(2-pyrazinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082357-92-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082357-93-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-[[1-(1-oxo-3-phenylpropyl)-4-piperidinyl]methyl]phenyl)- (CA INDEX NAME)




RN 1082357-94-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-[[1-(1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl)- (CA INDEX NAME)




RN 1082357-95-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-96-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-97-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-98-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082357-99-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082358-00-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082358-01-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082358-10-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082358-24-4 HCAPLUS


Serial No.:10788,426

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 4-(methoxycarbonyl)phenyl ester (CA INDEX NAME)




RN 1082358-27-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082358-28-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082358-33-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082358-35-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, phenyl ester (CA INDEX NAME)




RN 1082359-35-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082359-37-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082359-38-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-44-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2R)-1-oxo-2-phenylpropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)


Absolute stereochemistry.




RN 1082359-46-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-47-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-52-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-55-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-56-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-59-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-63-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-64-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-66-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-70-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-72-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-73-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082359-77-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082359-78-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-80-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-81-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082359-86-1 HCAPLUS
CN Urea, N-[2-[[1-(2-cyclopentylacetyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 1082359-88-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-89-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-91-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-92-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082359-93-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082360-04-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082360-05-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082360-06-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082360-07-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082360-08-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082360-09-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082361-25-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1082361-50-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(2S)-1,4-dioxo-2-phenylpentyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 1082361-52-1 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082361-53-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1082361-60-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 1082361-71-4 1082361-72-5 1082361-74-7
1082361-76-9 1082361-79-2 1082361-81-6
1082361-82-7 1082361-85-0 1082361-88-3
1082361-90-7 1082361-91-8 1082361-93-0
1082361-97-4 1082361-98-5 1082362-00-2
1082362-01-3 1082362-04-6 1082362-06-8
1082362-07-9 1082362-08-0 1082362-19-3
1082362-20-6 1082363-33-4 1082363-34-5
1082363-36-7 1082363-37-8 1082363-42-5
1082363-43-6 1082363-45-8 1082363-47-0
1082363-50-5 1082363-51-6 1082363-53-8
1082363-77-6 1082363-80-1 1082363-81-2
1082363-83-4 1082363-96-9 1082364-01-9
1082364-44-0 1082364-45-1 1082364-46-2
1082364-47-3 1082364-48-4 1082364-49-5
1082364-51-9 1082364-52-0 1082364-53-1
1082364-54-2 1082364-55-3 1082364-56-4
1082364-57-5 1082364-58-6 1082364-59-7
1082364-60-0 1082364-61-1 1082364-62-2
1082364-63-3 1082364-64-4 1082364-65-5
1082364-66-6 1082364-67-7 1082364-68-8
1082364-69-9 1082364-70-2 1082364-71-3
1082364-72-4 1082364-73-5 1082364-74-6
1082364-75-7 1082364-76-8 1082364-77-9
1082364-78-0 1082364-79-1 1082364-80-4
1082364-83-7 1082364-86-0 1082364-88-2
1082364-89-3 1082364-90-6 1082364-94-0
1082364-97-3 1082364-98-4 1082365-17-0
1082365-23-8 1082365-26-1 1082366-10-6
1082366-11-7 1082366-15-1 1082366-16-2
1082366-18-4 1083176-76-4 1083176-79-7
1083176-85-5 1083176-87-7 1083176-88-8
1083176-90-2 1083176-91-3

RL: PRPH (Prophetic)


(Preparation of pyrazolyl phenyl urea derivatives as inhibitors of p38 kinase and/or tumor necrosis factor (TNF) inhibitors for the treatment of inflammations)

RN 1082361-71-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082361-72-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(2-[[1-(2-methoxy-2-phenylacetyl)-4-piperidiny]methyl]phenyl)- (CA INDEX NAME)




RN 1082361-74-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082361-76-9 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082361-79-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082361-81-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082361-82-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082361-85-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(2-methyl-1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 1082361-88-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082361-90-7 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1082361-91-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082361-93-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(3-thienylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082361-97-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082361-98-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082362-00-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082362-01-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1082362-04-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1082362-06-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
 [[1-(imidazo[2,1-b]benzothiazol-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]-
 (CA INDEX NAME)




RN 1082362-07-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082362-08-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082362-19-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1082362-20-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1082363-33-4 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(2,2,2-trifluoroacetyl)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1082363-34-5 HCAPLUS

CN Urea, N-[3-[[1-[(2R)-2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1082363-36-7 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(3-pyridinyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

RN 1082363-37-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(1H-imidazol-5-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)

RN 1082363-42-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




PAGE 1-A




RN 1082363-43-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082363-45-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082363-47-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082363-50-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082363-51-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082363-53-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082363-77-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1082363-80-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(3-pyridinyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 1082363-81-2 HCAPLUS
CN Urea, N-[4-[[1-[3-(1H-benzimidazol-2-yl)-1-oxopropyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Bu-t


RN 1082363-83-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(1H-imidazol-5-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082363-96-9 HCAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1082364-01-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-44-0 HCAPLUS
CN Urea, N-[3-([1-[3-(1H-benzimidazol-2-yl)-1-oxopropyl]-4-piperidinyl)methyl]phenyl)-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)



—Bu-t


RN 1082364-45-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1082364-46-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2R)-1,4-dioxo-2-phenylpentyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 1082364-47-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1082364-48-4 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1082364-49-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082364-51-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-52-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-53-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-54-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-55-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-56-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-57-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-58-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-59-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-60-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-61-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-62-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-63-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-64-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-65-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-66-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-67-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-68-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-69-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-70-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-71-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-72-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-73-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082364-74-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-75-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-76-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1082364-77-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(1-oxo-4-phenylbutyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082364-78-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-79-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-80-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(2-phenoxyacetyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082364-83-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-86-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-88-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-[[1-(1-oxo-3-phenoxypropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082364-89-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-90-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-94-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[2-
[[1-(4-pyridinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 1082364-97-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082364-98-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082365-17-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082365-23-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082365-26-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1082366-10-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-(2,2,2-trifluoroacetyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 1082366-11-7 HCAPLUS


CN Urea, N-[4-[[1-[(2R)-2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1082366-15-1 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(4-pyridinyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 1082366-16-2 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2R)-1,4-dioxo-2-phenylpentyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1082366-18-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1083176-76-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1083176-79-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1083176-85-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1083176-87-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1083176-88-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1083176-90-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1083176-91-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



IT 799283-67-3P 799283-68-4P 799283-69-5P
 799283-98-0P 799283-99-1P 799284-00-7P
 799284-01-8P 799284-02-9P 799284-03-0P
 799284-04-1P 799284-05-2P 799284-06-3P
 799284-07-4P 799284-08-5P 799284-09-6P
 799284-10-9P 799284-11-0P 799284-12-1P

799284-13-2P 799284-14-3P 799284-15-4P
799284-16-5P 799284-17-6P 799284-18-7P
799284-19-8P 799284-20-1P 799284-21-2P
799284-22-3P 799284-23-4P 799284-24-5P
799284-25-6P 799284-26-7P 799284-27-8P
799284-28-9P 799284-29-0P 799284-30-3P
799284-31-4P 799284-32-5P 799284-33-6P
799284-34-7P 799284-35-8P 799284-36-9P
799284-37-0P 799284-38-1P 799284-39-2P
799284-40-5P 799284-41-6P 799284-42-7P
799284-43-8P 799284-44-9P 799284-45-0P
799284-46-1P 799284-47-2P 799284-48-3P
799284-49-4P 799284-50-7P 799284-51-8P
799284-52-9P 799284-53-0P 799284-54-1P
799284-55-2P 799284-56-3P 799284-57-4P
799284-58-5P 799284-59-6P 799284-60-9P
799284-61-0P 799284-62-1P 799284-63-2P
799284-64-3P 799284-65-4P 799284-66-5P
799284-67-6P 799284-68-7P 799284-69-8P
799284-70-1P 799284-71-2P 799284-72-3P
799284-73-4P 799284-74-5P 799284-75-6P
799284-76-7P 799284-77-8P 799284-78-9P
799284-79-0P 799284-80-3P 799284-81-4P
799284-82-5P 799284-83-6P 799284-84-7P
799284-85-8P 799284-86-9P 799284-87-0P
799284-88-1P 799284-89-2P 799284-90-5P
799284-91-6P 799284-92-7P 799284-93-8P
799284-94-9P 799284-95-0P 799284-96-1P
799284-97-2P 799284-98-3P 799284-99-4P
799285-00-0P 799285-01-1P 799285-02-2P
799285-03-3P 799285-04-4P 799285-05-5P
799285-06-6P 799285-07-7P 799285-08-8P
799285-09-9P 799285-10-2P 799285-11-3P
799285-12-4P 799285-13-5P 799285-14-6P
799285-15-7P 799285-16-8P 799285-17-9P
799285-18-0P 799285-19-1P 799285-20-4P
799285-21-5P 799285-22-6P 799285-23-7P
799285-24-8P 799285-25-9P 799285-26-0P
799285-27-1P 799285-28-2P 799285-29-3P
799285-30-6P 799285-31-7P 799285-32-8P
799285-33-9P 799285-34-0P 799285-35-1P
799285-36-2P 799285-37-3P 799285-38-4P
799285-39-5P 799285-41-9P 799285-43-1P
799285-45-3P 799285-47-5P 799285-49-7P
799285-51-1P 799285-53-3P 799285-55-5P
799285-57-7P 799285-59-9P 799285-61-3P
799285-63-5P 799285-65-7P 799285-67-9P
799285-69-1P 799285-71-5P 799285-73-7P
799285-75-9P 799285-77-1P 799285-79-3P
799285-81-7P 799285-83-9P 799285-85-1P
799285-87-3P 799285-89-5P 799285-91-9P
799285-92-0P 799285-94-2P 799285-95-3P
799285-97-5P 799285-98-6P 799285-99-7P
799286-00-3P 799286-01-4P 799286-02-5P
799286-03-6P 799286-04-7P 799286-05-8P
799286-06-9P 799286-07-0P 799286-08-1P
799286-09-2P 799286-10-5P 799286-11-6P
799286-12-7P 799286-13-8P 799286-14-9P
799286-15-0P 799286-16-1P 799286-17-2P
799286-18-3P 799286-19-4P 799286-20-7P


799286-21-8P 799286-22-9P 799286-23-0P
 799286-24-1P 799286-25-2P 799286-26-3P
 799286-27-4P 799286-28-5P 799286-29-6P
 799286-30-9P 799286-31-0P 799286-32-1P
 799286-33-2P 799286-34-3P 799286-35-4P
 799286-36-5P 799286-37-6P 799286-38-7P
 799286-39-8P 799286-40-1P 799286-41-2P
 799286-42-3P 799286-44-5P 799286-45-6P
 799286-46-7P 799286-47-8P 799286-48-9P
 799286-49-0P 799286-50-3P 799286-51-4P
 799286-52-5P 799286-53-6P 799286-54-7P
 799286-55-8P 799286-56-9P 799286-57-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(inhibitor; preparation of pyrazolyl Ph urea derivs. as inhibitors of p38
 kinase and/or tumor necrosis factor (TNF))


RN 799283-67-3 HCAPLUS

CN Urea, N-[4-[[1-(2,4-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-
 (1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799283-68-4 HCAPLUS

CN Urea, N-[2-[[1-(2,4-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-
 (1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799283-69-5 HCAPLUS

CN Urea, N-[3-[[1-(2,4-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-
 (1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799283-98-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(1-oxido-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799283-99-1 HCAPLUS


CN Urea, N-[3-[[1-[2-(2,4-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799284-00-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(2R)-tetrahydro-5-oxo-2-furanyl]carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 799284-01-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2R)-2-methoxy-2-phenylacetyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 799284-02-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2S)-2-methoxy-2-phenylacetyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 799284-03-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799284-04-1 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1,2,3-thiadiazol-4-ylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799284-05-2 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1,6-naphthyridin-2-ylcarbonyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)

INDEX NAME)




RN 799284-06-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(1,8-naphthyridin-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799284-07-4 HCAPLUS

CN Urea, N-[3-[[1-[3-[(aminothioxomethyl)amino]benzoyl]-4-
piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-08-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[1-(4-methoxyphenyl)cyclopropyl]carbonyl]-4-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-09-6 HCAPLUS

CN Urea, N-[3-([1-[1-(5-bromo-2-pyrimidinyl)-3-piperidinyl]carbonyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799284-10-9 HCAPLUS

CN Urea, N-[3-([1-[1-(5-bromo-2-pyrimidinyl)-4-piperidinyl]carbonyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799284-11-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(3-([1-[1-(5-bromo-2-pyrimidinyl)-4-piperidinyl]carbonyl]-4-piperidinyl)methyl]phenyl)- (CA INDEX NAME)




RN 799284-12-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(1-methylcyclohexyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799284-13-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(1-methyl-1H-indol-3-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799284-14-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(1-methylcyclopropyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799284-15-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(1-naphthalenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


PAGE 1-A






RN 799284-16-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(1-phenylcyclopentyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799284-17-6 HCAPLUS

CN Urea, N-[3-[[1-[(2,2-difluoro-1,3-benzodioxol-5-yl)carbonyl]-4-
piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-18-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(2,2-dimethyl-1-oxopentyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799284-19-8 HCAPLUS

CN Urea, N-[3-([1-(2,3-dimethoxybenzoyl)-4-piperidinyl)methyl]phenyl)-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)




RN 799284-20-1 HCAPLUS

CN Urea, N-[3-([1-[2-(2,3-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl)-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)




RN 799284-21-2 HCAPLUS

CN Urea, N-[3-(1-(2-(2,3-dimethylphenoxy)acetyl)-4-piperidinyl)methyl]phenyl)-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)




RN 799284-22-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2,4,6-trimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-23-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2,4,6-trimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-24-5 HCAPLUS

CN Urea, N-[3-[[1-[2-(2,4-difluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-25-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2,4-dimethyl-5-thiazolyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-26-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2,5-dimethyl-3-furanyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-27-8 HCAPLUS

CN 3-Furansulfonamide, 4-[[4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]-2,5-dimethyl-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 799284-28-9 HCAPLUS

CN Urea, N-[3-[[1-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-29-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(2-(3-pyridinyl)-4-thiazolyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799284-30-3 HCAPLUS

CN Urea, N-[3-[[1-[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]benzoyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-31-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(4-pyridinyl)-4-thiazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799284-32-5 HCAPLUS

CN Urea, N-[3-[[1-[2-(5-chloro-3-methylbenzo[b]thien-2-yl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




PAGE 1-A

Bu-t

RN 799284-33-6 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(6-methoxy-3-benzofuranyl)acetyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)



Bu-t


RN 799284-34-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(trifluoromethyl)-1,6-naphthyridin-3-yl]carbonyl]-4-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-35-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(trifluoromethyl)-1,8-naphthyridin-3-yl]carbonyl]-4-
piperidinylmethyl]phenyl]- (CA INDEX NAME)




RN 799284-36-9 HCAPLUS

CN Urea, N-[3-[[1-[2-amino-3-pyridinyl]carbonyl]-4-
piperidinylmethyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-37-0 HCAPLUS

CN Urea, N-[3-[[1-[2-chloro-4-(methylsulfonyl)benzoyl]-4-
piperidinylmethyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-38-1 HCAPLUS

CN Urea, N-[3-([1-[(2-chloro-6-methoxy-4-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-39-2 HCAPLUS

CN Urea, N-[3-([1-[(2-chloro-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-40-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-[3-([1-[(2-fluorophenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799284-41-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-furanyl)-2-oxoacetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-42-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2-furanylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-43-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1-oxo-2-heptyn-1-yl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-44-9 HCAPLUS

CN Urea, N-[3-[[1-[(1,2-dihydro-6-methyl-2-oxo-4-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)



RN 799284-45-0 HCAPLUS


CN Urea, N-[3-[[1-[(1,2-dihydro-2-oxo-4-quinolinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)



RN 799284-46-1 HCAPLUS


CN Urea, N-[3-[[1-[(2-(2,3-dihydro-1H-inden-2-yl)acetyl)-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)]- (CA INDEX NAME)

pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-47-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-methoxyphenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-48-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-methyl-1,6-naphthyridin-3-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-49-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-methyl-3-furanyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-50-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-methyl-1H-indol-3-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-51-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-methyl-5-(1-piperidinylsulfonyl)-3-furanyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-52-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-methyl-5-(trifluoromethyl)-4-oxazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-53-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2-methyl-5-phenyl-3-furanyl)carbonyl]-4-piperidiny]methyl]phenyl]-
(CA INDEX NAME)




RN 799284-54-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2-methyl-1,8-naphthyridin-3-yl)carbonyl]-4-
piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799284-55-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]-4-
piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799284-56-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-methyl-3-pyridinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-57-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-naphthalenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-58-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-phenyl-5-(trifluoromethyl)-4-oxazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-59-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1,4-dioxo-2-phenylpentyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-60-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-61-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2-pyrazinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-62-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(2-quinoxalinylyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799284-63-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(tetrahydro-2-furanyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799284-64-3 HCAPLUS

CN Urea, N-[3-[[1-[2-[(4,6-dimethoxy-2-pyrimidinyl)thio]benzoyl]-4-
piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-65-4 HCAPLUS

CN Urea, N-[3-([1-[2-(3,4-difluorophenyl)acetyl]-4-piperidinyl)methyl]phenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-66-5 HCAPLUS

CN Urea, N-[3-([1-[2-(3,4-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-67-6 HCAPLUS

CN Urea, N-[3-([1-[2-(1,3-benzodioxol-5-yl)acetyl]-4-piperidinyl)methyl]phenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-68-7 HCAPLUS

CN Urea, N-[3-[[1-[3,5-bis(trifluoromethyl)benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-69-8 HCAPLUS

CN Urea, N-[3-[[1-[2-(3,5-difluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-70-1 HCAPLUS

CN Urea, N-[3-[[1-(3,5-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-71-2 HCAPLUS

CN Urea, N-[3-[[1-[2-(3,5-dimethoxyphenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799284-72-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(3,5-dimethyl-1H-pyrazol-4-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-73-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799284-74-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(3,5-dimethylphenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799284-75-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[3-(1,1,2,2-tetrafluoroethoxy)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHF₂

RN 799284-76-7 HCAPLUS

CN Urea, N-[3-[[1-[3-(2-cyanoethyl)benzoyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CN

RN 799284-77-8 HCAPLUS

CN Urea, N-[3-[[1-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1-oxo-2-propen-1-yl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


PAGE 1-A






RN 799284-78-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[3-(2-furanyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799284-79-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[3-(2-methoxyphenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799284-80-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[1-oxo-3-(2-thienyl)propyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)



RN 799284-81-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(4-fluorophenyl)-1,4-dioxobutyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 799284-82-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[3-(4-fluorophenyl)-1-oxopropyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)



RN 799284-83-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[3-(4-methylphenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B

Me


RN 799284-84-7 HCAPLUS

CN Urea, N-[3-[[1-[[6,7-dihydro-3-(methylsulfonyl)benzo[c]thien-1-
yl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-
methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799284-85-8 HCAPLUS

CN Acetamide, N-[3-[[4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-
piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 799284-86-9 HCAPLUS

CN Urea, N-[3-[[1-(3-amino-2-pyrazinyl)carbonyl]-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799284-87-0 HCAPLUS

CN Urea, N-[3-[[1-(3-butoxy-4-methoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799284-88-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(3-[[1-(2-(3-fluorophenyl)acetyl)-4-piperidinyl]methyl]phenyl)- (CA INDEX NAME)



RN 799284-89-2 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(3-furanylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799284-90-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[3-(1H-indol-3-yl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



—Bu-t


RN 799284-91-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[2-(3-methoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX
NAME)




RN 799284-92-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(3-methyl-2-furanyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799284-93-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(3-methyl-4-isoxazolyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799284-94-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(1-oxo-3-phenoxypropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-95-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[1-oxo-3-(3-pyridinyl)propyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)



RN 799284-96-1 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(3-thienylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799284-97-2 HCAPLUS

CN Urea, N-[3-[[1-[3-[(4,6-dimethoxy-2-pyrimidinyl)oxy]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 799284-98-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(3a,4,5,7a-tetrahydro-6-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799284-99-4 HCAPLUS

CN Urea, N-[3-[[1-[(4,5-dihydrobenzo[b]thien-6-yl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-00-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(4,5-dimethyl-2-furanyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799285-01-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(1,1,2,2-tetrafluoroethoxy)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




PAGE 1-A

—CHF₂


RN 799285-02-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(1,2,3-thiadiazol-4-yl)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799285-03-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(5-oxazolyl)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-04-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(2-thienyl)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



RN 799285-05-5 HCAPLUS


CN Urea, N-[3-[[1-[[4-(4-chlorophenyl)-2-thienyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 799285-06-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(4-methoxyphenyl)-1-oxobutyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 799285-07-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(4-methoxyphenyl)-2-thienyl]carbonyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)




RN 799285-08-8 HCAPLUS

CN Urea, N-[3-[1-[4-(difluoromethoxy)benzoyl]-4-piperidinyl]methyl]phenyl]-
N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)



RN 799285-09-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[4-(ethylamino)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799285-10-2 HCAPLUS


CN Urea, N-[3-[1-[4-[(1,1-dimethylethoxy)methyl]benzoyl]-4-

piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-11-3 HCAPLUS

CN Urea, N-[3-[[1-[4-amino-3-(trifluoromethoxy)benzoyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-12-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1,5-dioxo-5-phenylpentyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-13-5 HCAPLUS

CN Urea, N-[3-[[1-[2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-14-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(4-fluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-15-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(hydroxymethyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-16-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(2-methylpropyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-17-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(4-methoxy-2-methylbenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-18-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2-(4-methoxyphenoxy)acetyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-19-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(2-(4-methoxyphenyl)acetyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-20-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(4-methoxy-3-thienyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799285-21-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(1-oxo-4-phenylbutyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-22-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(1H-pyrazol-4-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799285-23-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-(trifluoromethyl)-3-pyridinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799285-24-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-[(4,6-dimethyl-2-pyrimidinyl)methylamino]benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Me


RN 799285-25-9 HCAPLUS

CN Urea, N-[3-[[1-[(5,6-dichloro-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-26-0 HCAPLUS

CN Urea, N-[3-[[1-[(5-chloro-1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799285-27-1 HCAPLUS

CN Urea, N-[3-[[1-[2-(5-chlorobenzo[b]thien-3-yl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




PAGE 1-A

—Bu-t


RN 799285-28-2 HCAPLUS

CN Urea, N-[3-[[1-[(5-chloro-2-thienyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-29-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[5-methoxy-2-(2,2,2-trifluoroethoxy)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-30-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methoxy-2-benzofuranyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-31-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-32-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-2-(trifluoromethyl)-3-furanyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-33-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-34-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-2-thienyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-35-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-36-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-4-isoxazolyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-37-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(5-methyl-2-pyrazinyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-38-4 HCAPLUS

CN Urea, N-[3-[[1-(bicyclo[2.2.1]hept-5-en-2-ylcarbonyl)-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-39-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799285-41-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[[6-(trifluoromethyl)-3-pyridinyl]carbonyl]-4-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-43-1 HCAPLUS

CN Urea, N-[3-[[1-[[6-amino-3-pyridinyl]carbonyl]-4-
piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-45-3 HCAPLUS

CN Urea, N-[3-[[1-[[6-chloro-3-pyridinyl]carbonyl]-4-
piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-47-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(6-methyl-2-pyridinyl) carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799285-49-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[(7-methoxy-2-benzofuranyl) carbonyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)




RN 799285-51-1 HCAPLUS

CN Urea, N-[3-[[1-[4-[(acetyloxy)methyl]benzoyl]-4-piperidinyl]methyl]phenyl]-
N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)




RN 799285-53-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[1-(2-methyl-1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799285-55-5 HCAPLUS

CN Urea, N-[3-[1-(6-benzothiazolylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-
[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)




RN 799285-57-7 HCAPLUS

CN Urea, N-[3-[1-(1H-benzotriazol-6-ylcarbonyl)-4-piperidinyl]methyl]phenyl]-
N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)




RN 799285-59-9 HCAPLUS

CN Urea, N-[3-[[1-(benzo[b]thien-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-61-3 HCAPLUS

CN Urea, N-[3-[[1-[(2,3-dihydro-5-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-63-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(4,5,6,7-tetrahydro-4-oxo-3-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-65-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1-oxobutyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-67-9 HCAPLUS

CN Urea, N-[3-[[1-(cyclobutylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-69-1 HCAPLUS

CN Urea, N-[3-[[1-(cyclohexylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-71-5 HCAPLUS

CN Urea, N-[3-([1-(2-cyclohexylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-73-7 HCAPLUS

CN Urea, N-[3-([1-(cyclopentylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-75-9 HCAPLUS

CN Urea, N-[3-([1-(2-cyclopentylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799285-77-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(5-oxo-2-pyrrolidinyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-79-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1-oxohexyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-81-7 HCAPLUS

CN Benzamide, N-[2-[4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 799285-83-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2,5-dioxo-4-imidazolidinyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-85-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1-oxo-3-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-87-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(thiazolo[3,2-a]benzimidazol-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799285-89-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(1H-indazol-3-ylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799285-91-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(1H-indol-3-yl)acetyl]-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)



RN 799285-92-0 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(4-pyridinylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)



RN 799285-94-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 799285-95-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 799285-97-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-(2-methoxyacetyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799285-98-6 HCAPLUS

CN 1-Piperidinebutanoic acid, 4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-γ-oxo-, methyl ester (CA INDEX NAME)



RN 799285-99-7 HCAPLUS


CN Urea, N-[3-[[1-[2-(dimethylamino)acetyl]-4-piperidiny]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799286-00-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[4-[[4,6-dimethyl-2-pyrimidinyl]amino]benzoyl]-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 799286-01-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-
[[1-[3-[[4,6-dimethyl-2-pyrimidinyl)methyl]amino]benzoyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 799286-02-5 HCAPLUS

CN Acetamide, N-[2-[4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-1-methyl-2-oxoethyl]- (CA INDEX NAME)




RN 799286-03-6 HCAPLUS

CN Acetamide, N-[2-[4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 799286-04-7 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(phenylamino)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-05-8 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-

[[1-(3-pyridinylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-06-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[[1-[2-(2-methylphenyl)acetyl]-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-07-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[[1-[2-(2-phenoxyacetyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-08-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[[1-[2-(2-quinolinylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-09-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(3-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-10-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(4-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-11-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-(6-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-12-7 HCAPLUS

CN Urea, N-[3-[[1-(2-benzo[b]thien-3-ylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-13-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(2-thienyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-14-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[1-[2-(3-thienyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-15-0 HCAPLUS


CN Urea, N-[4-[[1-[2-(2,4-dimethoxyphenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799286-16-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2R)-2-methoxy-2-furanyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 799286-17-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2R)-2-methoxy-2-phenylacetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 799286-18-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(2S)-2-methoxy-2-phenylacetyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 799286-19-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-4-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-20-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(1,2,3-thiadiazol-4-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799286-21-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(1,6-naphthyridin-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799286-22-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(1,8-naphthyridin-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799286-23-0 HCAPLUS


CN Urea, N-[4-[[1-[3-(aminothioxomethyl)amino]benzoyl]-4-

piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-24-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[1-(4-methoxyphenyl)cyclopropyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-25-2 HCAPLUS


CN Urea, N-[4-[[1-[1-(5-bromo-2-pyrimidinyl)-3-piperidinyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799286-26-3 HCAPLUS


CN Urea, N-[4-[[1-[1-(5-bromo-2-pyrimidinyl)-4-piperidinyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(1-methylcyclohexyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799286-29-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(1-methyl-1H-indol-3-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799286-30-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(1-methylcyclopropyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799286-31-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(1-naphthalenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)


PAGE 1-A



PAGE 2-A




RN 799286-32-1 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
 INDEX NAME)




RN 799286-33-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[1-oxo-3-(1-piperidinyl)propyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799286-34-3 HCAPLUS

CN Urea, N-[4-[[1-[(2,2-difluoro-1,3-benzodioxol-5-yl)carbonyl]-4-
piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-35-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(2,2-dimethyl-1-oxopentyl)-4-piperidinyl)methyl]phenyl]- (CA INDEX
NAME)




RN 799286-36-5 HCAPLUS

CN Urea, N-[4-[[1-(2,3-dimethoxybenzoyl)-4-piperidinyl)methyl]phenyl]-N'-[3-
(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-37-6 HCAPLUS

CN Urea, N-[4-[[1-[2-(2,3-dimethoxyphenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-38-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(2,3-dimethylphenoxy)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-39-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2,4,6-trimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-40-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2,4,6-trimethylbenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-41-2 HCAPLUS

CN Urea, N-[4-[[1-[2-(2,4-difluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-42-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2,4-dimethyl-5-thiazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-44-5 HCAPLUS

CN Urea, N-[4-([1-(2,5-dimethoxybenzoyl)-4-piperidinyl]methyl)phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-45-6 HCAPLUS

CN Urea, N-[4-([1-(2-(2,5-dimethoxyphenyl)acetyl]-4-piperidinyl]methyl)phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-46-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-([1-[(2,5-dimethyl-3-furanyl)carbonyl]-4-piperidinyl]methyl)phenyl]- (CA INDEX NAME)




RN 799286-47-8 HCAPLUS

CN 3-Furansulfonamide, 4-[[4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]-2,5-dimethyl-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 799286-48-9 HCAPLUS


CN Urea, N-[4-[[1-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799286-49-0 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2-3-pyridinyl)-4-thiazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]-

(CA INDEX NAME)




RN 799286-50-3 HCAPLUS

CN Urea, N-[4-[[1-[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-51-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(4-pyridinyl)-4-thiazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-52-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(6-methoxy-3-benzofuranyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




PAGE 1-B

Bu-t

RN 799286-53-6 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
 [[1-[[2-(trifluoromethyl)-1,6-naphthyridin-3-yl]carbonyl]-4-
 piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-54-7 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
 [[1-[[2-(trifluoromethyl)-1,8-naphthyridin-3-yl]carbonyl]-4-
 piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-55-8 HCAPLUS

CN Urea, N-[4-[[1-[(2-amino-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-56-9 HCAPLUS

CN Urea, N-[4-[[1-(2-benzofuranylcarbonyl)-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 799286-57-0 HCAPLUS

CN Urea, N-[4-[[1-[2-chloro-4-(methylsulfonyl)benzoyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)



IT	799286-58-1P	799286-59-2P	799286-60-5P
	799286-61-6P	799286-62-7P	799286-63-8P
	799286-64-9P	799286-65-0P	799286-66-1P
	799286-67-2P	799286-68-3P	799286-69-4P
	799286-70-7P	799286-71-8P	799286-72-9P
	799286-73-0P	799286-74-1P	799286-75-2P
	799286-76-3P	799286-77-4P	799286-78-5P
	799286-79-6P	799286-81-0P	799286-82-1P
	799286-83-2P	799286-84-3P	799286-85-4P
	799286-86-5P	799286-87-6P	799286-88-7P
	799286-89-8P	799286-90-1P	799286-91-2P
	799286-92-3P	799286-93-4P	799286-94-5P
	799286-95-6P	799286-96-7P	799286-97-8P
	799286-98-9P	799286-99-0P	799287-00-6P
	799287-01-7P	799287-02-8P	799287-03-9P
	799287-04-0P	799287-05-1P	799287-06-2P
	799287-07-3P	799287-08-4P	799287-09-5P
	799287-10-8P	799287-11-9P	799287-12-0P
	799287-13-1P	799287-14-2P	799287-15-3P
	799287-16-4P	799287-17-5P	799287-18-6P
	799287-19-7P	799287-20-0P	799287-21-1P
	799287-23-3P	799287-24-4P	799287-25-5P
	799287-26-6P	799287-27-7P	799287-28-8P
	799287-29-9P	799287-30-2P	799287-31-3P
	799287-32-4P	799287-33-5P	799287-34-6P
	799287-35-7P	799287-36-8P	799287-37-9P
	799287-38-0P	799287-39-1P	799287-40-4P
	799287-41-5P	799287-42-6P	799287-43-7P
	799287-44-8P	799287-45-9P	799287-46-0P
	799287-47-1P	799287-48-2P	799287-49-3P
	799287-50-6P	799287-51-7P	799287-52-8P
	799287-53-9P	799287-54-0P	799287-55-1P
	799287-56-2P	799287-57-3P	799287-58-4P
	799287-59-5P	799287-60-8P	799287-61-9P
	799287-62-0P	799287-63-1P	799287-64-2P
	799287-65-3P	799287-66-4P	799287-67-5P
	799287-68-6P	799287-69-7P	799287-71-1P
	799287-72-2P	799287-73-3P	799287-74-4P
	799287-75-5P	799287-76-6P	799287-77-7P
	799287-78-8P	799287-79-9P	799287-80-2P
	799287-81-3P	799287-82-4P	799287-83-5P
	799287-84-6P	799287-85-7P	799287-86-8P
	799287-87-9P	799287-88-0P	799287-89-1P
	799287-90-4P	799287-91-5P	799287-92-6P
	799287-93-7P	799287-94-8P	799287-95-9P
	799287-96-0P	799287-97-1P	799287-98-2P
	799287-99-3P	799288-00-9P	799288-01-0P


799288-02-1F 799288-03-2F 799288-04-3F
 799288-05-4F 799288-06-5F 799288-07-6F
 799288-08-7F 799288-09-8F 799288-10-1F
 799288-11-2F 799288-12-3F 799288-13-4F
 799288-14-5F 799288-15-6F 799288-16-7F
 799288-17-8F 799288-18-9F 799288-19-0F
 799288-20-3F 799288-21-4F 799288-22-5F
 799288-23-6F 799288-24-7F 799288-25-8F
 799288-26-9F 799288-27-0F 799288-28-1F
 799288-29-2F 799288-30-5F 799288-31-6F
 799288-32-7F 799288-33-8F 799288-34-9F
 799288-35-0F 799288-36-1F 799288-37-2F
 799288-38-3F 799288-39-4F 799288-40-7F
 799288-41-8F 799288-42-9F 799288-43-0F
 799288-44-1F 799288-45-2F 799288-46-3F
 799288-47-4F 799288-50-9F 799288-53-2F
 799288-56-5F 799288-59-8F 799288-62-3F
 799288-65-6F 799288-68-9F 799288-71-4F
 799288-74-7F 799288-77-0F 799288-80-5F
 799288-83-8F 799288-86-1F 799288-91-8F
 799288-94-1F 799288-98-5F 799289-04-6F
 799289-10-4F 799289-16-0F 799289-23-9F
 799289-29-5F 799289-37-5F 799291-31-9F
 799291-32-0F 799291-33-1F 799291-34-2F
 799291-35-3F 799291-37-5F 799291-38-6F
 799291-39-7F 799291-41-1F 799291-43-3F
 799291-44-4F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of pyrazolyl Ph urea derivs. as inhibitors of p38 kinase and/or tumor necrosis factor (TNF))


RN 799286-58-1 HCAPLUS

CN Urea, N-[4-[[1-[(2-chloro-6-methoxy-4-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-59-2 HCAPLUS

CN Urea, N-[4-[[1-[(2-chloro-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-60-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-(2-fluorophenyl)acetyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-61-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-furanylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799286-62-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-2-heptyn-1-yl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)



RN 799286-63-8 HCAPLUS


CN Urea, N-[4-[[1-[(1,2-dihydro-6-methyl-2-oxo-4-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-64-9 HCAPLUS

CN Urea, N-[4-[[1-[(1,2-dihydro-2-oxo-4-quinolinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


PAGE 1-A






RN 799286-65-0 HCAPLUS

CN Urea, N-[4-[[1-[2-(2,3-dihydro-1H-inden-2-yl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-66-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(2-methoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-67-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2-methyl-1,6-naphthyridin-3-yl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-68-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(2-methyl-3-furanyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799286-69-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(2-methyl-1H-indol-3-yl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799286-70-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[[2-methyl-5-(1-piperidinylsulfonyl)-3-furanyl]carbonyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-71-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-methyl-5-(trifluoromethyl)-4-oxazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-72-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-methyl-5-phenyl-3-furanyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-73-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-methyl-1,8-naphthyridin-3-yl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-74-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-75-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2-methyl-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-76-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(2-naphthalenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799286-77-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-phenyl-5-(trifluoromethyl)-4-oxazolyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-78-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1,4-dioxo-2-phenylpentyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-79-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-81-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-pyrazinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-82-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-quinoxaliny carbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-83-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(tetrahydro-2-furanyl carbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-84-3 HCAPLUS

CN Urea, N-[4-[[1-[2-[(4,6-dimethoxy-2-pyrimidinyl)thio]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-85-4 HCAPLUS

CN Urea, N-[4-[[1-[2-(3,4-difluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-86-5 HCAPLUS

CN Urea, N-[4-[[1-(3,4-dimethoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799286-87-6 HCAPLUS

CN Urea, N-[4-([1-[2-(3,4-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-88-7 HCAPLUS

CN Urea, N-[4-([1-[2-(1,3-benzodioxol-5-yl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-89-8 HCAPLUS

CN Urea, N-[4-([1-[3,5-bis(trifluoromethyl)benzoyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-90-1 HCAPLUS

CN Urea, N-[4-([1-[2-(3,5-difluorophenyl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-91-2 HCAPLUS

CN Urea, N-[4-([1-[2-(3,5-dimethoxybenzoyl)-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-92-3 HCAPLUS

CN Urea, N-[4-([1-[2-(3,5-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799286-93-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(3,5-dimethyl-1H-pyrazol-4-yl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799286-94-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-95-6 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(3,5-dimethylphenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799286-96-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[3-(1,1,2,2-tetrafluoroethoxy)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHF₂

RN 799286-97-8 HCAPLUS

CN Urea, N-[4-[[1-[3-(2-cyanoethyl)benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CN

RN 799286-98-9 HCAPLUS
 CN Urea, N-[4-[[1-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1-oxo-2-propen-1-yl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 799286-99-0 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[3-(2-furanyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-00-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[3-(2-methoxyphenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-01-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[1-oxo-3-(2-thienyl)propyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-02-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(4-fluorophenyl)-1,4-dioxobutyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-03-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[3-(4-fluorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



RN 799287-04-0 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[3-(4-methylphenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)



— Me


RN 799287-05-1 HCAPLUS

CN Urea, N-[4-[[1-[[6,7-dihydro-3-(methylsulfonyl)benzo[c]thien-1-yl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-06-2 HCAPLUS

CN Acetamide, N-[3-[[4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 799287-07-3 HCAPLUS

CN Urea, N-[4-[[1-(3-amino-4-hydroxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-08-4 HCAPLUS

CN Urea, N-[4-[[1-[(3-amino-2-pyrazinyl)carbonyl]-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-09-5 HCAPLUS

CN Urea, N-[4-[[1-(3-butoxy-4-methoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-10-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-[2-(3-fluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl)- (CA INDEX NAME)



RN 799287-11-9 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(3-furanylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799287-12-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[3-(1H-indol-3-yl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



—Bu-t


RN 799287-13-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(3-methoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX
NAME)




RN 799287-14-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(3-methyl-2-furanyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799287-15-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(3-methyl-2-benzofuranyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799287-16-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(3-methyl-4-isoxazolyl)carbonyl]-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799287-17-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-3-phenoxypropyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799287-18-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-3-(3-pyridinyl)propyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)



RN 799287-19-7 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(3-thienylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799287-20-0 HCAPLUS

CN Urea, N-[4-[[1-[3-[(4,6-dimethoxy-2-pyrimidinyl)oxy]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

OMe


RN 799287-21-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(3a,4,5,7a-tetrahydro-6-benzofuranyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-23-3 HCAPLUS

CN Urea, N-[4-[[1-[(4,5-dihydrobenzo[b]thien-6-yl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799287-24-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(4,5-dimethyl-2-furanyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-25-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-

[[1-[4-(1,1,2,2-tetrafluoroethoxy)benzoyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHF₂


RN 799287-26-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-(1,2,3-thiadiazol-4-yl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 799287-27-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-(5-oxazolyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-28-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(2-thienyl)benzoyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-29-9 HCAPLUS

CN Urea, N-[4-[[1-[[[4-(4-chlorophenyl)-2-thienyl]carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799287-30-2 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(4-methoxyphenyl)-1-oxobutyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)



—OMe


RN 799287-31-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-(4-methoxyphenyl)-2-thienyl]carbonyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)




RN 799287-32-4 HCAPLUS

CN Urea, N-[4-[[1-[4-(difluoromethoxy)benzoyl]-4-piperidinyl]methyl]phenyl]-
N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)




RN 799287-33-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(ethylamino)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-34-6 HCAPLUS

CN Urea, N-[4-[[1-[4-[(1,1-dimethylethoxy)methyl]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-35-7 HCAPLUS

CN Urea, N-[4-[[1-[4-amino-3-(trifluoromethoxy)benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-36-8 HCAPLUS

CN Urea, N-[4-[[1-[4-(4-amino-5-chloro-2-methoxybenzoyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-37-9 HCAPLUS

CN Urea, N-[4-[[1-[2-(4-aminophenyl)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-38-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1,5-dioxo-5-phenylpentyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-39-1 HCAPLUS

CN Urea, N-[4-[[1-[2-(4-chlorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-40-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(4-fluorophenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-41-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(hydroxymethyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-42-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[4-(2-methylpropyl)benzoyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-43-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(4-methoxy-2-methylbenzoyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799287-44-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(4-methoxyphenoxy)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799287-45-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(4-methoxyphenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799287-46-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(4-methoxy-3-thienyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-47-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-4-phenylbutyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799287-48-2 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(4-(trifluoromethyl)-3-pyridinyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799287-49-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-[[4,6-dimethyl-2-pyrimidinyl)methyl]amino]benzoyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 799287-50-6 HCAPLUS

CN Urea, N-[4-[[1-[[5,6-dichloro-3-pyridinyl]carbonyl]-4-
piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-51-7 HCAPLUS

CN Urea, N-[4-[[1-(1H-benzimidazol-6-ylcarbonyl)-4-piperidinylmethyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-52-8 HCAPLUS

CN Urea, N-[4-[[1-[(5-chloro-1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]-4-piperidinylmethyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799287-53-9 HCAPLUS

CN Urea, N-[4-[[1-[2-(5-chlorobenzo[b]thien-3-yl)acetyl]-4-piperidinylmethyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




PAGE 1-A

-Bu-t


RN 799287-54-0 HCAPLUS

CN Urea, N-[4-[[1-[(5-chloro-2-thienyl)carbonyl]-4-piperidinyl]methyl]phenyl]-
N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX
NAME)




RN 799287-55-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[5-methoxy-2-(2,2,2-trifluoroethoxy)benzoyl]-4-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-56-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(5-methoxy-2-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]-
(CA INDEX NAME)




RN 799287-57-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[5-methyl-1-phenyl-1H-pyrazol-4-yl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-58-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[5-methyl-2-(trifluoromethyl)-3-furanyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-59-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-60-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(5-methyl-2-thienyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799287-61-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-62-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(5-methyl-4-isoxazolyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799287-63-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[(5-methyl-2-pyrazinyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA
INDEX NAME)




RN 799287-64-2 HCAPLUS

CN Urea, N-[4-[[1-(bicyclo[2.2.1]hept-5-en-2-ylcarbonyl)-4-
piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-65-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]carbonyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-66-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[6-(trifluoromethyl)-3-pyridinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-67-5 HCAPLUS

CN Urea, N-[4-[[1-[6-amino-3-pyridinyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-68-6 HCAPLUS

CN Urea, N-[4-[[1-[6-chloro-3-pyridinyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-69-7 HCAPLUS

CN Urea, N-[4-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-71-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(6-methyl-2-pyridinyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-72-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(7-methoxy-2-benzofuranyl)carbonyl]-4-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799287-73-3 HCAPLUS

CN Urea, N-[4-[[1-[4-(acetyloxy)methyl]benzoyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-74-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-methyl-1-oxo-2-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-75-5 HCAPLUS

CN Urea, N-[4-[[1-(6-benzothiazolylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-76-6 HCAPLUS

CN Urea, N-[4-([1-(1H-benzotriazol-6-ylcarbonyl)-4-piperidinyl]methyl)phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-77-7 HCAPLUS

CN Urea, N-[4-([1-(benzo[b]thien-2-ylcarbonyl)-4-piperidinyl]methyl)phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-78-8 HCAPLUS

CN Urea, N-[4-([1-[(2,3-dihydro-5-benzofuranyl)carbonyl]-4-piperidinyl]methyl)phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-79-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-(4,5,6,7-tetrahydro-4-oxo-3-benzofuranyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-80-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-(1-oxobutyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-81-3 HCAPLUS

CN Urea, N-[4-[[1-(cyclobutylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-82-4 HCAPLUS

CN Urea, N-[4-([1-(cycloheptylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-83-5 HCAPLUS

CN Urea, N-[4-([1-(cyclohexylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-84-6 HCAPLUS

CN Urea, N-[4-([1-(2-cyclohexylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799287-85-7 HCAPLUS

CN Urea, N-[4-[[1-(cyclopentylcarbonyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-86-8 HCAPLUS

CN Urea, N-[4-[[1-(2-cyclopentylacetyl)-4-piperidinyl]methyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 799287-87-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[5-oxo-2-pyrrolidinyl]carbonyl]-4-piperidinyl]methyl]phenyl)- (CA INDEX NAME)




RN 799287-88-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxoheptyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-89-1 HCAPLUS

CN Benzamide, N-[2-[4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 799287-90-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(2,5-dioxo-4-imidazolidinyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-91-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1-oxo-3-phenylpropyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-92-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1H-imidazol-5-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-93-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(thiazolo[3,2-a]benzimidazol-2-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-94-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2H-indazol-3-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-95-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-96-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1H-indol-3-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799287-97-1 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-[2-(1H-indol-3-yl)-2-oxoacetyl]-4-piperidiny]methyl]phenyl)- (CA INDEX NAME)




RN 799287-98-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-(1H-indol-5-ylcarbonyl)-4-piperidiny]methyl]phenyl)- (CA INDEX NAME)




RN 799287-99-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-(1H-indol-6-ylcarbonyl)-4-piperidiny]methyl]phenyl)- (CA INDEX NAME)




RN 799288-00-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(4-pyridinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799288-01-0 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(hexahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799288-02-1 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 799288-03-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-methoxyacetyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-04-3 HCAPLUS

CN 1-Piperidinebutanoic acid, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-gamma-oxo-, methyl ester (CA INDEX NAME)




RN 799288-05-4 HCAPLUS

CN Urea, N-[4-[[1-[2-(dimethylamino)acetyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799288-06-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-[2-[(4,6-dimethyl-2-pyrimidinyl)amino]benzoyl]-4-piperidinyl)methyl]phenyl)- (CA INDEX NAME)



RN 799288-07-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-(4-[[1-[3-[(4,6-dimethyl-2-pyrimidinyl)amino]benzoyl]-4-piperidinyl)methyl]phenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 799288-08-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[4-[(4,6-dimethyl-2-pyrimidinyl)amino]benzoyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 799288-09-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[3-[[[(4,6-dimethyl-2-pyrimidinyl)methyl]amino]benzoyl]-4-
piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 799288-10-1 HCAPLUS

CN Acetamide, N-[2-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-1-methyl-2-oxoethyl]- (CA INDEX NAME)




RN 799288-11-2 HCAPLUS

CN Acetamide, N-[2-[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 799288-12-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(phenylamino)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-13-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(3-pyridinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-14-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-[2-(2-methylphenyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX
NAME)




RN 799288-15-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(2-phenoxyacetyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799288-16-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(2-pyridinylcarbonyl)-4-piperidiny]methyl]phenyl]- (CA INDEX NAME)




RN 799288-17-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-
[[1-(2,2-dimethyl-1-oxopropyl)-4-piperidiny]methyl]phenyl]- (CA INDEX
NAME)




RN 799288-18-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(1H-pyrrol-3-ylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-19-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(2-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 799288-20-3 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(3-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-21-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(4-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 799288-22-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-(6-quinolinylcarbonyl)-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-23-6 HCAPLUS

CN Urea, N-[4-[[1-(2-benzo[b]thien-3-ylacetyl)-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799288-24-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(2-thienyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-25-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[1-[2-(3-thienyl)acetyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 799288-26-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-27-0 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-28-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,5-dimethoxyphenyl)-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-29-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 799288-30-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-1,3-benzodioxol-5-yl-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-31-6 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3,4-dimethoxyphenyl)-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-32-7 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dimethoxyphenyl)-4-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl)methyl]- (CA INDEX NAME)




RN 799288-33-8 HCAPLUS

CN 1-Piperidinecarboxamide, 4-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl)methyl]-N-(3,5-dimethyl-4-isoxazolyl)- (CA INDEX NAME)




RN 799288-34-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3-chloro-4-methoxyphenyl)-4-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl)methyl]- (CA INDEX NAME)




RN 799288-35-0 HCAPLUS

CN 1-Piperidinecarboxamide, 4-([3-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl]methyl]-N-3-thienyl)- (CA INDEX NAME)




RN 799288-36-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-[4-(difluoromethoxy)phenyl]-4-([3-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl]methyl)- (CA INDEX NAME)




RN 799288-37-2 HCAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-([3-([3-([3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino)carbonyl]amino)phenyl]methyl)- (CA INDEX NAME)




RN 799288-38-3 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 799288-39-4 HCAPLUS

CN 1-Piperidinecarboxamide, N-(4-acetylphenyl)-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-40-7 HCAPLUS

CN 1-Piperidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-41-8 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]-N-(4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 799288-42-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-(5-chloro-2,4-dimethoxyphenyl)-4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-43-0 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(5-methyl-2-(trifluoromethyl)-3-furanyl)- (CA INDEX NAME)





RN 799288-44-1 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)




RN 799288-45-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(6-fluoro-4H-1,3-benzodioxin-8-yl)- (CA INDEX NAME)




RN 799288-46-3 HCAPLUS

CN Benzoic acid, 3-[[[4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 799288-47-4 HCAPLUS

CN Benzoic acid, 4-[[[4-[[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 799288-50-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-53-2 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-56-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-(2,5-dimethoxyphenyl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-59-8 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(2-methyl-5-phenyl-3-furanyl)- (CA INDEX NAME)




RN 799288-62-3 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 799288-65-6 HCAPLUS

CN 1-Piperidinecarboxamide, N-1,3-benzodioxol-5-yl-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-68-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3,4-dimethoxyphenyl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-71-4 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dimethoxyphenyl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]- (CA INDEX NAME)




RN 799288-74-7 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl)methyl]-N-(3,5-dimethyl-4-isoxazolyl)- (CA INDEX NAME)




RN 799288-77-0 HCAPLUS

CN 1-Piperidinecarboxamide, N-(3-chloro-4-methoxyphenyl)-4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-80-5 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-3-thienyl]- (CA INDEX NAME)




RN 799288-83-8 HCAPLUS

CN 1-Piperidinecarboxamide, N-[4-(difluoromethoxy)phenyl]-4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-86-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)





RN 799288-91-8 HCAPLUS

CN 1-Piperidinecarboxamide, N-(4-acetylphenyl)-4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-94-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 799288-98-5 HCAPLUS


CN 1-Piperidinecarboxamide, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 799289-04-6 HCAPLUS




CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-[5-methyl-2-(trifluoromethyl)-3-furanyl]- (CA INDEX NAME)




CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



CN 1-Piperidinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-N-(6-




PAGE 1-A



PAGE 2-A


RN 799289-29-5 HCAPLUS

CN Benzoic acid, 3-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 799289-37-5 HCAPLUS


CN Benzoic acid, 4-[[[4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-1-piperidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 799291-31-9 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[[1-[(2R)-1-oxo-2-phenylpropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 799291-32-0 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[[[1-[(2S)-1-oxo-2-phenylpropyl]-4-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 799291-33-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, phenylmethyl ester (CA INDEX NAME)




RN 799291-34-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 2-methylpropyl ester (CA INDEX NAME)




RN 799291-35-3 HCAPLUS

CN Urea, N-[4-[(1-acetyl-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799291-37-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-(1-acetyl-3-oxo-3-phenyl-1-propen-1-yl)-4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)



RN 799291-38-6 HCAPLUS


CN Urea, N-[4-[[1-[[[4,5-dihydro-6-benzofuranyl]carbonyl]-4-piperidinyl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 799291-39-7 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 799291-41-1 HCAPLUS

CN Urea, N-[3-([1-[2-(2,5-dimethoxyphenyl)acetyl]-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 799291-43-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 4-methoxyphenyl ester (CA INDEX NAME)



RN 799291-44-4 HCAPLUS

CN Urea, N-[3-([1-[2-(2,5-dimethoxybenzoyl)-4-piperidinyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



IT 799283-54-8P 799294-79-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of pyrazolyl Ph urea derivs. as inhibitors of

p38

kinase and/or tumor necrosis factor (TNF))


RN 799283-54-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 799294-79-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 19 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

Serial No.:10/788,426


ACCESSION NUMBER: 2004:965067 HCAPLUS Full-text
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin; Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424 <--
WO 2004096224	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1473043	A1	20041103	EP 2003-9587	20030429 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
AU 2004233576	A1	20041111	AU 2004-233576	20040424 <--
CA 2523868	A1	20041111	CA 2004-2523868	20040424 <--
EP 1622619	A2	20060208	EP 2004-729366	20040424 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004009919	A	20060425	BR 2004-9919	20040424 <--
JP 2006524634	T	20061102	JP 2006-500099	20040424 <--
MX 2005011656	A	20051215	MX 2005-11656	20051028 <--
NO 2005005605	A	20051128	NO 2005-5605	20051128 <--
PRIORITY APPLN. INFO.:			EP 2003-9587	A 20030429 <--
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121
			WO 2004-EP4363	W 20040424

ED Entered STN: 12 Nov 2004

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preps. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 284461-73-0, BAY-43-9006
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (drug combinations for diseases involving cell proliferation and
 migration or apoptosis or angiogenesis including protein tyrosine
 kinase receptor antagonists and radiotherapy)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX
 NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 20 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:802884 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:289056
 TITLE: Medical use of ras antagonists for the treatment of
 capillary malformation
 INVENTOR(S): Vikkula, Miikka; Boon, Laurence; Eerola, Iiro
 PATENT ASSIGNEE(S): Universite Catholique de Louvain, Belg.
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083458	A1	20040930	WO 2003-EP2913	20030320 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2515519	A1	20040930	CA 2003-2515519	20030320 <--
AU 2003214145	A1	20041011	AU 2003-214145	20030320 <--
EP 1604037	A1	20051214	EP 2003-709806	20030320 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20060141472	A1	20060629	US 2005-546692	20050928 <--

PRIORITY APPLN. INFO.:

WO 2003-EP2913

W 20030320 <--

ED Entered STN: 01 Oct 2004

AB The invention relates to the field of vascular anomalies and methods for diagnosing and treating them. The invention provides for the causative gene (RASAl) and mutations therein which are useful for diagnosing inherited capillary malformations. The invention further provides RASAl antagonists for use in treatment of capillary malformations.


IT 284461-73-G, BAY 43-9006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Raf protein inhibitor; diagnosis and treatment of vascular anomalies using primers to detect RASAl gene mutations and ras protein antagonists)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 21 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:633440 HCAPLUS Full-text

DOCUMENT NUMBER: 141:167784

TITLE: Compositions and methods to treat heart failure

INVENTOR(S): Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J., Jr.

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064730	A2	20040805	WO 2004-US1069	20040114 <--
WO 2004064730	A3	20050324		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
AU 2004206860	A1	20040805	AU 2004-206860	20040114 <--
CA 2511970	A1	20040805	CA 2004-2511970	20040114 <--

Serial No.:10/788,426

EP 1615878	A2	20060118	EP 2004-702228	20040114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1738793	A	20060222	CN 2004-80002177	20040114 <--
CN 100345823	C	20071031		
JP 2006515884	T	20060608	JP 2006-500973	20040114 <--
NZ 540878	A	20080630	NZ 2004-540878	20040114 <--
US 20050159416	A1	20050721	US 2004-890829	20040714 <--
US 7491826	B2	20090217		
MX 2005007513	A	20050921	MX 2005-7513	20050713 <--
IN 2005DN03136	A	20070302	IN 2005-DN3136	20050714 <--
US 20060241110	A1	20061026	US 2006-541596	20060425 <--
US 7399866	B2	20080715		
PRIORITY APPLN. INFO.:				
			US 2003-440133P	P 20030114 <--
			US 2003-440183P	P 20030114 <--
			US 2003-476086P	P 20030604 <--
			US 2003-476517P	P 20030605 <--
			US 2003-501376P	P 20030908 <--
			WO 2004-US1069	W 20040114

OTHER SOURCE(S): MARPAT 141:167784

ED Entered STN: 06 Aug 2004

AB Certain substituted urea derivs. selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


IT 1055935-78-8 1055936-00-9 1055936-01-0
 1055936-02-1 1055936-04-3 1055936-06-5
 1055936-11-2 1055936-14-5 1055936-20-3
 1055936-26-9 1055936-75-8 1055936-78-1
 1055936-79-2 1055936-81-6 1055936-83-8
 1055936-86-1 1055936-87-2 1055936-89-4
 1055936-92-9 1055936-94-1 1055936-96-3
 1055936-97-4 1055937-00-2 1055937-09-1
 1055937-12-6 1055937-23-9 1055938-03-8
 1055938-05-0 1055938-22-1 1055938-53-8
 1055938-55-0 1055938-56-1 1055938-58-3
 1055938-73-2 1055938-88-9 1055939-04-2
 1055939-18-8 1055939-89-3 1055939-91-7
 1055939-92-8 1055939-95-1 1055939-98-4
 1055940-01-6 1055940-02-7 1055940-03-8
 1055940-04-9 1055940-05-0 1055940-08-3
 1055940-14-1 1055940-20-9 1055940-34-5
 1055940-35-6 1055940-36-7 1055940-37-8
 1055940-38-9 1055940-39-0 1055940-40-3
 1055940-41-4 1055940-42-5 1055940-54-9
 1055940-55-0 1055940-56-1 1055940-59-4
 1055940-81-2 1055940-82-3 1055940-84-5
 1055940-86-7 1055940-87-8 1055941-01-9
 1055941-17-7 1055941-18-8 1055941-19-9
 1055941-20-2 1055941-21-3 1055941-38-2
 1055941-39-3 1055941-47-3 1055942-11-4
 1055942-13-6 1055942-14-7 1055942-15-8
 1055942-45-4 1055942-50-1 1055942-76-1
 1055942-77-2 1055942-78-3 1055942-79-4
 1055942-80-7 1055942-85-2 1055942-88-5
 1055942-89-6 1055942-90-9 1055942-91-0
 1055943-09-3 1055943-10-6 1055943-11-7
 1055943-12-8 1055943-15-1 1055943-16-2
 1055943-17-3 1055943-18-4 1055943-19-5
 1055943-20-8 1055943-21-9 1055943-22-0
 1055943-23-1 1055943-25-3 1055943-28-6

RL: PRPH (Prophetic)

(Compositions and methods to treat heart failure)

RN 1055935-78-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)



RN 1055936-00-9 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-01-0 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-02-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[6-(cyanomethyl)-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-04-3 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-06-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1055936-11-2 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[[[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]amino]carbonyl]amino]-N-(aminoiminomethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-14-5 HCAPLUS

CN Urea, N-[3-([(3R)-1-acetyl-3-piperidinyl]oxy)-5-fluorophenyl]-N'-(5-methoxy-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-20-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(1-methyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-26-9 HCAPLUS

CN 1-Piperidineacetic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-α-oxo-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-75-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-78-1 HCAPLUS

CN Urea, N-[3-[[3-(3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-[6-(cyanomethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-79-2 HCAPLUS

CN Urea, N-[3-[[3-(3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-[6-(cyanomethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-81-6 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-83-8 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(tetrahydro-2-furanyl)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-86-1 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[[[(3R)-1-[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-87-2 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[1H-imidazol-2-ylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055936-89-4 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1055936-92-9 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[(6-ethyl-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-94-1 HCAPLUS

CN Urea, N-[3-[[[(3R,5R)-1-acetyl-5-hydroxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-96-3 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055936-97-4 HCAPLUS

CN Urea, N-[3-[[[(3R,5R)-1-acetyl-5-hydroxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-00-2 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-09-1 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(5-chloro-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-12-6 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(tetrahydro-2H-pyran-4-yl)carbonyl]-3-piperidinyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055937-23-9 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-03-8 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-(1-azetidinyldicarbonyl)-3-piperidinyl]oxy]-5-fluorophenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-05-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3R)-1-(1-methylethyl ester), (3R)-1-pyridinylamino)carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-22-1 HCAPLUS

CN Urea, N-[3-[[[(3R,5S)-1-acetyl-5-methoxy-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-53-8 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[(3R)-1-[(tetrahydro-2-furanyl)carbonyl]-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-55-0 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-1H-imidazol-2-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-56-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[(3R)-1-(pyridinylamino)carbonyl]amino]phenoxy]-, 2-methoxyethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-58-3 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-(6-methoxymethyl)-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-73-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[3-(3R)-1-(tetrahydro-2-furanyl)carbonyl]-3-piperidinyloxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055938-88-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(5-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-04-2 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-methoxy-, methyl ester, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055939-18-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 1055939-89-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[3-pyridinylamino)carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-91-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[(3R)-1-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-92-8 HCAPLUS

CN Urea, N-[3-[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-fluoro-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-95-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055939-98-4 HCAPLUS

CN Urea, N-[3-[(3R)-1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-01-6 HCAPLUS

CN Urea, N-[3-[(3R)-1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(2-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-02-7 HCAPLUS


CN Urea, N-[3-fluoro-5-[(3R)-1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-(3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055940-03-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1055940-04-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1055940-05-0 HCAPLUS
CN Urea, N-[3-fluoro-5-[[[(3R)-1-(2-methoxy-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055940-08-3 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 1055940-14-1 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-5-methoxy]-, methyl ester, (3R,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055940-20-9 HCAPLUS


CN Urea, N-[3-[(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 1055940-34-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-35-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-36-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-[6-(methoxymethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-37-8 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(phenylmethoxy)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-38-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[(1,6-dihydro-6-oxo-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-39-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[6-(cyanomethyl)-3-pyridinyl]amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-40-3 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[(4-formyl-1-piperidinyl)carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-41-4 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[[(2S)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-42-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-54-9 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(4-piperidinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-55-0 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(1-pyrrolidinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-56-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[(5-chloro-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-59-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(5-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-81-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-82-3 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-aminomethyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055940-84-5 HCAPLUS


CN Urea, N-[3-fluoro-5-[[[(2R)-tetrahydro-2-furanyl]carbonyl]-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055940-86-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1055940-87-8 HCAPLUS
CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-(methoxymethyl)-3-pyridinyl]amino]carbonyl]amino]phenoxy]-5-hydroxy-N,N-dimethyl-, (3R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1055941-01-9 HCAPLUS
CN Urea, N-[3-fluoro-5-[[1-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 1055941-17-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-18-8 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(2-methyl-1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-19-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 1055941-20-2 HCAPLUS

CN Urea, N-[3-fluoro-5-[[1-(2-methoxyacetyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)




RN 1055941-21-3 HCAPLUS

CN Urea, N-[3-[[1-[2-(dimethylamino)acetyl]-3-piperidinyloxy]-5-fluorophenyl]-N'-3-pyridinyl]- (CA INDEX NAME)




RN 1055941-38-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 1055941-39-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)



RN 1055941-47-3 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 1055942-11-4 HCAPLUS

CN Urea, N-[3-fluoro-5-[[(3R)-1-formyl-3-piperidinyloxy]phenyl]-N'-(6-formyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-13-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[(4-pyridazinylamino)carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-14-7 HCAPLUS

CN Urea, N-[3-fluoro-5-[[(3R)-1-(4-morpholinylcarbonyl)-3-piperidinyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-15-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 5-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-oxo-, 1,1-dimethylethyl ester, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-45-4 HCAPLUS

CN Urea, N-(1,6-dihydro-6-oxo-3-pyridinyl)-N'-[3-fluoro-5-[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-50-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, methyl ester, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-76-1 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-[[[(1,6-dihydro-6-oxo-3-pyridinyl)amino]carbonyl]amino]-5-fluorophenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055942-77-2 HCAPLUS


CN Urea, N-[3-[(1-acetyl-3-piperidinyloxy)-5-fluorophenyl]-N'-(2-(hydroxymethyl)-3-pyridinyl)]- (CA INDEX NAME)



RN 1055942-78-3 HCAPLUS

CN Urea, N-[3-[(1-acetyl-3-piperidinyloxy)-5-fluorophenyl]-N'-(6-(1,3,4-oxadiazol-2-ylmethyl)-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-79-4 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1055942-80-7 HCAPLUS

CN Urea, N-[6-(cyanomethyl)-3-pyridinyl]-N'-[3-fluoro-5-[[3-(3-piperidinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-85-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-5-methoxy-, methyl ester, (3R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-88-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-89-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-4-methoxy-, methyl ester, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-90-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1-methylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055942-91-0 HCAPLUS

CN Urea, N-[3-fluoro-5-[[[(3R)-1-(1-oxopropyl)-3-piperidinyl]oxy]phenyl]-N'-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-09-3 HCAPLUS

CN Urea, N-[3-[[[(3S)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-[6-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-10-6 HCAPLUS

CN Urea, N-[3-([(3R)-1-acetyl-3-piperidinyl]oxy)-5-fluorophenyl]-N'-2-oxazolyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-11-7 HCAPLUS

CN Urea, N-[3-([(3R)-1-acetyl-3-piperidinyl]oxy)-5-fluorophenyl]-N'-(2-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-12-8 HCAPLUS

CN Urea, N-[3-([(3R)-1-acetyl-3-piperidinyl]oxy)-5-fluorophenyl]-N'-(6-ethyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-15-1 HCAPLUS


CN Urea, N-[3-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)-N'-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)- (CA INDEX NAME)]-5-fluorophenyl]-N'-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1055943-16-2 HCAPLUS


CN Urea, N-[3-[(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 1055943-17-3 HCAPLUS

CN Urea, N-[3-fluoro-5-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)]-1-formyl-3-piperidinyl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-18-4 HCAPLUS

CN Urea, N-(6-ethyl-3-pyridinyl)-N'-[3-fluoro-5-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)]-1-formyl-3-piperidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-19-5 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-20-8 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-ethynyl-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-21-9 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-formyl-3-piperidinyl]oxy]phenyl]-N'-(6-(1-methylethyl)-3-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-22-0 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-(1-methylethyl)-3-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-23-1 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-5-oxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-25-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(4-pyridazinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1055943-28-6 HCAPLUS


CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(4-pyridazinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 732245-95-3P 732246-03-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (compds. to treat congestive heart failure)
 RN 732245-95-3 HCAPLUS
 CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyloxy]-5-fluorophenyl]-N'-3-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-03-6 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 732246-14-9 732246-15-0 732246-17-2
 732246-18-3 732246-19-4 732246-20-7
 732246-22-9 732246-23-0 732246-24-1
 732246-26-3 732246-39-8 732246-40-1
 732246-42-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compds. to treat congestive heart failure)
 RN 732246-14-9 HCAPLUS

CN Urea, N-[3-[(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 732246-15-0 HCAPLUS

CN Urea, N-[3-[(1-acetyl-3-piperidinyl)oxy]-5-fluorophenyl]-N'-3-pyridinyl- (CA INDEX NAME)



RN 732246-17-2 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 732246-18-3 HCAPLUS

CN Urea, N-[3-[[[(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-19-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-20-7 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-22-9 HCAPLUS

CN Urea, N-[3-[[3(3R)-1-acetyl-3-piperidinyl]oxy]-5-fluorophenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-23-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-24-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-26-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-39-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-40-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino]carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-42-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 732246-06-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(comps. to treat congestive heart failure)

RN 732246-06-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 22 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:533967 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:65147

TITLE: Method for treating diseases associated with abnormal tyrosine kinase activity by administering a DNA methylation inhibitor and a tyrosine kinase inhibitor
Lyons, John; Rubinfeld, Joseph

INVENTOR(S): USA

PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S.

Ser. No. 71,849.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040127453	A1	20040701	US 2002-206854	20020726 <--
US 6998391	B2	20060214		
US 20030147813	A1	20030807	US 2002-71849	20020207 <--
CA 2474174	A1	20030814	CA 2003-2474174	20030206 <--
WO 2003065995	A2	20030814	WO 2003-US3537	20030206 <--
WO 2003065995	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003215065	A1	20030902	AU 2003-215065	20030206 <--
EP 1572075	A2	20050914	EP 2003-710881	20030206 <--
EP 1572075	A3	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060140947	A1	20060629	US 2005-181368	20050713 <--
PRIORITY APPLN. INFO.:				
			US 2002-71849	A2 20020207 <--
			US 2002-206854	A 20020726 <--
			WO 2003-US3537	W 20030206 <--


ED Entered STN: 02 Jul 2004

AB Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.

IT 284461-73-0, BAY 43-9006
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Raf kinase inhibitor; treating diseases associated with abnormal tyrosine kinase activity by administering DNA methylation inhibitors and tyrosine kinase inhibitors)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 23 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:123969 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:166948
 TITLE: Raf pathway inhibitors in oncology
 AUTHOR(S): Bollag, Gideon; Freeman, Scott; Lyons, John F.; Post, Leonard E.
 CORPORATE SOURCE: Plexxikon Inc, Berkeley, CA, 94710, USA
 SOURCE: Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(12), 1436-1441
 CODEN: COIDAZ; ISSN: 1472-4472
 PUBLISHER: Thomson Current Drugs
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 ED Entered STN: 16 Feb 2004

AB A review. Recognition of the importance of the Raf pathway in the proliferation and survival of tumor cells recently increased with the discovery of activating BRAF mutations in human tumors. Therefore, in addition to a role in controlling tumors with Ras mutations and activated

growth factor receptors, inhibitors of the Raf pathway may harbor therapeutic potential in tumors carrying a BRAF oncogene. A variety of agents have been discovered that interfere with the Raf pathway, including antisense oligonucleotides and small mols. These inhibitors block the expression of Raf protein, block Ras/Raf interaction, block its kinase activity, or block the kinase activity of the Raf target protein mitogen-activated protein kinase. Raf pathway inhibitors that are currently undergoing clin. evaluation show promising signs of anticancer efficacy with a very tolerable safety profile. Indeed, the Raf inhibitor BAY-43-9006 recently entered phase III clin. trials. Here, we review the current development status of potential Raf pathway therapeutics.


IT 284461-73-0, BAY-43-9006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Raf pathway inhibitors were currently in clin. trial and showed promising anticancer efficacy with very tolerable safety profile and BAY-43-9006 recently entered phase III clin. trial)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 24 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:12708 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:70551

TITLE: A Phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

AUTHOR(S): Richly, H.; Kupsch, P.; Passage, K.; Grubert, M.; Hilger, R. A.; Kredtke, S.; Voliotis, D.; Scheulen, M. E.; Seeber, S.; Strumberg, D.

CORPORATE SOURCE: West German Cancer Center, University of Essen, Essen, Germany

SOURCE: International Journal of Clinical Pharmacology and Therapeutics (2003), 41(12), 620-621

CODEN: ICTHEK; ISSN: 0946-1965

PUBLISHER: Dustri-Verlag Dr. Karl Feistle

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 08 Jan 2004

AB Objective: The primary objective of this phase I study was to define the safety profile of BAY 43-9006 administered in combination with doxorubicin. Patients and methods: Twenty-nine patients with advanced, refractory solid


tumors were treated with doxorubicin (60mg/m²) every 3 wk for 6 consecutive cycles. BAY 43-9006 in combination with doxorubicin chemotherapy was administered at 3 dose levels. Results: Toxicity and response were evaluable in a total of 24 out of 29 enrolled patients. Dose-limiting toxicity was observed at various dose levels. Doxorubicin plasma Cmax/AUC values increased on escalating the dose of BAY 43-9006. Patients with liver metastases and elevated values of AST and conjugated bilirubin, compared to patients with normal hepatic function, showed a higher AUC for doxorubicin at all dose levels. Conclusions: Our data suggest a pharmacol. interaction of BAY 43-9006 at DL 400 mg bid with doxorubicin resulting in significantly increased AUC for doxorubicin.

IT 284461-73-0, BAY 43-9006

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (clin. and pharmacokinetic study of Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 25 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:12707 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:70550

TITLE: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors

AUTHOR(S): Moss, K.; Steinbild, S.; Baas, F.; Reil, M.; Buss, P.; Mersmann, S.; Voliotis, D.; Schwartz, B.; Brendel, E.

CORPORATE SOURCE: Tumor Biology Center at the Albert-Ludwigs-University Freiburg, Leverkusen, Germany

SOURCE: International Journal of Clinical Pharmacology and Therapeutics (2003), 41(12), 618-619
CODEN: ICTHEK; ISSN: 0946-1965

PUBLISHER: Dustri-Verlag Dr. Karl Feistle

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 08 Jan 2004

AB Classical cytotoxic anticancer drugs generally have specific actions but also interfere with signalling pathways. A logical approach is therefore to combine the Raf kinase inhibitor (RKI) with classical cytotoxic agents since

recent work has shown that the RKI BAY 43-9006 and CPT-11 have additive or synergistic actions. Objective: Because a pharmacol. drug-drug interaction cannot be ruled out, interaction studies were started using the RKI BAY 43-9006 in combination with the most important anticancer drugs, such as CPT-11. Patients and methods: The study protocol included three groups of 6 patients with solid tumors given different RKI doses and the same dosage of CPT-11. Blood samples for measurement of CPT-11 and SN-38 were obtained both during and in the absence of RKI treatment. Results: Ests. of toxicity, response and pharmacokinetics during the first RKI dose could be made in a total of 9/18 patients. All symptoms of toxicity were considered to be due to CPT-11 or RKI. The PK evaluation showed no significant differences for CPT-11 and SN-38, with or without RKI. Conclusions: The combination CPT-11 and SN-38 PK is not significantly influenced by the addition of RKI. There is no indication that the PK of RKI are influenced significantly by CPT-11 and SN-38.


IT 284461-73-0, BAY 43-9006

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug-drug interaction pharmacokinetic study with Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 26 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:12706 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:17009

TITLE: Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006

AUTHOR(S): Heim, M.; Sharifi, M.; Hilger, R. A.; Scheulen, M. E.; Seeber, S.; Strumberg, D.

CORPORATE SOURCE: West German Cancer Center, University of Essen, Essen, Germany

SOURCE: International Journal of Clinical Pharmacology and Therapeutics (2003), 41(12), 616-617

CODEN: ICTHEK; ISSN: 0946-1965

PUBLISHER: Dustri-Verlag Dr. Karl Feistle

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 08 Jan 2004

AB A study was conducted to evaluate the effects of combining BAY 43-9006 and cytotoxic drugs (paclitaxel, 5-FU, oxaliplatin, and SN-38) on human cancer cells using 4 sequencing protocols and to analyze the effect of RKI on colorectal cancer cells showing marked resistance against SN-38. Results showed the additive action or moderate synergy using RKI in combination with numerous cytotoxic agents and the marked reduction of oxaliplatin activity by RKI in human carcinoma cells. These indicate that Raf kinase activity might be important for oxaliplatin-induced cytotoxicity. Furthermore, lacking cross-resistance between SN-38 and RKI might provide a rationale for designing clinical trials using CPT-11 in combination with BAY 43-9006 in patients with colorectal cancer.

IT 284461-73-0, BAY 43-9006
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006 in relation to resistance to SN-38)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 27 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:12705 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:349958

TITLE: Circadian rhythm in the regulation of the MAP kinase pathway - pitfall in the determination of surrogate parameters?

AUTHOR(S): Hilger, R. A.; Diaz-Carballo, D.; Bauer, S.; Kredtke, S.; Scheulen, M. E.; Seeber, S.; Strumberg, D.

CORPORATE SOURCE: Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, Germany

SOURCE: International Journal of Clinical Pharmacology and Therapeutics (2003), 41(12), 614-615

CODEN: ICTHEK; ISSN: 0946-1965

PUBLISHER: Dustri-Verlag Dr. Karl Feistle

DOCUMENT TYPE: Journal


LANGUAGE: English

ED Entered STN: 08 Jan 2004

AB A method for the quantification of the inhibitory potency of BAY 43-9006, a novel potent and orally active inhibitor of Raf kinase, measuring the phosphorylated (activated) extracellular signal-regulated kinase (ERK) as a biomarker, was developed. A circadian rhythm in phosphorylation of ERK1/2

proteins after phorbol myristate acetate stimulation was observed. It was demonstrated that biomarker measurements could be complicated by circadian variability of the specific mol. target. Phosphorylated ERK1/2 may serve as a biomarker for drugs targeting the mitogen-activated protein kinase cascade. However, the demonstrated circadian regulation demands strict protocols for the realization of biomarker analyses.

IT 284461-73-G, BAY 43-9006
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (circadian rhythm in regulation of MAP kinase pathway)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinocarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 28 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:950982 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 140:16736
 TITLE: Preparation of diarylurea derivatives useful for the treatment of protein kinase dependent diseases
 INVENTOR(S): Floersheimer, Andreas; Furet, Pascal; Manley, Paul William; Bold, Guido; Boss, Eugen; Guagnano, Vito; Vaupel, Andrea
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 170 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099771	A2	20031204	WO 2003-EP5634	20030528 <--
WO 2003099771	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2484288	A1	20031204	CA 2003-2484288	20030528 <--
AU 2003242591	A1	20031212	AU 2003-242591	20030528 <--

AU 2003242591	B2	20070726		
BR 2003011313	A	20050215	BR 2003-11313	20030528 <--
EP 1511730	A2	20050309	EP 2003-755147	20030528 <--
EP 1511730	B1	20081210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656073	A	20050817	CN 2003-812280	20030528 <--
JP 2005527622	T	20050915	JP 2004-507429	20030528 <--
NZ 536781	A	20071221	NZ 2003-536781	20030528 <--
AT 417037	T	20081215	AT 2003-755147	20030528 <--
ZA 2004008314	A	20060726	ZA 2004-8314	20041014 <--
IN 2004CN02670	A	20070720	IN 2004-CN2670	20041125 <--
MX 2004011789	A	20050331	MX 2004-11789	20041126 <--
NO 2004005521	A	20041217	NO 2004-5521	20041217 <--
US 20060128734	A1	20060615	US 2005-515113	20051208 <--
PRIORITY APPLN. INFO.:			GB 2002-12413	A 20020529 <--
			GB 2003-5684	A 20030312 <--
			GB 2003-9219	A 20030423 <--
			WO 2003-EP5634	W 20030528 <--

OTHER SOURCE(S): MARPAT 140:16736
 ED Entered STN: 07 Dec 2003
 GI



I

AB The invention relates to the use of diaryl urea derivs. [I; G is not present and Z = a radical of the formula Q; A = CH, N, N→O; Al = N, N→O, with the proviso that not more than one of A and Al can be N→O; n = 1, 2; m = 0-2; p = 0, 2, 3; q = 0-5; X = (un)substituted NH if p = 0; or if p is 2 or 3, X = nitrogen which together with (CH2)p and the bonds represented in dotted (interrupted) lines (including the atoms to which they are bound) forms a ring, or X = CHK (wherein K = H or lower alkyl) and p = 0, with the proviso that the bonds represented in dotted lines, if p = 0, are absent; Y1 = O, S, CH2; Y2 = O, S, NH; with the proviso that (Y1)n-(Y2)m does not include O-O, S-S, NH-O, NH-S or S-O groups; R1, R2, R3, R5 = independently H or an inorg. or organic moiety or any two of them together form a lower alkyleneedioxy bridge bound via the oxygen atoms, and the remaining one of these moieties is hydrogen or an inorg. or organic moiety; R4 (if present, i.e., if q is not zero) is an inorg. or organic moiety] or tautomers thereof or pharmaceutically acceptable salts thereof in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compns. for use in the treatment of said diseases, especially a proliferative disease depending on any one or more of the following (tyrosine) protein kinases such as ras, Abl, VEGF-receptor tyrosine kinase, Flt3, and/or Bcr-Abl activity. Also disclosed are the use of the compds. I for the manufacture of pharmaceutical compns. for use in the treatment of said diseases, methods of use of the compds. I in the treatment of said diseases, pharmaceutical preps. comprising the compds. I for the treatment of said diseases, processes for the manufacture of the compds. I, the use or methods of use of the compds. I as mentioned above, and/or the compds. I for use in the treatment of the animal or human body. For example,

N-(4-(pyridin-4-yloxy)phenyl)-N'-(4-2,2,2-trifluoroethoxy-3-trifluoromethylphenyl)urea and N-[4-[6-(4-hydroxyphenylamino)pyrimidin-4-yl]phenyl]-N'-(4-2,2,2-trifluoroethoxy-3-trifluoromethylphenyl)urea at 10 μ M inhibited gene c-Abl protein kinase by 98%, Kdr receptor tyrosine kinase by 100 and 96%, resp., and Flt3 receptor tyrosine kinase by 100%.

IT 630125-68-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of diarylurea derivs. useful for the treatment

of

protein kinase dependent diseases and proliferative diseases)

RN 630125-68-7 HCAPLUS

CN Urea, N-[4-[2-(1-pyrrolidinylcarbonyl)-4-pyridinyl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 630122-85-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylurea derivs. useful for the treatment of protein kinase dependent diseases and proliferative diseases)

RN 630122-85-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 29 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:737931 HCAPLUS [Full-text](#)


DOCUMENT NUMBER: 139:255332

TITLE: Method for selecting antitumor drug sensitivity-determining factors and method for predicting antitumor drug sensitivity using the selected factors

Serial No.:10/788,426


INVENTOR(S): Aoki, Yuko; Hasegawa, Kiyoshi; Ishii, Nobuya; Mori, Kazushige
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076660	A1	20030918	WO 2002-JP2354	20020313 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2478640	A1	20030918	CA 2002-2478640	20020313 <--
AU 2002238874	A1	20030922	AU 2002-238874	20020313 <--
EP 1483401	A1	20041208	EP 2002-705127	20020313 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1625602	A	20050608	CN 2002-828958	20020313 <--
JP 2005519610	T	20050707	JP 2003-574857	20020313 <--
US 20050118600	A1	20050602	US 2005-507389	20050120 <--
PRIORITY APPLN. INFO.:			WO 2002-JP2354	W 20020313 <--
ED	Entered STN:	19 Sep 2003		
AB	Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate anal. with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the resp. genes to drug sensitivity was determined to select genes with a high degree of contribution. In addition, the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values determined exptl. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens associated with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).			
IT	284461-73-0, BAY 439006 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method for selecting antitumor drug sensitivity-determining factors and predicting antitumor drug sensitivity using the selected factors)			
RN	284461-73-0 HCAPLUS			
CN	2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)			



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 30 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:736198 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 139:301125
 TITLE: BAY-43-9006 (Bayer/Onyx)
 AUTHOR(S): Lee, John T.; McCubrey, James A.
 CORPORATE SOURCE: Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858-4353, USA
 SOURCE: Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(6), 757-763
 CODEN: COIDAZ; ISSN: 1472-4472
 PUBLISHER: Thomson Current Drugs
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 ED Entered STN: 19 Sep 2003
 AB A review. Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by Feb. 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
 IT 284461-73-0, BAY 43-9006
 RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (BAY 43-9006 for treatment of cancer patients)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 31 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:696888 HCAPLUS Full-text
 DOCUMENT NUMBER: 139:230482
 TITLE: Preparation of 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
 INVENTOR(S): Cirillo, Pier F.; Regan, John R.; Hammach, Abdelhakim
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072569	A1	20030904	WO 2003-US7268	20030219 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473634	A1	20030904	CA 2003-2473634	20030219 <--
AU 2003213806	A1	20030909	AU 2003-213806	20030219 <--
US 20030232865	A1	20031218	US 2003-369847	20030219 <--
US 7041669	B2	20060509		
EP 1480973	A1	20041201	EP 2003-711498	20030219 <--
EP 1480973	B1	20080213		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005518447	T	20050623	JP 2003-571275	20030219 <--
AT 386030	T	20080315	AT 2003-711498	20030219 <--
ES 2299689	T3	20080601	ES 2003-711498	20030219 <--
PRIORITY APPLN. INFO.:			US 2002-359809P	P 20020225 <--
			WO 2003-US7268	W 20030219 <--

OTHER SOURCE(S): MARPAT 139:230482
 ED Entered STN: 05 Sep 2003
 GI



AB Benzo-fused urea compds. of formula I [A = (substituted) alkylene; Ar = pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, thiophene; L = O, S, NH, alkylene, etc.; Q = Ph, pyridine, pyrimidine, imidazole, furan, pyran, morpholine, etc.; X = O, S] are prepared. The compds. inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathol. conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compds. and compns., and pharmaceutical compns. comprising these compds. Thus, II was prepared from 4-amino-1-naphthol hydrochloride, 2,4-dichloropyrimidine, cyclopropanemethylamine and 5-amino-3-tert-butyl-1-methylpyrazole.

IT 591772-76-8F


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzo-fused cycloalkyl urea compds. as inhibitors of cytokine production)


RN 591772-76-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[[[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-N-methyl-N-phenyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 32 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:633416 HCAPLUS Full-text
 DOCUMENT NUMBER: 139:173786
 TITLE: Method for treating diseases associated with abnormal kinase activity
 INVENTOR(S): Lyons, John; Rubinfeld, Joseph
 PATENT ASSIGNEE(S): Supergen, Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003065995	A2	20030814	WO 2003-US3537	20030206 <--
WO 2003065995	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20030147813	A1	20030807	US 2002-71849	20020207 <--
US 20040127453	A1	20040701	US 2002-206854	20020726 <--
US 6998391	B2	20060214		
CA 2474174	A1	20030814	CA 2003-2474174	20030206 <--
AU 2003215065	A1	20030902	AU 2003-215065	20030206 <--
EP 1572075	A2	20050914	EP 2003-710881	20030206 <--
EP 1572075	A3	20051207		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-71849	A1 20020207 <--
			US 2002-206854	A1 20020726 <--
			WO 2003-US3537	W 20030206 <--

ED Entered STN: 15 Aug 2003

AB Methods are provided for treating diseases associated with abnormal activity of kinases such as chronic myelogenous leukemia. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor such as imatinib mesylate to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor

family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.


IT 284461-73-0, BAY 43-9006

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of diseases associated with abnormal kinase activity with serine/threonine kinase inhibitor and DNA methylation inhibitor)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 33 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:476541 HCAPLUS Full-text

DOCUMENT NUMBER: 139:143192

TITLE: Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors

AUTHOR(S): DeGrendele, Heather

CORPORATE SOURCE: USA

SOURCE: Clinical Colorectal Cancer (2003), 3(1), 16-18

CODEN: CCCLCF; ISSN: 1533-0028

PUBLISHER: Cancer Information Group

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ED Entered STN: 23 Jun 2003

AB A review. BAY 43-9006 is the first orally active Raf kinase inhibitor to undergo clin. testing and has shown promise in the treatment of colorectal cancer. Treatment with BAY 43-9006 has resulted in stable disease in 37 % of patients across this phase I series, with 42 % of colorectal cancer patients achieving stable disease. Among patients achieving stable disease, 27 have been on therapy for over 6 mo without progression. Toxicity associated with this regimen is mild, with few grade 3/4 adverse events reported. Furthermore, fluorescence-activated cell sorter (FACS) anal. demonstrated that treatment with BAY 43-9006 could result in the inhibition of extracellular signal-regulated kinase (ERK) activation. Based on this phase I data, 2 phase II trials, including one in patients with colorectal cancer, have been initiated, and phase III trials are planned for 2003. At the 38th Annual Meeting of the American Society of Clin. Oncol., Vincent and colleagues reported on preclin. studies combining BAY 43-9006 with irinotecan, vinorelbine, or gemcitabine in human xenografts models. They demonstrated that BAY 43-9006 combined with cytotoxic or cytostatic agents is at least as efficacious as the individual agents administered alone. With this as

rationale, multiple phase I/II studies are being designed to investigate the role of BAY 43-9006 in combination with standard chemotherapy.


IT 284461-73-0, BAY 43-9006

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(activity of Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 34 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:454071 HCAPLUS Full-text

DOCUMENT NUMBER: 139:30782

TITLE: RAF-MEK-ERK pathway inhibitors to treat cancer

INVENTOR(S): Lyons, John F.; Bollag, Gideon

PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047523	A2	20030612	WO 2002-US38402	20021203 <--
WO 2003047523	A3	20060223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2466762	A1	20030612	CA 2002-2466762	20021203 <--
AU 2002365899	A1	20030617	AU 2002-365899	20021203 <--
AU 2002365899	B2	20070913		
US 20030125359	A1	20030703	US 2002-308721	20021203 <--


Serial No.:10/788,426

US 7307071 B2 20071211
 JP 2005526008 T 20050902 JP 2003-548784 20021203 <--
 EP 1578346 A2 20050928 EP 2002-804478 20021203 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 PRIORITY APPLN. INFO.: US 2001-336886P P 20011204 <--
 WO 2002-US38402 W 20021203 <--
 ED Entered STN: 13 Jun 2003
 AB Materials and methods for treating certain cancers are described, preferably
 cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and
 more preferably chronic myelogenous leukemia, and which cancer is preferably
 resistant to the inhibitor of Bcr-Abl tyrosine kinase, imatinib.
 IT 284461-73-0, BAY 43-9006
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (BAY 43-9006; RAF-MEK-ERK pathway inhibitors to treat cancer)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-
 (trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX
 NAME)




L42 ANSWER 35 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:396605 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:401725
 TITLE: Preparation of antibiotic
 2-[[[4-(aminosulfonyl)phenyl]ureido]thiazoles
 INVENTOR(S): Bauser, Marcus; Beyer, Dieter; Broetz, Heike;
 Endermann, Rainer; Hauswald, Markus; Kroll,
 Hein-Peter; Pohlmann, Jens; Schiffer, Guido; Siegel,
 Stephan
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 32 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10155684	A1	20030522	DE 2001-10155684	20011113 <--
PRIORITY APPLN. INFO.:			DE 2001-10155684	20011113 <--
OTHER SOURCE(S): MARPAT 138:401725				
ED Entered STN: 23 May 2003				
GI				




- AB [[(Aminosulfonyl)phenyl]ureido]thiazoles [I; R1 = (un)substituted alkyl, Ph; R2 = H, alkyl; NR1R2 = (un)substituted piperazino, (un)substituted piperidino; e.g., N-[3-[[4-(4-methoxy-2-quinazolinyl)-1- piperazinyl]sulfonyl]phenyl]-N'-(1,3-thiazol-2-yl)urea which demonstrated a MIC of 0.8 µg/mL against H. influenzae SP7 and 0.4 µg/mL against S. pneumoniae G9A], useful as antibiotics, are prepared
- IT 529515-98-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of antibiotic 2-[[[(aminosulfonyl)phenyl]ureido]thiazoles)
- RN 529515-98-8 HCAPLUS
- CN 4-Piperidinecarboxylic acid, 1-[[3-[[2-thiazolylamino]carbonyl]amino]phenyl]sulfonyl]- (CA INDEX NAME)



- IT 529515-25-1P 529515-26-2P 529515-90-0P
 529516-10-7P 529516-11-8P 529516-12-9P
 529516-13-0P 529516-14-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of antibiotic 2-[[[(aminosulfonyl)phenyl]ureido]thiazoles)
- RN 529515-25-1 HCAPLUS
- CN Urea, N-[3-[[4-[[4-methoxycyclohexyl]carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)




- RN 529515-26-2 HCAPLUS
- CN Urea, N-[3-[[4-[[3-methoxycyclohexyl]carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)




RN 529515-90-0 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[3-[[2-thiazolylamino]carbonyl]amino]phenyl]sulfonyl]-, ethyl ester (CA INDEX NAME)




RN 529516-10-7 HCAPLUS

CN Urea, N-[3-[[4-[(4-methyl-1-piperidiny)carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)




RN 529516-11-8 HCAPLUS

CN Urea, N-[3-[[4-[(4-methyl-1-piperaziny)carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)




RN 529516-12-9 HCAPLUS

CN Urea, N-2-thiazolyl-N'-[3-[[4-(4-thiomorpholinylcarbonyl)-1-piperidinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 529516-13-0 HCAPLUS

CN Urea, N-[3-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)



RN 529516-14-1 HCAPLUS

CN Urea, N-[3-[[4-[[4-(2-ethyl-1-piperazinyl)carbonyl]-1-piperidinyl]sulfonyl]phenyl]-N'-2-thiazolyl- (CA INDEX NAME)



L42 ANSWER 36 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:282524 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:304064

TITLE: Preparation of phenylurea derivatives as vanilloid receptor agonists

INVENTOR(S): Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro, Hiroshi; Mochizuki, Manabu

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029199	A1	20030410	WO 2002-JP9995	20020927 <--
WO 2003029199	A9	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

Serial No.:10/788,426


CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002332331 A1 20030414 AU 2002-332331 20020927 <--
 EP 1437344 A1 20040714 EP 2002-768103 20020927 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2004339061 A 20041202 JP 2002-282514 20020927 <--
 US 20040259912 A1 20041223 US 2004-489621 20040312 <--
 PRIORITY APPLN. INFO.: JP 2001-300564 A 20010928 <--
 WO 2002-JP9995 W 20020927 <--
 OTHER SOURCE(S): MARPAT 138:304064
 ED Entered STN: 11 Apr 2003
 GI




AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.

IT 508216-76-0P 508216-98-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylurea derivs. as vanilloid receptor agonists)

RN 508216-76-0 HCAPLUS
 CN 4-Piperidinecarboxamide, 1-[2-(diphenylmethoxy)-5-
 [(phenylamino)carbonyl]amino]benzoyl]- (CA INDEX NAME)



RN 508216-98-6 HCAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[2-(diphenylmethoxy)-5-
 [[(phenylamino)carbonyl]amino]benzoyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L42 ANSWER 37 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:208292 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 139:269975
 TITLE: Oncolytic Raf kinase inhibitor
 AUTHOR(S): Sorbera, L. A.; Castaner, J.; Bozzo, J.; Leeson, P. A.
 CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
 SOURCE: Drugs of the Future (2002), 27(12),
 1141-1147
 CODEN: DRFUD4; ISSN: 0377-8282
 PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

ED Entered STN: 18 Mar 2003

AB A review with refs. The Ras/Raf/MEK pathway is a signaling module that controls cell growth and survival. Activation of this pathway results in a cascade of events from the cell surface to the nucleus ultimately affecting cellular proliferation, apoptosis, differentiation and transformation. Raf is a serine/threonine kinase that is a downstream effector enzyme of Ras. When activated, Raf goes on to activate MEK1 and MEK2 kinases which in turn phosphorylate and activate ERK1 and ERK2 which translocate to the nucleus where they stimulate pathways required for translation initiation and transcription activation leading to proliferation. Raf kinase has been validated as a potential and attractive target for hyperproliferative disorders such as cancer. Research has recently focused on efforts to discover potent Raf kinase inhibitors and several low-mol.-weight Raf kinase inhibitors have been described. Bis-aryl ureas were identified within this program using medicinal chemical-directed syntheses or combinatorial libraries. After high-throughput screening of more than 200,000 compds. against recombinant Raf-1 kinase, the orally active Bay-43-9006 was identified as having potent

inhibitory activity and was chosen for further development as a treatment for cancer. Bay-43-9006 has exhibited potent in vitro activity against several tumor cell lines and has displayed efficacy in human tumor xenograft models. Moreover, results from phase I development in patients with a variety of cancer types indicates promising clin. efficacy for the compound

IT 284461-73-0, Bay-43-9006
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oncolytic Raf kinase inhibitor)
 RN 284461-73-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 38 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:946279 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:24719

TITLE: Preparation of 1,4-disubstituted benzo-fused

cycloalkyl ureas as antiinflammatory agents

Cirillo, Pier F.; Hickey, Eugene R.

Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098869	A2	20021212	WO 2002-US16720	20020524 <--
WO 2002098869	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446193	A1	20021212	CA 2002-2446193	20020524 <--
AU 2002310156	A1	20021216	AU 2002-310156	20020524 <--

Serial No.:10/788,426

US 20030100608	A1	20030529	US 2002-154535	20020524 <--
US 6720321	B2	20040413		
EP 1414810	A2	20040506	EP 2002-737211	20020524 <--
EP 1414810	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534787	T	20041118	JP 2003-501992	20020524 <--
AT 338035	T	20060915	AT 2002-737211	20020524 <--
ES 2269709	T3	20070401	ES 2002-737211	20020524 <--
MX 2003011006	A	20040227	MX 2003-11006	20031128 <--
PRIORITY APPLN. INFO.:		US 2001-295909P	P	20010605 <--
		WO 2002-US16720	W	20020524 <--
OTHER SOURCE(S):		CASREACT 138:24719; MARPAT 138:24719		
ED Entered STN: 13 Dec 2002				
GI				




AB The title compds. [I; n = 1-5; cycloalkyl can be optionally substituted by 1-2 R1 or R2; X = O; p = 0-1; z = 0-1; A = fused (un)saturated (un)substituted ring containing 3-5 carbon atoms; L = a bond, O, NH, CO, CS, etc.; J = CH2, (CH2)2, CH2CHMe, CH2CHOH, CHOH, CO; Q = (un)substituted Ph, naphthyl, pyridinyl, etc.; R1 = (un)substituted Ph, CH2Ph, naphthyl, etc.; R2 = alkyl, haloalkyl, acyl, etc.], useful for treating a cytokine mediated diseases (no biol. data), were prepared Thus, reacting 4-[2-(morpholin-4-yl)ethoxynaphthalen-1-ylamine with trans-2-phenylcyclopropyl isocyanate in THF afforded II.

IT 478044-72-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,4-disubstituted benzo-fused cycloalkyl ureas as antiinflammatory agents)

RN 478044-72-3 HCAPLUS

CN Urea, N-(2-cyclohexylcyclopropyl)-N'-[4-[[2-(1-pyrrolidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 39 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:888719 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:384854

TITLE: Preparation of diaryl ureas as antiinflammatory agents

INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach,

Abdelhakim; Moss, Neil; Regan, John Robinson

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508 <--
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2445003	A1	20021121	CA 2002-2445003	20020508 <--
AU 2002305500	A1	20021125	AU 2002-305500	20020508 <--
EP 1392661	A1	20040303	EP 2002-734324	20020508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004530690	T	20041007	JP 2002-589462	20020508 <--
US 20030008868	A1	20030109	US 2002-143322	20020510 <--
US 6852717	B2	20050208		
MX 2003010487	A	20040309	MX 2003-10487	20031114 <--
PRIORITY APPLN. INFO.:				
			US 2001-291425P	P 20010516 <--
			WO 2002-US14733	W 20020508 <--


ED Entered STN: 22 Nov 2002

GI




- AB The title diaryl ureas, useful in pharmaceutic compns. for treating a cytokine mediated diseases or conditions involving inflammation such as chronic inflammatory diseases, were prepared Thus, treating 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et3N in DMF followed by addition of Et4NCN, and treatment of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.
- IT 476010-99-8P 476011-03-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diaryl ureas as antiinflammatory agents)
- RN 476010-99-8 HCAPLUS
- CN 4-Thiazolecarboxylic acid, 2-[[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(1-pyrrolidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]amino]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 476011-03-7 HCAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-
 [(methylamino)carbonyl]-4-pyridinyl]oxy]-1-
 naphthalenyl]amino]carbonyl]amino]phenyl]amino]-, ethyl ester (CA INDEX
 NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 40 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:814091 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 137:310705
 TITLE: Preparation of 1,4-disubstituted benzo-fused arylureas
 for chronic inflammatory diseases
 INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach,
 Abdelhakim; Moss, Neil; Mueller, Kristen; Regan, John
 Robinson
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083628	A1	20021024	WO 2002-US8504	20020321 <--
W: AE, AU, BG, BR, BY, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, UZ, VN, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2443697	A1	20021024	CA 2002-2443697	20020321 <--
AU 2002254302	A1	20021028	AU 2002-254302	20020321 <--
EP 1381592	A1	20040121	EP 2002-723527	20020321 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2005507367	T	20050317	JP 2002-581385	20020321 <--
US 20030083333	A1	20030501	US 2002-120028	20020410 <--
US 6765009	B2	20040720		
MX 2003009000	A	20040212	MX 2003-9000	20031002 <--
PRIORITY APPLN. INFO.:				
			US 2001-283642P	P 20010413 <--
			WO 2002-US8504	W 20020321 <--
OTHER SOURCE(S): CASREACT 137:310705; MARPAT 137:310705				
ED Entered STN: 25 Oct 2002				
GI				



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = fused (un)saturated (un)substituted ring containing 3-5 C atoms; G = Ph, naphthyl, benzocyclobutanyl, dihydronaphthyl, etc.; L = O, NH, CO, CS, etc.; Q = Ph, naphthyl, pyridinyl, pyrimidinyl, etc.; Y (covalently attached to Q) = O, CO, NH, CONH, etc.; n = 0-2; X = O, S] were prepared For instance, 4-amino-1-naphthol•HCl was converted to the N-Boc derivative and alkylated with 4-(2-chloroethyl)morpholine•HCl (CH₃CN, K₂CO₃, 80°, 3 h); the product was deprotected to give 4-[2-(morpholin-4-yl)ethoxy]naphth-1-ylamine. This intermediate was reacted with phosgene (CH₂Cl₂/H₂O/NaHCO₃, 0°) and the resulting intermediate coupled to 5-tert-butyl-3-methylcarbamoyl-2-methoxyaniline (preparation given) to afford II. I are useful in pharmaceutical compns. for treating, e.g., rheumatoid arthritis, osteoarthritis, Crohn's disease, etc.


IT 473269-78-2P 473269-79-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 1,4-disubstituted benzo-fused arylureas for chronic inflammatory diseases)

RN 473269-78-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-, methyl ester (CA INDEX NAME)



RN 473269-79-3 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-
 [(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-
 (CA INDEX NAME)



IT 473269-80-6P 473269-81-7P 473269-83-9P
 473270-22-3P, 4-[4-[4-[N'-(5-tert-Butyl-3-((methanesulfonyl)amino)-2-methoxyphenyl)ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]piperazine-1-carboxylic acid tert-butyl ester 473270-24-5P,
 N-[3-[N'-(4-[2-((4-Acetylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-5-tert-butyl-2-methoxyphenyl]methanesulfonamide 473270-27-8P,
 4-[4-[4-[N'-(5-tert-Butyl-3-((methanesulfonyl)amino)-2-methoxyphenyl)ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]piperazine-1-carboxylic acid ethylamide 473270-31-4P,
 N-[5-tert-Butyl-3-[N'-(4-[2-((4-ethylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-2-methoxyphenyl]methanesulfonamide 473270-35-8P, N-[5-tert-Butyl-3-[N'-(4-[2-(2,6-dimethylmorpholine-4-carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-2-methoxyphenyl]methanesulfonamide 473270-40-5P,
 N-[5-tert-Butyl-3-[N'-(4-[2-((3-ethylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-2-methoxyphenyl]methanesulfonamide 473270-44-9P, N-[5-tert-Butyl-3-[N'-(4-[2-((3-ethyl-4-methylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-2-methoxyphenyl]methanesulfonamide 473270-48-3P,
 N-[3-[N'-(4-[2-((4-Acetyl-3-ethylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl)ureido]-5-tert-butyl-2-methoxyphenyl]methanesulfonamide 473270-50-7P,
 4-[4-[4-[N'-(5-tert-Butyl-3-((methanesulfonyl)amino)-2-methoxyphenyl)ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]-2-



ethylpiperazine-1-carboxylic acid ethylamide 473270-52-9P,
 4-[4-[4-[N'-(5-tert-Butyl-3-((methanesulfonyl)amino)-2-methoxyphenyl]ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]-2-ethylpiperazine-1-carboxylic acid tert-butyl ester 473270-54-1P,
 N-[5-tert-Butyl-2-methoxy-3-[N'-(4-[2-((4-methylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]methanesulfonamide 473270-60-9P,
 N-[5-tert-Butyl-2-methoxy-3-[N'-(4-[2-(pyrrolidine-1-carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]methanesulfonamide 473270-64-3P,
 N-[5-tert-Butyl-2-methoxy-3-[N'-(4-[2-(piperidine-1-carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]methanesulfonamide 473270-66-5P,
 4-[4-[N'-(5-tert-Butyl-3-((methanesulfonyl)amino)-2-methoxyphenyl]ureido]naphthalen-1-yloxy]pyridine-2-carboxylic acid diethylamide 473270-70-1P 473270-72-3P 473270-89-2P 473270-91-6P 473270-94-9P,
 [5-tert-Butyl-3-[N'-(4-[2-(diethylcarbamoyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-2-methoxyphenyl]carbamic acid methyl ester 473270-98-3P
 , [5-tert-Butyl-2-methoxy-3-[N'-(4-[2-(pyrrolidine-1-carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]carbamic acid methyl ester 473271-00-0P,
 [5-tert-Butyl-2-methoxy-3-[N'-(4-[2-(piperidine-1-carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]carbamic acid methyl ester 473271-05-5P,
 [5-tert-Butyl-2-methoxy-3-[N'-(4-[2-((4-methylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]phenyl]carbamic acid methyl ester 473271-07-7P,
 [3-[N'-(4-[2-((4-Acetyl piperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-5-tert-butyl-2-methoxyphenyl]carbamic acid methyl ester 473271-09-9P,
 [5-tert-Butyl-3-[N'-(4-[2-((4-ethylcarbamoyl piperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-2-methoxyphenyl]carbamic acid methyl ester 473271-10-2P
 , 4-[4-[4-[N'-(5-tert-Butyl-2-methoxy-3-methoxycarbonylaminophenyl)ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]piperazine-1-carboxylic acid tert-butyl ester 473271-12-4P,
 [5-tert-Butyl-3-[N'-(4-[2-((4-ethylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-2-methoxyphenyl]carbamic acid methyl ester 473271-14-6P,
 [5-tert-Butyl-3-[N'-(4-[2-(2,6-dimethylmorpholine-4-carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-2-methoxyphenyl]carbamic acid methyl ester 473271-18-0P,
 [3-[N'-(4-[2-((4-Acetyl-3-ethylpiperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-5-tert-butyl-2-methoxyphenyl]carbamic acid methyl ester 473271-20-4P,
 [5-tert-Butyl-3-[N'-(4-[2-((3-ethyl-4-ethylcarbamoyl piperazine-1-yl)carbonyl)pyridin-4-yloxy]naphthalen-1-yl]ureido]-2-methoxyphenyl]carbamic acid methyl ester 473271-22-6P,
 4-[4-[4-[N'-(5-tert-Butyl-2-methoxy-3-methoxycarbonylaminophenyl)ureido]naphthalen-1-yloxy]pyridine-2-carbonyl]-2-ethylpiperazine-1-carboxylic acid tert-butyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 1,4-disubstituted benzo-fused arylureas for chronic inflammatory diseases)

RN 473269-80-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[4-[5-(1,1-dimethylethyl)-2-methoxy-3-[(methysulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 473269-81-7 HCAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-
 [(methoxycarbonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-
 (CA INDEX NAME)




RN 473269-83-9 HCAPLUS

CN Carbamic acid, [3-[[[4-[[2-[(dimethylamino)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-methyl ester (9CI) (CA INDEX NAME)




PAGE 2-A



RN 473270-22-3 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyridinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 473270-24-5 HCAPLUS
 CN Methanesulfonamide, N-[3-[[[4-[[2-[(4-acetyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 473270-27-8 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[[4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-
 [(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-
 pyridinyl]carbonyl]-N-ethyl- (CA INDEX NAME)




RN 473270-31-4 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-3-[[[4-[[2-[(4-ethyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]- (CA INDEX NAME)





PAGE 2-A

RN 473270-35-8 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-3-[[[4-[[2-[(2,6-dimethyl-4-morpholinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]- (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 473270-40-5 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-3-[[[4-[[2-[(3-ethyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]- (CA INDEX NAME)



RN 473270-44-9 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-3-[[[4-[[2-[(3-ethyl-4-methyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]- (CA INDEX NAME)






PAGE 2-A


RN 473270-48-3 HCAPLUS
 CN Methanesulfonamide, N-[3-[[[4-[[2-[(4-acetyl-3-ethyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 473270-50-7 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[[4-[[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyridinyl]carbonyl]-N,2-diethyl- (CA INDEX NAME)



RN 473270-52-9 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyridinyl]carbonyl]-2-ethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)






PAGE 2-A


RN 473270-54-1 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-[(4-methyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 473270-60-9 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(1-pyrrolidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 473270-64-3 HCAPLUS
 CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(1-piperidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)






PAGE 2-A

RN 473270-66-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-
 [(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-
 N,N-diethyl- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A


RN 473270-70-1 HCAPLUS
 CN Methanesulfonamide, N-[3-[[[4-[[2-[[(3S)-3-(dimethylamino)-1-
 pyrrolidinyl]carbonyl]-4-pyridinyl]oxy]-1-
 naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 473270-72-3 HCAPLUS



CN Methanesulfonamide, N-[3-[[[4-[[2-[(1,1-dimethylethyl)-2-methoxyphenyl]-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-1-pyrrolidinyl]carbonyl]-4-pyridinyl]oxy]-1-

Absolute stereochemistry.





RN 473270-89-2 HCAPLUS
 CN Carbamic acid, [3-[[[[4-[[2-[[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 473270-91-6 HCAPLUS
 CN Carbamic acid, [3-[[[[4-[[2-[[{(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-, methyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.




RN 473270-94-9 HCAPLUS
 CN Carbamic acid, [3-[[[[4-[[2-[(diethylamino)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 473270-98-3 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(1-pyrrolidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 473271-00-0 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(1-piperidinylcarbonyl)-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)





PAGE 2-A

RN 473271-05-5 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-[(4-methyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 473271-07-7 HCAPLUS
 CN Carbamic acid, [3-[[[4-[[2-[(4-acetyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 473271-09-9 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-3-[[[4-[[2-[[4-
 [(ethylamino)carbonyl]-1-piperazinyl]carbonyl]-4-pyridinyl]oxy]-1-
 naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]-, methyl ester (9CI)
 (CA INDEX NAME)




RN 473271-10-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methoxycarbonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyridinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




PAGE 2-A



RN 473271-12-4 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-3-[[[4-[[2-[(4-ethyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]-, methyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 473271-14-6 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-3-[[[4-[[2-[(2,6-dimethyl-4-morpholinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]-, methyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 473271-18-0 HCAPLUS

CN Carbamic acid, [3-[[[4-[[2-[(4-acetyl-3-ethyl-1-piperazinyl)carbonyl]-4-pyridinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A

RN 473271-20-4 HCAPLUS
 CN Carbamic acid, [5-(1,1-dimethylethyl)-3-[[[4-[[2-[[3-ethyl-4-
 [(ethylamino)carbonyl]-1-piperazinyl]carbonyl]-4-pyridinyl]oxy]-1-
 naphthalenyl]amino]carbonyl]amino]-2-methoxyphenyl]-, methyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 473271-22-6 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[4-[[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-
 3-[(methoxycarbonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-
 2-pyridinyl]carbonyl]-2-ethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



IT 473269-82-8, 4-[4-[N'-(5-tert-Butyl-2-methoxy-3-methoxycarbonylamino)phenyl]ureido]naphthalen-1-yloxy]pyridine-2-carboxylic acid methyl ester
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1,4-disubstituted benzo-fused arylureas for chronic inflammatory diseases)

RN 473269-82-8 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methoxycarbonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 41 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:785445 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:296904
 TITLE: BAY 43-9006: Preclinical data
 AUTHOR(S): Wilhelm, Scott; Chien, Du-Shieng
 CORPORATE SOURCE: Bayer Research Center, Institute for Preclinical Drug Development, Pharmaceutical Division, Bayer Corporation, West Haven, CT, 06516, USA
 SOURCE: Current Pharmaceutical Design (2002), 8(25), 2255-2257
 CODEN: CPDEFP; ISSN: 1381-6128
 PUBLISHER: Bentham Science Publishers
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 ED Entered STN: 15 Oct 2002
 AB A review. The drug design and discovery efforts described in the previous section led to the development of a novel, small mol. Raf-1 kinase inhibitor, BAY 43-9006, which belongs to a class that can be broadly described as bis-aryl ureas. BAY 43-9006 was identified during a large medicinal chemical optimization program, and this compound was selected for further pharmacol. characterization based on its potent inhibition of Raf-1 (IC50 12 nM) and its


favorable kinase selectivity profile [2, 3]. In vitro and in vivo expts. were designed to demonstrate effective blockade of the Raf/MEK/ERK signaling pathway in tumor cells and for antitumor efficacy in human xenograft models.

IT 284461-73-0, BAY 43-9006

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor BAY 43-9006)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 42 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:785444 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:362317

TITLE: BAY 43-9006: Early clinical data in patients with advanced solid malignancies

AUTHOR(S): Hotte, Sebastien J.; Hirte, Hal W.

CORPORATE SOURCE: Department of Medicine, Hamilton Regional Cancer Centre, McMaster University and Division of Medical Oncology, Hamilton, ON, Can.

SOURCE: Current Pharmaceutical Design (2002), 8(25), 2249-2253

CODEN: CPDEFF; ISSN: 1381-6128

PUBLISHER: Bentham Science Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ED Entered STN: 15 Oct 2002

AB A review. Various signaling pathways can confer the malignant phenotype to a cell. Ras signaling proteins have been found to play an important role in controlling cellular growth. Raf-1 is a protein kinase that exerts its effects downstream of Ras in the mitogen-activated protein kinase pathway and is thus likely to be crucial in the development of the malignant phenotype. BAY 43-9006 is an orally administered selective inhibitor of Raf-1 and the first compound of its class to enter clin. trials. This article describes the early clin. data of BAY 43-9006 in patients with advanced, refractory solid tumors. To date, over 60 patients have been treated as part of four Phase I clin. trials. Dose levels have ranged from 50mg once weekly to 200mg twice-daily in continuous administration. The drug has been generally well tolerated with no dose limiting toxicity yet encountered. The more common toxicities have involved the gastrointestinal tract (diarrhea, nausea, abdominal cramping) and the skin (pruritus, rash, cheilitis). Pharmacokinetic evaluations have found BAY 43-9006 to have considerable interpatient variability. However, there seems to be an increase in Cmax and AUC values


with increasing dose. There is no clear effect of food on bioavailability. Splitting the dose to twice-daily administration has shown increases in Cmax and AUC values but is also accompanied by considerable interpatient variability.

IT 475207-59-1, BAY 43-9006 mono-p-tosylate
 RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (BAY 43-9006 for patients with advanced solid neoplasm)
 RN 475207-59-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0


CMF C21 H16 C1 F3 N4 O3



CM 2

CRN 104-15-4


CMF C7 H8 O3 S



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 43 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:713341 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:384728
 TITLE: A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
 Bankston, Donald; Dumas, Jacques; Natero, Reina; Riedl, Bernd; Monahan, Mary-Katherine; Sibley, Robert
 AUTHOR(S): Pharmaceutical Division, Bayer Research Center, West Haven, CT, 06516, USA
 CORPORATE SOURCE: Organic Process Research & Development (2002), 6(6), 777-781
 SOURCE:

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:384728
 ED Entered SIN: 20 Sep 2002
 GI




AB Urea I (BAY 43-9006), a potent Raf kinase inhibitor, was prepared in four steps from picolinic acid with an overall yield of 63%. Significant process research enabled isolation of each intermediate and target without chromatog. purification, and overall yield increases >50% were observed compared to those from previous methods. This report focuses on improved synthetic strategies for production of scaled quantities of I for preclin., toxicol. studies. These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.

IT 284461-73-0P, BAY 43-9006
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (scalable four-step synthesis of a Raf kinase inhibitor urea BAY 43-9006 from picolinic acid)

RN 284461-73-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 44 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:515125 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:210415

TITLE: Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists
 AUTHOR(S): De Lucca, George V.; Kim, Ui T.; Johnson, Curt; Vargo,

Brian J.; Welch, Patricia K.; Covington, Maryanne;
 Davies, Paul; Solomon, Kimberly A.; Newton, Robert C.;
 Trainor, George L.; Decicco, Carl P.; Ko, Soo S.
 Experimental Station, Bristol-Myers Squibb Company,
 Wilmington, DE, 19880-0336, USA

CORPORATE SOURCE:

SOURCE:

Journal of Medicinal Chemistry (2002),
 45(17), 3794-3804
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 137:210415

ED Entered STN: 11 Jul 2002


AB Structure-activity relationship (SAR) studies of initial screening hits from our corporate library of compds. and a structurally related series of CCR1 receptor antagonists were used to determine that an N-(alkyl)benzylpiperidine is an essential pharmacophore for selective CCR3 antagonists. Further SAR studies that introduced N-(ureidoalkyl) substituents improved the binding potency of these compds. from the micromolar to the low nanomolar range. This new series of compds. also displays highly potent, in vitro functional CCR3-mediated antagonism of eotaxin-induced Ca²⁺ mobilization and chemotaxis of human eosinophils.

IT 455259-70-8P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (discovery and structure-activity relationship of
 N-(ureidoalkyl)benzylpiperidines as CCR3 receptors antagonists)

RN 455259-70-8 HCAPLUS

CN Urea, N-[2-[(4-benzoyl-1-piperidinyl)methyl]phenyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 45 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:72070 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:134677

TITLE: Substituted 2-(S)-hydroxy-3-[(piperidin-4-yl-methyl)amino]propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)ethylamines as beta-3 adrenergic receptor agonists, antidiabetics, and antiobesity agents

INVENTOR(S): Steffan, Robert John; Ashwell, Mark Anthony; Pelletier, Jeffrey Claude; Solvibile, William Ronald; Matelan, Edward Martin

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 216 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006255	A2	20020124	WO 2001-US22363	20010716 <--
WO 2002006255	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020037907	A1	20020328	US 2001-903738	20010712 <--
US 6506901	B2	20030114		
PRIORITY APPLN. INFO.:			US 2000-218753P	P 20000717 <--
OTHER SOURCE(S): MARPAT 136:134677				
ED Entered STN: 25 Jan 2002				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides title compds. I and their pharmaceutically acceptable salts [wherein A = OCH₂, bond; R = (un)substituted aryl or certain N/O/S heterocyclyl; R1 = (cyclo)alkyl, alkoxy, (cyclo)alkylamino, (un)substituted aryl, arylamino, arylalkyl, or heterocyclyl; Z = bond, SO₂, CO]. I are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension, and frequent urination. The compds. are particularly useful in the treatment or inhibition of type II diabetes. They are also useful for increasing lean meat deposition and/or increasing the lean meat to fat ratio in animals, particularly mammals. Approx. 240 individual compds. and addnl. salts were prepared by either standard or combinatorial methods. For instance, invention compound II was prepared by reaction of the (S)-isomeric epoxide III with the corresponding amine. II had an EC₅₀ of 0.001 μ M against cloned human β 3 adrenoceptors in vitro, with a maximal response comparable to isoproterenol.


IT 392691-41-7P, 1-[4-(4-Carbamoylpiperidine-1-sulfonyl)phenyl]-3-phenylurea 392691-46-2P,
 1-[4-[3-(2-Pyridyl)ureido]phenyl]sulfonylpiperidin-4-yl]carboxaldehyde
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of piperidine hydroxyaminopropyl ether and hydroxyethylamine derivs. as β 3 adrenergic receptor agonists, antidiabetics, and antiobesity agents)

RN 392691-41-7 HCAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-
 [(phenylamino)carbonyl]amino]phenyl]sulfonyl]- (CA INDEX NAME)



RN 392691-46-2 HCAPLUS
 CN Urea, N-[4-[(4-formyl-1-piperidinyl)sulfonyl]phenyl]-N'-2-pyridinyl- (CA
 INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 46 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:731369 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 135:288778

TITLE: Preparation of indeno[1,2-c]pyrazol-4-ones as
 inhibitors of cyclin dependent kinases

INVENTOR(S): Nugiel, David A.; Carini, David J.; Dimeo, Susan V.;
 Yue, Eddy W.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA

SOURCE: U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of U.S.
 Ser. No. 639,618.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010027195	A1	20011004	US 2000-731304	20001206 <--
US 6407103	B2	20020618		
US 6413957	B1	20020702	US 2000-639618	20000815 <--
CA 2420164	A1	20020502	CA 2000-2420164	20001020 <--
AU 2001012168	A	20020506	AU 2001-12168	20001020 <--
EP 1414804	A1	20040506	EP 2000-973682	20001020 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2004524277	T	20040812	JP 2002-537713	20001020 <--
PRIORITY APPLN. INFO.:				
			US 1998-82476P	P 19980421 <--
			US 1999-295078	B1 19990420 <--
			US 2000-639618	A2 20000815 <--
			WO 2000-US28952	W 20001020 <--

OTHER SOURCE(S): MARPAT 135:288778

ED Entered STN: 07 Oct 2001

GI



AB The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula [X = O, S, (un)substituted NH; R1 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, NH2, C3-10 membered carbocyclyl, 3-10 membered heterocycle containing 1-4 heteroatoms selected from O, N, and S; R2 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, (CF2)mCF3, C3-10 membered carbocyclyl, 3-10 membered heterocycle containing 1-4 heteroatoms selected from O, N, and S; wherein m = 0, 1-4]. These compds. are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits known as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compds. or a pharmaceutically acceptable salt form thereof. Alternatively, cancer or other proliferative diseases can be treated by administering a therapeutically effective combination of one of the compds. of the present invention and one or more other known anti-cancer or anti-proliferative agents (no data). Thus, hydrogenation of di-Me 3-nitrophthalate over 5% Pd-C in methanol in a Parr shaker at 50 psi for 2 h followed by acetylation with Ac2O in pyridine at 25° for 2 h gave 79% di-Me 3-acetamidophthalate which was treated with NaH in DMF and cyclocondensed with 4-methoxyacetophenone at 90° for 20 min to give 30% 2-(4-methoxybenzoyl)-4-acetamidoindane-2,3-dione. Cyclocondensation of the latter triketone with hydrazine hydrate in the presence of p-TsOH in ethanol under reflux for 2 h gave I (R1 = Me, X = O, R2 = 4-methoxyphenyl).


IT 364735-88-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indeno[c]pyrazolones as inhibitors of cyclin dependent kinases)

RN 364735-88-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2,3-dihydro-4-[[[4-morpholinylamino]carbonyl]amino]-1,3-dioxo-1H-inden-2-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L42 ANSWER 47 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:842102 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 134:17320

TITLE: Preparation of novel dinaphthyl ureas as glucose uptake enhancers

INVENTOR(S): Spevak, Wayne; Lum, Robert T.; Shi, Songyuan; Mancham, Prasad; Kozlowski, Michael R.; Schow, Steven R.

PATENT ASSIGNEE(S): Telik, Inc., USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071506	A2	20001130	WO 2000-US14644	20000525 <--
WO 2000071506	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, BF, BJ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 234557	B	20050621	TW 2000-89109745	20000520 <--
CA 2374225	A1	20001130	CA 2000-2374225	20000525 <--
EP 1181271	A2	20020227	EP 2000-936360	20000525 <--
EP 1181271	B1	20050119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103409	T2	20020521	TR 2001-3409	20000525 <--
BR 2000011550	A	20020604	BR 2000-11550	20000525 <--
HU 2002001306	A2	20020928	HU 2002-1306	20000525 <--
HU 2002001306	A3	20050428		
US 6458998	B1	20021001	US 2000-579279	20000525 <--
JP 2003500381	T	20030107	JP 2000-619763	20000525 <--
NZ 515743	A	20030829	NZ 2000-515743	20000525 <--
AU 776438	B2	20040909	AU 2000-51684	20000525 <--
AT 287394	T	20050215	AT 2000-936360	20000525 <--
ES 2233386	T3	20050616	ES 2000-936360	20000525 <--

Serial No.:10/788,426

IL 146576	A	20061005	IL 2000-146576	20000525 <--
ZA 2001009641	A	20030224	ZA 2001-9641	20011122 <--
NO 2001005713	A	20011220	NO 2001-5713	20011123 <--
MX 2001012079	A	20030630	MX 2001-12079	20011126 <--
KR 746870	B1	20070807	KR 2001-715133	20011126 <--
HK 1046399	A1	20050902	HK 2002-106271	20020826 <--
US 20030135063	A1	20030717	US 2002-237583	20020906 <--
US 7071231	B2	20060704		



PRIORITY APPLN. INFO.:

US 1999-136128P	P	19990526 <--
US 2000-579279	A1	20000525 <--
WO 2000-US14644	W	20000525 <--

OTHER SOURCE(S): MARPAT 134:17320

ED Entered STN: 01 Dec 2000

GI



AB The title compds. [I; R1, R2 = SO2NR72, CONR72, NR7SO2R7, etc.; R5, R6 = H, alkyl, CN, etc.; R7 = H, alkyl, aryl, etc.; Y = a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide linkage; x = 0-2; the linker connects a carbon designated as c to a carbon designated as d, and is NR3C(:K)NR4 (wherein K = O, S, NH, etc.; R3, R4 = H, alkyl; R3, R4 together = (CH2)2, (CH2)3, (CH2)4, etc.), N:C(NR112)NR4 (R11 = H, CN, alkyl); NR3C(NR112):N, etc.], useful for treating conditions associated with hyperglycemia, especially Type II diabetes, were prepared and formulated. E.g., a multi-step synthesis of the urea II which produced a 13% decrease in blood glucose levels, a 42% decrease in plasma insulin levels, and a 15% decrease in plasma triglyceride levels in the ob/ob mouse model of Type II diabetes, was given. The compds. I are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose.


IT 309932-96-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel dinaphthyl ureas as glucose uptake enhancers)

RN 309932-96-5 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1,1'-[carbonylbis(imino-6,2-naphthalenediylsulfonyl)]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CO₂H

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 48 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:682365 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:316147

ORIGINAL REFERENCE NO.: 129:64518h,64519a

TITLE: Preparation of nicotinamides as PDE4 D isoenzymes inhibitors

INVENTOR(S): Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob; Kleinman, Edward Fox

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 200 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845268	A1	19981015	WO 1998-IB315	19980310 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2285548	A1	19981015	CA 1998-2285548	19980310 <--
CA 2285548	C	20060711		
AU 9862273	A	19981030	AU 1998-62273	19980310 <--
AU 738037	B2	20010906		

Serial No.:10/788,426

EP 971894 A1 20000119 EP 1998-904343 19980310 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO
TR 9902432 T2 20000121 TR 1999-2432 19980310 <--
JP 2000510481 T 20000815 JP 1998-542528 19980310 <--
BR 9810733 A 20000912 BR 1998-10733 19980310 <--
HU 2000001243 A2 20000928 HU 2000-1243 19980310 <--
HU 2000001243 A3 20001030
TW 519539 B 20030201 TW 1998-87104586 19980326 <--
AP 1388 A 20050414 AP 1998-1218 19980402 <--
ZA 9802853 A 19991004 ZA 1998-2853 19980403 <--
HR 980181 B1 20030630 HR 1998-181 19980403 <--
US 6380218 B1 20020430 US 1999-308956 19990527 <--
BG 64356 B1 20041130 BG 1999-103725 19990909 <--
NO 9904791 A 19991201 NO 1999-4791 19991001 <--
NO 314182 B1 20030210
MX 9909099 A 20000228 MX 1999-9099 19991004 <--
US 20020111495 A1 20020815 US 2002-62811 20020131 <--
JP 2004083583 A 20040318 JP 2003-201291 20030724 <--
US 1997-43403P P 19970404 <--
JP 1998-542528 A3 19980310 <--
WO 1998-IB315 W 19980310 <--
US 1998-105120P P 19981021 <--
US 2001-265240P P 20010131 <--
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 129:316147
ED Entered STN: 28 Oct 1998
GI




I

AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH2, O, NH, SO, SO2, S; R1 is H, alkyl, cycloalkyl, aryl, etc.; R2, R3 together with attached carbon form carbonyl group or cycloalkyl ring; R2, R3, R4 is independently H, OH, CN, CO2H, alkyl, etc.; R5 is cyclic, bicyclic, aryl; R6, R7 and R8 are each independently H, CN, COOH, NO2, OH, alkyl, etc.] and pharmaceutical composition are prepared for the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.
IT 214756-06-6P 214756-07-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamides as PDE4 D isoenzymes inhibitors)


RN 214756-06-6 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-[[[(2-methoxyphenyl)amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 214756-07-7 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-[[[(1-naphthalenylamino)carbonyl]amino]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Search History

```

L1          STRUCTURE UPLOADED
L2          3 SEA SSS SAM L1
L3          STRUCTURE UPLOADED
L4          5 SEA SSS SAM L1 AND L3
L5          SCR 1840
L6          7 SEA SSS SAM L5 AND (L1 AND L3)

FILE 'HCAPLUS' ENTERED AT 15:57:56 ON 06 APR 2009
L7          1 SEA SPE=ON ABB=ON PLU=ON US2004-788426/APPS

FILE 'REGISTRY' ENTERED AT 16:03:41 ON 06 APR 2009
L8          369 SEA SPE=ON ABB=ON PLU=ON (10118-90-8/BI OR 102676-47-1/BI
OR 103222-11-3/BI OR 10540-29-1/BI OR 10596-23-3/BI OR
106133-20-4/BI OR 107007-99-8/BI OR 107868-30-4/BI OR 108736-35
-2/BI OR 108852-90-0/BI OR 110267-81-7/BI OR 110942-02-4/BI OR
111266-55-8/BI OR 112809-51-5/BI OR 112887-68-0/BI OR 113427-24
-0/BI OR 114084-78-5/BI OR 114285-68-6/BI OR 114977-28-5/BI OR
115956-12-2/BI OR 117091-64-2/BI OR 118072-93-8/BI OR 119413-54
-6/BI OR 120511-73-1/BI OR 121181-53-1/BI OR 121584-18-7/BI OR
123-30-8/BI OR 123760-07-6/BI OR 123774-72-1/BI OR 123948-87-8/
BI OR 124508-66-3/BI OR 125-02-0/BI OR 125-84-8/BI OR 127-07-1/
BI OR 129453-61-8/BI OR 129488-09-1/BI OR 129488-10-4/BI OR
129497-78-5/BI OR 129580-63-8/BI OR 129612-87-9/BI OR 13010-47-
4/BI OR 130167-69-0/BI OR 132446-35-6/BI OR 1327-53-3/BI OR
13311-84-7/BI OR 134-46-3/BI OR 13422-55-4/BI OR 134404-52-7/BI
OR 134774-45-1/BI OR 135086-76-9/BI OR 135729-62-3/BI OR
136279-32-8/BI OR 13647-35-3/BI OR 138069-52-0/BI OR 13909-09-6
/BI OR 139691-76-2/BI OR 140194-24-7/BI OR 140709-07-5/BI OR
141256-04-4/BI OR 145941-26-0/BI OR 146665-77-2/BI OR 147-94-4/
BI OR 147149-76-6/BI OR 147149-98-2/BI OR 14769-73-4/BI OR
148-82-3/BI OR 151-73-5/BI OR 153559-49-0/BI OR 154-42-7/BI OR
154-93-8/BI OR 154361-50-9/BI OR 15663-27-1/BI OR 158681-49-3/B
I OR 159074-77-8/BI OR 159520-56-6/BI OR 162635-04-3/BI OR
162652-95-1/BI OR 16268-82-9/BI OR 163648-72-4/BI OR 164656-23-
9/BI OR 165245-96-5/BI OR 16595-80-5/BI OR 169590-42-5/BI OR
170729-80-3/BI OR 171335-80-1/BI OR 173146-27-5/BI OR 173937-91
-2/BI OR 174402-32-5/BI OR 174722-31-7/BI OR 179324-69-7/BI OR
180064-38-4/BI OR 180288-69-1/BI OR 180916-16-9/BI OR 182133-25
-1/BI OR 182167-02-8/BI OR 183319-69-9/BI OR 18378-89-7/BI OR
184475-35-2/BI OR 18883-66-4/BI OR 190977-41-4/BI OR 191732-72-
6/BI OR 192185-72-1/B
L9          205 SEA SPE=ON ABB=ON PLU=ON L8 AND NR>=3
L10         135 SEA SPE=ON ABB=ON PLU=ON L9 AND N>=2 AND O>=1
L11         0 SEA SPE=ON ABB=ON PLU=ON L6 AND L10
L12         7 SEA SSS SAM L5 AND (L1 AND L3)
L13         2810 SEA SSS FUL L5 AND (L1 AND L3)
L14         1 SEA SPE=ON ABB=ON PLU=ON L13 AND L8
L15         2809 SEA SPE=ON ABB=ON PLU=ON L13 NOT L14

FILE 'HCAPLUS' ENTERED AT 16:12:14 ON 06 APR 2009
L16         814 SEA SPE=ON ABB=ON PLU=ON L13
L17         75 SEA SPE=ON ABB=ON PLU=ON L16 AND (PRY<=2003 OR AY<=2003 OR
PY<=2003)
L18         13 SEA SPE=ON ABB=ON PLU=ON DUMA J?/AU
L19         345 SEA SPE=ON ABB=ON PLU=ON BOYER S?/AU

```

Serial No.:10788,426

L20 1854 SEA SPE=ON ABB=ON PLU=ON VERMA S?/AU
 L21 12 SEA SPE=ON ABB=ON PLU=ON ADNANE L?/AU
 L22 60165 SEA SPE=ON ABB=ON PLU=ON CHEN Y?/AU
 L23 15934 SEA SPE=ON ABB=ON PLU=ON LEE W?/AU
 L24 0 SEA SPE=ON ABB=ON PLU=ON PHILLIPS B?/AU
 L25 16458 SEA SPE=ON ABB=ON PLU=ON SMITH R?/AU
 L26 16458 SEA SPE=ON ABB=ON PLU=ON SMITH R?/AU
 L27 2169 SEA SPE=ON ABB=ON PLU=ON SCOTT W?/AU
 L28 2303 SEA SPE=ON ABB=ON PLU=ON BURKE J?/AU
 L29 58323 SEA SPE=ON ABB=ON PLU=ON CHEN J?/AU
 L30 58323 SEA SPE=ON ABB=ON PLU=ON CHEN J?/AU
 L31 1090 SEA SPE=ON ABB=ON PLU=ON PHILLIPS B?/AU
 L32 5608 SEA SPE=ON ABB=ON PLU=ON FAN J?/AU
 L33 137 SEA SPE=ON ABB=ON PLU=ON MIRANDA K?/AU
 L34 9 SEA SPE=ON ABB=ON PLU=ON RAUDENBUSH B?/AU
 L35 58 SEA SPE=ON ABB=ON PLU=ON REDMAN A?/AU
 L36 2853 SEA SPE=ON ABB=ON PLU=ON SHAO J?/AU
 L37 404 SEA SPE=ON ABB=ON PLU=ON SU N?/AU
 L38 24362 SEA SPE=ON ABB=ON PLU=ON WANG G?/AU
 L39 1023 SEA SPE=ON ABB=ON PLU=ON YI L?/AU
 L40 5479 SEA SPE=ON ABB=ON PLU=ON ZHU Q?/AU
 L41 27 SEA SPE=ON ABB=ON PLU=ON (L18 OR L19 OR L20 OR L21 OR L22
 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR
 L40) AND L17

 FILE 'HCAPLUS' ENTERED AT 16:22:37 ON 06 APR 2009
 L42 48 SEA SPE=ON ABB=ON PLU=ON L17 NOT L41